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General introduction
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Evidence-based surgery
Surgical innovations comprise new techniques, modified strategies, or innovative 
instruments. The evidence base for many of these innovations—and therefore for much 
of current surgical practice—is vastly weaker than for most modern drug treatments. 
It has been shown that only half of all new experimental treatments will prove to be 
better than established treatments when tested in randomized trials.1 At the same 
time technological innovation is an important driver of the cost growth in healthcare.2 
Because new treatments are not always evaluated in trials or abandoned after negative 
outcomes a part of innovations increases healthcare costs without having added value for 
patients. The latter is especially true in surgery. Surgical trials are difficult and rare; some 
interventions have been widely adopted without rigorous evaluation.3 Besides this, the 
introduction of new surgical procedures and devices is not yet regulated in most countries. 
Hence, these procedures and devices may become widely used with little evidence of 
their efficacy and cost-effectiveness. This is different for drugs, where both the Food and 
Drug Administration (United States) and the European Medicines Agency require new 
treatments to undergo rigorous premarket clinical trials.4 The result of the current drug 
approval system, however, is a 8-15-year wait for new treatments with an estimated 
average cost to market between $500 million a nd $2 billion.5 To come to more evidence 
based surgery in terms of effectiveness and efficiency, without jeopardizing innovation, 
we need creative and effective scientific approaches to reduce healthcare expenses, while 
still improving patient outcomes by innovation.
The IDEAL (Innovation, Development, Exploration, Assessment, Long-term study) 
collaboration developed a framework for the stages in surgical innovation including a set 
of recommendations on how evaluations should be conducted at each stage.6 The IDEAL 
collaboration did not, however, take into account cost-effectiveness, norms and values of 
its social context, and its transdisciplinary aspects. Medical professionals, patients, health 
care insurers, manufacturers of medical devices, and policy makers would benefit from 
accurate information on costs and benefits. An efficient and evidence based health care 
system should enhance the ability of these stakeholders to make informed choices about 
the implementation and use of new procedures and devices. Therefore, there is a need to 
improve the scientific tools and methods to inform evidence based decisions in surgery.
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Decision modeling
Decision-analytic modeling is a method, which synthesizes evidence to inform decisions. 
In a decision analytical model, two or more alternatives can be compared in terms of 
costs and/or effects. This analysis can be used to examine whether new procedures/
technologies are more effective, to which extent the use of new technologies influences 
the costs of a healthcare pathway and to determine  whether the new technology 
represents value for money. Based on the available evidence combined in a model, 
a decision can be made whether a new technology should be implemented, if further 
evidence should be obtained or that the technology should be abandoned. Regardless of 
the availability of evidence, there will always be, to a greater or lesser extent, uncertainty 
regarding the costs and consequences of the technology. Value of information analyses 
can be performed to examine the value of acquiring additional information, and reducing 
uncertainty, through further research. These analyses show on which parameters further 
research is most valuable. With these analyses we can make informed decisions about 
new technologies, and about how to make efficient use of available resources for (further) 
research. Therewith, a decision analytical model can be an ideal starting point for clinical 
decision problems and the development of technologies. It can provide a fundament for 
further research and an evaluative framework for decision making. 
From population to the individual patient
Evidence based treatment decisions based on decision models could improve outcome 
for a population of patients. However, a physician does not see an ‘average patient’ from a 
certain population. Optimal treatment could differ between individuals within a specified 
population, for instance a population that is specified within a randomized controlled 
trial. Research should help physicians making an optimal decision for their patients. Up 
to now, individual patient characteristics are often not taken into account when making 
evidence based decision models.  Since real evidence based decision making has the care 
for individual patients as its top priority, it is crucial to bridge the gap between evidence 
based decision making and personalized healthcare.7 
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The case of evidence based decision making for neck management in oral cancer 
In this thesis we study the value of several management strategies for patients with 
early oral squamous cell carcinoma (OSCC). This empirical example offers the unique 
opportunity to assess the opportunities and challenges of an evidence based approach 
for the evaluation of (surgical) innovation. OSCC is an important health issue in numerous 
countries. Because of important trade-offs underlying the surgical treatment of OSCC 
many decision problems exist in this field. An evidence based approach could therefore 
fulfill a need for stakeholders in this field. 
Etiology
Each year, more than half a million patients worldwide are diagnosed with squamous-cell 
carcinoma (SCC) of the head and neck worldwide.8 An important part of the SCCs in this 
region arise in the oral cavity. Tobacco use, alcohol consumption and betel quid chewing 
are the main risk factors in the etiology of intraoral cancer.9,10 The incidence of OSCC 
is higher in men, which is mainly due to the greater exposure to the risk factors.11 Men 
aged over 50 are, therefore the main risk group, although the ratio of males to females 
has decreased.12 
Unfortunately, the epidemiological data concerning ‘oral cancer’ often includes both oral 
cavity and oropharyngeal cancers, which actually have different etiology, are diagnosed 
at different stages, and treated in different ways. Patients with oral cavity squamous cell 
carcinoma (OCSCC) generally present with early stage disease and the primary treatment 
is surgery with or without (chemo-)radiotion. Oropharyngeal cancers are mostly more 
advanced at the time of diagnosis and primary treatment for these patients is more likely 
to be (chemo-)radiation.13 This thesis focus on early stage OSCC. 
Diagnosis of neck metastases
The most important factor in early stage OCSCC is spread of cancer to regional lymph 
nodes in the neck. Widely used preoperative neck staging techniques include palpation, 
ultrasound (US) with or without fine needle aspiration cytology (+/- FNAC), computed 
tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography 
(PET) scanning.
Surgical management of the neck
The presence of regional metastases decreases survival by approximately 50%.14 
Therefore, adequate treatm ent of metastatic lymph nodes in the neck is considered 
crucial to improve oncologic outcomes for these patients. 
Neck dissection is the standard surgical treatment for cancer in the regional lymph nodes 
of the neck. The purpose of a neck dissection is to remove those lymph nodes containing 
metastatic cancer.15 Depending on the extend, neck dissections are generally classified 
into four categories:
11
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1. Radical, consisting of the dissection of all the lymphatic tissue in level I-V including 
removal of the spinal accessory nerve, sternocleidomastoid muscle and internal jugular 
vein. 
2. Modified radical, or any alteration of the radical procedure that involves preservation 
of one or more non-lymphatic structures of the neck.
3. Selective, including supramohyoid, posterolateral, lateral and anterior, each 
representing a specific procedure that preserves one or more lymph node groups routinely 
removed in radical neck dissection 
4. Extended, or any alteration involving removal of additional lymph node groups or 
non-lymphatic structures relative to the radical procedure.16
In addition, neck dissections can be therapeutic, if there are metastases detected (cN+) 
or elective or “prophylactic” if no metastases are detected (cN0) during clinical diagnoses.
To further clarify the nomenclature a more rational nomenclature has been proposed 
more recently.17
Neck dissection is invasive and shoulder dysfunction, cosmetic deformity, cutaneous 
paresthesia, and chronic neck and shoulder pain syndrome are well-recognized side effects 
of neck dissection that influence a patient’s quality of life.18-20. Preserving structures (i.e. 
performing less radical types of dissections) result in less shoulder complaints and in a 
higher quality of life.21-25
Trade-off
The surgical management of regional lymph nodes includes a difficult trade-off between 
increasing prognoses by removing those lymph nodes involved by or at risk for involvement 
by metastatic cancer. On the other hand, quality of life could be reduced by shoulder 
complaints or complications  as a result of removing those lymph nodes.
Management decisions in cN+
The trade-off between survival prognoses and quality of life plays a role when metastases 
are detected. In this case the radical and modified radical neck dissection are considered 
as standard  treatment. However, in many cases this results in overtreatment because 
metastases are not present in all levels of the neck. Some surgeons are therefore exploring 
the efficacy of selective neck dissection in cases of a clinically positive neck (cN+) with 
limited disease, in an effort to reduce morbidity without reducing oncologic safety.26,27
Management decisions in cN0
The trade-off between prognoses and quality of life is even more present for patients 
with a clinically uninvolved neck (cN0). This is caused by the lack of sensitivity of current 
used diagnostic modalities, which results in a high incidence of occult, i.e. undetected, 
metastases. In patients with a cN0 neck occult metastases have been reported in 20% up 
to 44% of the patients.26 
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For many years, two strategies have been used to treat the neck of these patients: elective 
neck dissection (END) or watchful waiting (WW). Proponents of END consider it to be 
the current gold-standard procedure for the cN0 neck, as it not only provides valuable 
prognostic information regarding nodal status, but it is also therapeutic for patients 
who have occult metastases in the regional lymph nodes of the neck. A disease-survival 
advantage has been demonstrated for elective neck dissection in a meta-analysis 
comparing elective neck dissection versus observation in cN0 patients.26,28 Proponents 
of watchful waiting argue that most patients who develop metastases somewhere in the 
future, will be diagnosed early, if closely observed, and most can be salvaged successfully 
with a therapeutic neck dissection at time of relapse.29,30 This treatment strategy, thereby, 
avoids the unnecessary morbidity of neck dissection in the majority of node-negative 
patients in whom the neck dissection was not needed. The trade-off between prognosis 
and quality of life could be influenced by new diagnostic modalities that could make a 
better distinction between patients with or without neck metastases.
Objectives/aims:
The overall aim of this thesis is to inform decisions in the management of OCSCC patients 
in an evidence based manner. 
More specific aims are:
1. To evaluate the need for evidence based surgery in general, and more particularly 
regarding diagnostic and surgical innovations in OCSCC 
2. To assess various management strategies for the neck in early stage OCSCC 
patients on their cost-effectiveness
3. To bridge the gap between evidence based decision making and personalized 
healthcare in the management of the neck in OCSCC patients 
Thesis outline
Part 1 of this thesis starts with the costs of lower value surgery, which indicates the general 
need for evidence based surgery in monetary terms (Chapter 2). Chapter 3 consists of 
a description of (inter)national practice variations in the management of the neck in 
OCSCC patients. Variation in practice could be an indicator of the absence of evidence 
based recommendations or guidelines.  Chapter 4 describes the results of an interactive 
evaluation in which we interviewed all relevant stakeholders regarding their needs of 
surgical innovations and research in head and neck cancer. 
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Part 2 is focused on evidence based management in OCSCC patients. Decision modeling 
was used to synthesize the relevant evidence regarding the various management 
options to provide estimates of effects and/or costs. Chapter 5 comprises a diagnostic 
meta-analysis of the accuracy of a sentinel lymph node biopsy (SLNB) for the prediction 
of neck node involvement in OCSCC. The diagnostic accuracy of the SLNB was also an 
important parameter for a decision model of the management of the N0 neck in OCSCC. 
In this model (Chapter 6), five strategies for the management of the N0 neck in early stage 
OCSCC are compared regarding their cost-effectiveness. Besides this value of information 
analysis for missing evidence was performed. This value of information analysis showed 
that more evidence regarding quality of life after different procedures was of high value. 
Therefore,  we also studied the quality of life after different procedures (Chapter 7). 
Chapter 8 describes a decision model of the management of a clinical positive neck. This 
model evaluates survival, quality of life and costs associated with SND in patients with 
early stage OCSCC with singular nodal disease, compared to MRND. 
Part 3 is about personalized decision making. Decision modeling provides results for 
an ‘average patient in an a priori defined population. Physicians therefore still need to 
make subjective decisions for the individual patient. In chapter 9 we explored the value 
of individualized care by constructing a personalized decision model for patients with a 
cN0 neck. 
In chapter 10 we will discuss the overall implications of our evidence based approach for 
surgical treatment and innovations in general and for surgical management of the neck in 
OCSCC patients in particular. 
14
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Abstract
Background: Several initiatives have focused on defining healthcare services that provide 
little or no benefit. No longer performing these lower value procedures might save 
considerable costs. In contrast to medicines, surgical procedures can be applied without 
robust studies, so particularly in surgery lower value procedures might be identified. It is 
important to translate lists of lower value services into meaningful metrics of avoidable 
costs to inform policy makers and providers how to bend the cost curve. 
Methods and findings: We calculated avoidable costs associated with surgical procedures 
included in the ‘do not do’ recommendations of the National Institute for Health and 
Clinical Excellence, using both indication specific Dutch utilization data and more general 
utilization data from England, and actual costs from cost(-effectiveness) studies and 
reimbursement tariffs. We also extrapolated the results to all potential lower value surgical 
procedures, varying the assumption of lower value surgery to be between 5 and 33%. 
The estimated costs that could be saved by not performing proven lower value surgery 
in the Netherlands were €11 million and €8 million per year using actual costs and 
reimbursement tariffs, respectively. An extrapolation of this result to all surgical 
procedures showed a potential cost saving that varied between €63 million and €419 
million per year. Data from England showed cost savings of about 48.5 million using actual 
costs. Extrapolation of the data from England showed a potential cost saving between 
€382 million and €2.5 billion. 
Conclusions: Lower value surgical procedures are creating a significant waste in healthcare. 
Evidence-based surgery could reduce this waste and thereby result in considerable savings.
19
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Introduction
The current financial climate requires all healthcare systems to find ways of controlling 
costs without cutting quality of care. One way to achieve this is to no longer perform costly 
activities that provide little or no health benefit to patients. Several recent initiatives, 
including the Choosing Wisely campaign by the American Board of Internal Medicine 
Foundation and the ‘do not do’ recommendations of the National Institute for Health 
and Clinical Excellence (NICE), have focused on directly defining these (lower value) 
activities.31,32 Although challenging, it is important to translate these evidence-based 
lists of lower value services into meaningful metrics of avoidable costs to inform policy 
makers and providers how to bend the cost curve. 
It has been estimated that for 30-50% of all surgical procedures the effectiveness has not 
been studied.33 This implies that the procedures that are proven to be of lower value 
according to recent initiatives are only part of all existing lower value activities.31,32 
Others have shown that about half of all new therapeutic interventions are not better 
than their best alternative.1 In contrast to medicines, surgical procedures and devices can 
be applied without robust clinical studies. Hence, particularly in surgery many lower value 
procedures might be identified, and large potential cost savings may exist. 
We used existing evidence-based lists to calculate the avoidable costs of lower value 
surgery.
Methods
Our approach consisted of five interrelated steps. First, we searched for existing evidence 
regarding lower value surgical procedures, where lower value was defined as having little 
or no health gain compared to their best alternative. Second, the yearly volumes of these 
procedures were obtained. Third, costs for the procedures and their alternatives were 
determined. Fourth, a calculation model was constructed to calculate avoidable costs by 
not performing these specific procedures. Fifth, we extrapolated our findings to estimate 
the total potential cost savings at the national level by not performing all lower value 
surgical procedures, including those for which no evidence exists, assuming that this is a 
fixed percentage of all surgical procedures. 
Step 1: Selection of lower value surgical procedures
Several organizations within different countries started initiatives to identify and reduce 
the use of lower value care of which the Choosing Wisely campaign, an Australian initative 
and the NICE ‘do not do’ campaign are probably best known. 31,34,32
We used NICE’s ‘do not do’ recommendations to select surgical procedures that are 
deemed to deliver little or no health gain. NICE provides national guidance and advice to 
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improve health and social care in England, but many of their results are adopted in other 
countries in Western Europe. Based on both available data and expert consultation, we 
selected those surgical procedures that are performed in the Netherlands. 
Step 2: Volumes
Volumes of the selected procedures in step 1 were based on indication specific utilization 
data from the Dutch Hospital Data (DHD), an institute that manages the national data of 
all performed procedures in Dutch hospitals.35 Some of the do not do recommendations 
were more specific than as presented in the DHD database. For these procedures, we 
assumed that 50% of the obtained volume actually related to the specific indication. In 
a sensitivity analysis we varied this percentage from 33% up to 66%. We also used more 
general utilization data from the Hospital Episode Statistics of the National Health Service 
(England).36 Where the Dutch volume data could be linked to specific indications, this was 
not possible for the data from England. We therefore applied the Dutch indication-specific 
percentage of performed procedures to the utilization data from England. Ethical approval 
was not required, as this modeling study only used anonymous data from databases and 
previously performed studies.
Step 3: Costs
Unit costs of the procedures and their alternatives were derived using both actual costs 
and reimbursement tariffs. The alternative procedures were drawn from the ‘do not do’ 
recommendations when mentioned and otherwise from medical literature and expert 
opinions. 
To obtain actual costs we used the reported cost-effectiveness studies in the NICE 
guidelines. If such studies were not available, we searched the literature for relevant 
cost-effectiveness studies. If possible, we took into account both direct cost (e.g. costs 
of the procedure) and indirect cost (e.g. complication costs and costs of retreatment). 
When no cost-effectiveness study was available, we searched for studies that reported 
on the costs of the (single) procedure, or the alternative. In such cost studies only direct 
healthcare cost are reported. If no data could be retrieved, we used the cost data of our 
own University medical centre. Costs in currencies other than Euros were converted to 
Euros by using the exchange rate of the year for which the costs were presented. Costs 
were inflated to the year 2012 with price index rates.37 Furthermore, we used Dutch 
procedure and indication specific reimbursement tariffs from Achmea, which is with 
approximately 5 million insured individuals one of the largest health care insurance 
companies in the Netherlands.38
Step 4: Calculation Model
To calculate the potential cost savings of the selected surgical procedures, we multiplied 
the volumes by the differences in both actual costs and reimbursement tariffs of these 
surgical procedures and their alternatives. To enable comparisons between countries 
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and health care systems, we additionally calculated avoidable costs per 1000 inhabitants. 
For this purpose we used a number of 16,730,348 inhabitants in the Netherlands and 
53,500,000 in England in 2012.39,40 The English volumes were only multiplied by 
differences in actual costs since reimbursement tariffs were only available for the Dutch 
situation. 
Step 5: Extrapolation model
Since effectiveness data are still lacking for many surgical procedures, it is expected that the 
identified lower value procedures represent only a percentage of all lower value surgical 
procedures. Therefore, we also extrapolated our results assuming that 20% of all surgical 
procedures are of lower value. This number was used since the effectiveness has not been 
studied for about 40% of all interventions and about half of all (new) interventions are 
not more effective than their best alternatives.33,1 In a sensitivity analysis we varied this 
percentage between 5% and 33%. 
Results 
Procedures
The ‘do not do’ recommendations of NICE32 consist of 949 recommendations of which 
52 were related to surgical procedures. Twenty-three of these procedures (44%) are not 
performed in the Netherlands. For the 29 remaining lower value surgical procedures, 
indication-specific and overall volumes were requested from Dutch Hospital Database 
(DHD). For four procedures no data could be obtained because of the absence of a specific 
code for the procedure (see appendix). Three procedures for Barret-Oesofagus, that were 
mentioned separately in NICE, were combined in the DHD. We therefore included 23 
lower value surgical procedures in our further analyses (see also Table 1). Since indication 
specific utilization data were not available in England, we used the same 23 surgical 
procedures so that we could apply the Dutch indication specific percentages to the overall 
utilization data from the Hospital Episode Statistics of the NHS.35
Volumes
Indication-specific volumes and assumptions based on the Dutch data regarding the lower 
value surgical procedures are presented in Table 2. The frequency of all 23 lower value 
surgical procedures was 11,802 operations per year in the Netherlands. The two most 
often performed lower value procedures were facet denervation for non-specific low 
back pain and adenoidectomy for otitis media with 5,423 and 1,718 procedures yearly, 
respectively (Table 3). Table 3 provides an overview of the volumes of the 23 procedures 
in England. When we applied the Dutch indication-specific percentages per procedure to 
the data from England, the frequency of all 23 lower value surgical procedures was 29,196 
operations per year.
22
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Table 1:  Overview of the included surgical procedures as reported in the NICE do not do 
recommendations
23
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Table 2: Dutch utilization volumes (obtained from the DHD database) of the surgical procedures 
reported in the NICE do not do recommendations
* For these procedures the assumption was made that 50% of the obtained volume was actually 
performed for the specific indication reported in the NICE do not do recommendations. In sensitivity 
analyses these percentage were varied from 33% up to 66%.
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Costs
Table 4 provides an overview of the actual costs and reimbursement tariffs of the 
different procedures and their alternatives. For 13 procedures (57%) the alternative was 
either watchful waiting or doing nothing, whereas for the other 10 procedures (43%) an 
alternative less invasive procedure (e.g. medicines) was reported as the best alternative. 
For 15 of the 23 procedures (65%) both direct and indirect costs were obtained; for the 
other 8 (35%) only direct cost were reported.
Calculation model
Table 5 shows the avoidable costs for each lower value surgical procedure using both 
actual costs and reimbursement tariffs for the Dutch situation. The two procedures 
that are responsible for the highest potential cost saving when using actual costs were 
arthroscopic lavage and debridement for osteoarthritis of the knee, and facet denervation 
for non-specific low back pain, with potential cost savings of about €2.3 million and 
€2.0 million, respectively. When using reimbursement tariffs, facet denervation for 
non-specific low back pain and adenoidectomy as an adjuvant treatment for otitis media 
were responsible for the highest potential cost saving with  €3.5 million and €1.1 million 
respectively. 
The total potential cost savings associated with lower value surgical procedures were 
€10.6 million and €8.2 million per year using cost prices and reimbursement tariffs, 
respectively. Taking into account the total number of inhabitants, the avoidable costs 
per 1,000 inhabitants were €633 and €489 using actual costs and reimbursement tariffs, 
respectively. The sensitivity analyses (Table 6) showed that using a variation of 33% to 
66% regarding the volume indication, the potential avoidable costs varied from about 
€8.4 million to €12.6 million (€504 to €754 per 1000 inhabitants) per year using actual 
costs and from about €7.0 to €9.3 million (€419 to €554 per 1000 inhabitants) using 
reimbursement tariffs.
Table 7 shows the avoidable costs for each lower value surgical procedure using the 
utilization data from England together with the Dutch indication specific percentages 
per procedure. Axillary lymph node dissection in breast cancer patients and arthroscopic 
lavage and debridement for osteoarthritis of the knee were the two procedures with 
the highest potential cost savings, with potential cost savings of €17.8 and €8.9 million 
respectively. The total potential cost savings were about €48 million. Taking into account 
the number of inhabitants, the avoidable costs were €906 per 1000 inhabitants in England. 
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Table 4: Costs prices and reimbursement tariffs of surgical procedures and their alternatives
* is difference with proton-pump inhibitors
28
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Table 5: Calculation model: Cost differences using obtained utilization volumes from the Nether-
lands and actual cost prices and reimbursement tariffs
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Table 6: Sensitivity analysis calculation model
* For the procedures for which specific volume data was not available because the reported indication 
in the ‘do not do’ recommendation was narrower than as presented in the DHD data
Table 7: Sub analysis: Cost differences using utilization volumes from England and actual cost prices
30
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Extrapolation model
Since 1,414,558 surgical procedures are performed per year in the Netherlands, the 11,802 
identified lower value surgical procedures represent 0.83% of all surgical procedures.52 
Using the assumption that 20% of all procedures are of lower value, the potential costs 
(using actual costs) that could be saved amount to approximately €254 million per year, 
i.e. €15,175 per 1000 inhabitants. A sensitivity analyses using a range of 5% up to 33% 
lower value surgery suggests that the potential avoidable costs range between €63 million 
and €419 million per year, which means €3,794 to €25,038 per 1000 inhabitants (Table 8). 
In England about 4,600,000 surgical procedures are performed yearly.   The 29,196 
identified lower value surgical procedures represent 0.63% of all surgical procedures. 
Assuming that 20% of all procedures are of lower value, the potential costs savings (using 
actual costs) that could be saved amount to about € 1.5 billion per year, and € 28,534 per 
1000 inhabitants. Sensitivity analyses assuming a range between 5 and 33% lower value 
procedures, showed a potential cost saving varying between €382 million and €2.5 billion, 
i.e. €7,133 and €47,081 per 1000 inhabitants (Table 9).
Table 8: Sensitivity analysis extrapolation model for the Netherlands: extrapolating results of 
calculation model using actual costs
Table 9: Subanalysis: Sensitivity analysis extrapolation model for England: extrapolating results of 
calculation model using actual costs
31
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Discussion
Our results show that about half (23 out of 52) of the proven lower value surgical 
procedures are not performed anymore, at least not in the Netherlands. On the other 
hand, our results also show that still about €60 million per year can be saved if the other 
proven lower value surgical procedures would not be performed anymore, in England 
and the Netherlands alone. If we extrapolate this to all potential lower value surgical 
procedures, conservatively assuming that the percentage of lower value surgery will be 
between 5% and 33%, the potential avoidable costs in the Netherlands and England alone 
vary between €445 million and €2.9 billion per year. 
These findings are consistent with the notion that avoidable costs are evident in healthcare 
and that overtreatment is one of the major contributors.(54) A claim-based study, focused 
on the US Medicare population, also showed a potential cost saving of billions using 
another subset of interventions.55
The major strength of this study is the combination of the NICE do not do recommendations 
with indication specific volumes and costs (both using cost-effectiveness studies and 
reimbursement tariffs). This provided the unique opportunity to calculate evidence-based 
potential cost savings of lower value surgical procedures. 
Some potential limitations should also be discussed. First, we realize that in practice there 
will always be (subsets of) patients for whom a specific procedure does provide health 
benefit. However, this does not mean that the use of the procedure should be continued 
in all patients. Instead, routine use should be stopped, and future research should be 
aimed at identifying those patients who benefit from the procedure, for example by 
means of individual patient data meta-analyses and stratified decision analysis.56,57 
Second, in England no indication specific utilization data were available. We therefore 
had to assume that the indication specific percentages in England were comparable to 
those in the Netherlands, whereas the overall utilization data of both countries show 
large variations in volume (taking the number of inhabitants into account). For example, 
the number of caesarean sections was much higher in England. However, in the best 
possible way our results provide an estimation of the potential cost savings in England, 
instead of providing exact numbers. Third, due to the lack of indication specific utilization 
data in England, we also had to exclude the 23 procedures that were not performed in 
the Netherlands from all further analyses (see Appendix). However, since NICE provides 
national guidance and advice to improve healthcare in England, it is expected that at 
least part of these 23 procedures will still be performed in England. As a consequence, 
our estimations are probably an underestimation of the potential cost savings of proven 
lower value procedures in England. Fourth, the indication-based volume data from Dutch 
Hospital Data used in the main analyses did not always exactly match the do not do 
recommendations, i.e. sometimes the do not do recommendations were more specific 
than could be obtained from Dutch hospital data. To match the more detailed indications 
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from the do not do recommendations we included only 50% of the obtained volumes in 
14 procedures. This has probably resulted in an underestimation of the potential cost 
savings. We provided a range of potential cost savings by performing a sensitivity analysis 
in which we varied this percentage (using 33 and 66%). Fifth, for 15 procedures we could 
use data from cost-effectiveness studies, whereas for the other eight procedures only the 
initial costs of treatment could be taken into account, which might again have led to an 
underestimation of the potential cost savings. For two procedures, we had to make an 
estimation of costs based on the same surgical procedure for a different indication. 
Despite these limitations the present study provides important insights in the extent of 
avoidable costs in surgical care. Considerable resources could be saved by not performing 
surgical care that is known to be of lower value for patients. Ultimately, this could lead 
to lower healthcare spending by society without jeopardizing patients’ health. The 
extrapolation model suggests that withholding lower value surgical procedures may 
play an important role in sustaining an affordable healthcare system. The most relevant 
question therefore is how to withhold these lower value surgical procedures since it is 
known that with hindsight judging procedures undesirable is difficult.31,58 Particularly 
in the surgical field, high quality research is often lacking, which is also reflected in the 
low percentage (i.e. 6%) of surgical procedures in the do not do recommendations.59 
Furthermore, abandoning procedures at a late stage is inefficient, given the considerable 
investments that have been made. The (early) assessment of the potential value of a 
surgical procedure as suggested by the IDEAL collaboration to steer its development and 
prevent ineffective surgical procedures from entering the market is needed and should be 
complemented by a system of governance to make decisions about whether to continue 
the development and use of new procedures and under what conditions.4,6,60
In conclusion, lower value surgical procedures are creating a significant waste in healthcare 
systems. Even our conservative estimations show a waste that amounts to billions of 
Euros in the Netherlands and England alone. Evidence-based surgery could reduce this 
waste and thereby result in considerable savings.
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Appendix: Overview of the lower value surgical procedures (as reported in the NICE do not do 
recommendations) that were no longer performed in the Netherlands and therefore excluded 
from the analyses
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*No specific code in Dutch hospital data
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Abstract
Background: Early oral cavity squamous cell carcinoma (OCSCC) management appears 
to vary both within and between countries. Variation in practice can be an indicator 
of absence of evidence-based management and may negatively influence survival and 
morbidity of OCSCC patients not receiving optimal treatment. The exact variation in 
practice and the relationship of the variation to differences in guidelines are unknown. 
This study aimed to report on these international variations in the Netherlands, UK, and 
USA, and to evaluate them. 
Methods: Information regarding the international variation in OCSCC management 
strategies was obtained from a questionnaire sent to representatives of head and neck 
cancer centers in the Netherlands, UK, and USA. Within-country and between-country 
variations were also assessed in light of the different guidelines and health systems. 
Results: In total, representatives of 45 HNC centers completed the questionnaire; 10 from 
the Netherlands, 26 from the UK and 9 from the USA. Our results demonstrate a distinct 
variation in the management strategy of OCSCC, both within and between countries. This 
variation was present in diagnostics, treatment and follow up. Only a small amount of 
variation between countries could be linked to differences in guidelines. 
Conclusions: In conclusion there is high variation in the management of the neck in OCSCC. 
There seem to be a need for direct evidence about optimal management decisions to 
establish more evidence-based management and more uniform practice patterns.
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Introduction
Cancers of the oral cavity are an important public health issue in many countries.61 
The vast majority of these cancers are oral cavity squamous cell carcinomas (OCSCC).11 
Regional lymph node metastases occur frequently and can decrease survival drastically 
compared with no regional lymph node involvement.14,62 Therefore, adequate diagnostic 
assessment and treatment of the neck is considered to be crucial. However, the head and 
neck region is anatomically complex, and treatments can have a high impact on quality 
of life.18,19,23 Therewith, decisions regarding both the assessment and treatment of the 
neck have been the subject of debate for many years. Multiple diagnostic modalities 
are available for detecting lymph node metastases, ranging from palpation to imaging 
techniques, such as computerized tomography (CT), magnetic resonance imaging (MRI), 
ultrasound (US), and ultrasound-guided fine-needle aspiration cytology (USgFNAC). Even 
when no metastases are demonstrated by these diagnostic modalities (i.e. clinically 
negative node [cN0]), a high rate of occult metastases remains. Traditionally, treatment 
of the cN0 neck consists of an elective dissection of the neck or a watchful waiting (WW) 
policy. More recently, the sentinel node biopsy (SNB) procedure has been added to the 
diagnostic armamentarium. With this procedure, the metastatic status of the neck can be 
more accurately assessed.63-65
Until recently, (modified) radical neck dissection was considered to be the appropriate 
surgical treatment if lymph node metastases were detected. After selective neck dissection 
became the standard type of dissection for the cN0 neck, the efficacy of selective neck 
dissections in the clinically positive neck (cN+) has been explored as well.26 The use and 
duration of regular follow-up of OCSCC patients after neck surgery and WW have also 
been questioned over the past few decades.66 
Despite the amount of research published in the literature, the management of early 
OCSCC appears to vary both within and between countries; even between countries with 
a similar level of development. Variation in practice can be an indicator of absence of 
evidence-based management and may negatively influence survival and morbidity in 
those OCSCC patient populations that do not receive optimal treatment. Moreover, the 
variation in practice may also hamper the execution of international multicenter trials.
However, the exact variation in practice is unknown. Furthermore, it is not known whether 
some variation could be explained by differences in organization of healthcare between 
countries or by differences in guidelines.
The aim of the current study was to report on the international variations in the 
management of early (T1–2) OCSCC in the Netherlands, UK, and USA. Furthermore, we 
will report on differences in guidelines and healthcare systems. 
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Materials and Methods
Design
This was a cross-sectional study using a convenience sample of centers treating OCSCC 
and an electronic online questionnaire (survey monkey).67
Questionnaire development
The questionnaire was based on both the literature and interviews with several specialists 
in the field of head and neck cancer (HNC), including two otolaryngologist/head and neck 
surgeons, three oral and maxillofacial head and neck surgeons, a radiologist specialized in 
HNC, and an oral cancer researcher. We piloted the questionnaire using five surgeons, and 
made some final adjustments based on their comments and suggestions before general 
distribution. 
Study group
To obtain information regarding the international variation in the management 
strategies for early OCSCC, questionnaires were sent to representatives of HNC centers 
in the Netherlands, UK, and USA. These countries were chosen because of their assumed 
high quality of care, but very different healthcare systems. In the Netherlands, the 
questionnaires were distributed in cooperation with the Dutch Head and Neck Society, 
representing all eight HNC centers and their partner centers. Questionnaires were sent by 
e-mail to the members of the eight centers. These members were asked to distribute the 
questionnaire to possible partner centers. In the UK, the questionnaires were distributed 
in cooperation with the British Association of Head & Neck Oncologists (BAHNO) a 
multi-disciplinary society for healthcare professionals involved in HNC. The link to the 
questionnaires was distributed by e-mail and on the website of the BAHNO. In the USA, 
HNC specialists involved in treatment and research in the field of oral cancer were directly 
contacted by e-mail in which a link to the questionnaire was attached. The centers were 
assured that the results were anonymous.
Questionnaire content
The questionnaire was divided into the following two parts: questions on diagnostics, 
management of the cN0 neck, management of the cN+ neck, and standard follow-up 
strategy; and choice of a preferred strategy for two hypothetical cases of OCSCC with cN0 
necks in two different scenarios (see Box 1 for a description of the cases).1,2 Participants 
were ask to choose a treatment strategy for each patient according to two different 
scenarios, consisting of different primary tumor characteristics. In scenario one, the 
largest surface tumor diameter is 1 cm and the depth of the invasion is 4 mm. In scenario 
two, the largest surface tumor diameter is 2 cm and the depth of the invasion is 7 mm.
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Box 1: Description of hypothetical patient examples
Healthcare systems and guidelines
As sources of information on the distribution of healthcare systems, we used both 
the internet site and the report ‘OECD in Figures’ of the Organisation for Economic 
Co-operation and Development (OECD). For guideline comparisons, we used guidelines 
provided by the professional HNC organizations in the included countries.68-70
Data analysis
Within-country evaluations were performed for the Netherlands, UK, and USA to explore 
the current situation in the centers treating HNC. Between-country comparisons were 
performed to assess differences in trends among neck treatment in OCSCC of the included 
countries. These differences were also assessed with regard to the different guidelines 
and healthcare systems
Results
Participants
In total, representatives of 45 different HNC centers completed the questionnaire: 10 
from the Netherlands; 26 from the UK; and nine from the USA. Table 1 shows the number 
of patients treated per center in 2013. 
Patient I
Man, 75 years of age with squamous cell carcinoma of the tongue and a clinically negative neck. This 
man has been smoking 20 cigarettes and drinking 2 units of alcohol on average every day for the past 50 
years. He has multiple co-morbidities and has been living in a retirement home for 5 years. His quality of 
life is relatively low at present. He has some problems performing his daily activities, has pain (in his back 
and shoulder), and is quite anxious after receiving the diagnosis of oral cavity cancer. He also has some 
shoulder complaints. He is unable to lift objects above his head because of these complaints. However, the 
shoulder complaints are not always present.
Patient II
Woman, 55 years of age with a clinically negative squamous cell carcinoma of the tongue. This woman 
does not smoke, but drinks a few units of alcohol on average every day. She has no co-morbidity and works 
full time as a schoolteacher at a primary school. Her quality of life is currently relatively high. She has no 
problems with her daily activities and no pain, but is slightly anxious after receiving the diagnosis of oral 
cavity cancer. She has no shoulder complaints at present.
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Table 1: Number of patients with oral cavity squamous cell carcinoma at treated at the responding centers
Diagnosis
Table 2 provides an overview of the diagnostic modalities used to assess the neck in the 
Netherlands, UK, and USA, as well as the recommendations in the national guidelines. 
More specific information about diagnosis, i.e. which modality is deemed most reliable 
and the criteria for USgFNAC, is presented  below. 
In the Netherlands, all centers use USgFNAC, which is deemed to be the most reliable 
modality by all centers. The minimum axial size of the largest lymph node that should 
be present to indicate USgFNAC differed among the centers, as well as the method to 
measure this axial size. A minimum axial size of 5 mm is used as the criterion in seven 
centers (70%), whereas the other three centers (30%) use 3, 4, or 10 mm cut-off points, 
respectively. Seven centers (70%) measure the minimum axis diameter of the suspected 
lymph nodes, while two (20%) measure the long axis diameter, and one (10%) does not 
use a standard axis. 
In the UK, 24 centers (92.3%) use USgFNAC. However, only 12 centers deem USgFNAC 
(46.2%) to be the most reliable method, whereas eight centers deem positron emission 
tomography (PET), PET combined with computerized tomography (PET-CT), or CT the 
most reliable diagnostic modality. Minimum axial size of the suspected lymph node, as 
an indication for USgFNAC, is 10 mm in nine centers and 5 mm in two centers; the other 
centers do not use a strict cut-off point.
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In the USA, all centers use CT and all centers deem CT or PET/PET-CT to be the most reliable 
method. The minimal  axial size of the lymph node required to perform an USgFNAC is 
10 mm in all four centers using USgFNAC. Two centers perform fine needle aspiration 
without US guidance, and one center performs CT-guided fine needle aspiration biopsies.
Table 2: Diagnostic modalities performed to detect neck lymph node metastases.*
CT = computed tomography, MRI = magnetic resonance imaging, PET = positron emision tomography, 
USgFNAC = ultrasound-guided fine needle aspiration cytology.
*Multiple diagnostic modalities could have been selected by one center.
Management of the clinically negative neck
Table 3 provides an overview of the treatment strategies in patients with a cN0 neck in 
the Netherlands, UK, and USA, and the recommendations of the respective guidelines. 
Table 4 provides an overview of the important primary tumor characteristics used in 
management decisions concerning the neck. More detailed information about these 
tumor characteristics is given in Tables A1–A3 in the appendix. Tables A4–A6 show details 
of the techniques used to measure the depth of invasion of the primary tumor, the 
techniques to detect sentinel nodes and the chosen strategies depending on the results 
of the SNB, respectively.
In the Netherlands, both WW and elective neck dissection (END) are frequently used 
strategies. Furthermore 40% of the centers perform an SNB procedure in at least some of 
their patients. Primary tumor size is the main characteristic that influences the decision 
for a certain strategy.
In the UK, most centers use END and WW as strategies for the cN0 patients. Five centers 
(19%) sometimes perform an SNB procedure. Tumor size and depth of invasion are the 
main characteristics used to make treatment decisions.
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In the USA, all centers perform ENDs, whereas about half of the centers use WW. In 22% 
of the centers, an SNB is performed. Depth of invasion, tumor size, and tumor site are all 
deemed to be important for treatment decisions. 
Table 3: Treatment strategies performed in early stage clinically negative oral cavity squamous 
cell carcinoma.*
END = elective neck dissection, SNB = sentinel node biopsy.
*Multiple strategies could have been selected by one center.
Management of the clinically positive neck
Table 5 shows the primary treatment strategies in the case of a cN+ neck, and the 
recommendations of each of the national guidelines.
In the Netherlands, all centers use modified radical neck dissection as a strategy for cases 
with cN+ necks. Seven centers (70%) also perform selective neck dissections in selected 
cases with cN+ necks, of which two centers (29%) perform neck dissections of levels I–III 
and the other five (71%) level I-IV. Radiotherapy is only used in one (10%) of the centers 
in some of the cN+ cases.
In the UK, 15 (58%) centers perform modified radical neck dissection for cases with cN+ 
necks; 23 (50%) centers use selective neck dissections, which involve levels I–IV in most 
cases (65%). Radiotherapy is used in half of the included centers in cN+ necks.
In the USA, eight centers (89%) use modified radical neck dissections, while six centers 
(67%) use selective neck dissections for cases with cN+ necks. 
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Table 4: Primary tumor characteristics influencing the choice for the strategy for a early stage 
clinically negative neck.*,†
*Multiple characteristics could have been selected by one center.
†More details about characteristics involved can be found in the mentioned appendix tables.
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Table 5: Chosen primary treatment strategies in the case of a clinically positive neck.*
*Multiple treatments could have been selected by one center.
Follow-up
Table 6 shows the time intervals used by the centers to follow their patients, and the 
recommendations in each of the national guidelines. The diagnostic modalities used to 
detect regional failure during follow-up are listed in Table A7.
In the Netherlands, palpation and USgFNAC are used by 90% of the centers in the 
follow-up. In the UK, most centers (81%) use palpation in the follow-up. Ultrasound, 
USgFNAC, CT, PET/PET-CT and MRI are all modalities that are used in about 50% of the 
centers. In the USA, most centers (89%) use palpation, but also CT (78%) or PET/PET-CT 
(44%) are frequently used during follow-up. 
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Table 6: Time intervals between follow‐up consultations
Case examples with a cN0 neck
Table 7 shows the chosen strategies of the centers in two hypothetical cases of OSCC with 
a cN0 neck, in two different scenarios. The cases and scenarios are presented in Box 1.
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Table 7: Chosen strategies for two patients with a clinically negative neck in two different scenarios
END = elective neck dissection, SNB = sentinel node biopsy, WW = watchful waiting.
Health statistics and guidelines
In 2011, 16.9% of the gross domestic product was used for healthcare in the USA, 12.1% 
in the Netherlands, and 9.3% in the UK. In the same year, the number of doctors per 
1000 inhabitants was 3.1 in the Netherlands, 2.7 in the UK, and 2.4 in the USA, and the 
number of CT scanners available per 1 million inhabitants was 40.9 in the USA, 12.5 in 
the Netherlands, and 8.0 in the UK. In 2010, the number of MRI scanners per 1 million 
inhabitants was 31.5, 12.2, and 6.2 for the USA, Netherlands, and UK respectively.
Some differences exist in guidelines between the countries. The currently used Dutch 
guideline is from 2004, but it is being updated, while the UK (2011) and USA (2014) have 
more recent (updated) guidelines. 
The biggest difference between the guidelines exists in diagnostics. The UK and US 
guidelines mention that CT or MRI should be performed to detect lymph node metastases. 
In the Dutch guideline, USgFNAC is recommended. In the UK guideline, USgFNAC is 
mentioned as an alternative to detect lymph node metastasis, while USgFNAC is not 
mentioned in the US guideline.
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On the management of cN0 and cN+ necks, the basic recommendations of the three 
guidelines generally match, although there are some marked differences. The US guideline 
is the only one that has a clear recommendation about the use of tumor depth for the 
choice of strategy. There is no hard recommendation about the use of SNB in any of the 
guidelines. The US National Comprehensive Cancer Network (NCCN) incorporated SNB in 
their guideline as follows: ‘Sentinel lymph node biopsy is an alternative to elective neck 
dissection for the identification of occult cervical metastasis in patients with early (T1 or 
T2) oral cavity carcinoma in centers where experience for this procedure is available’. In 
the current Dutch guideline, it is stated that SNB should not yet be considered as standard 
modality. In the concept of the updated Dutch guideline, SNB is also considered to be 
an alternative to END [not yet published]. In the UK guideline, SNB is not recommended 
outside of clinical trials.
In the Dutch and US guidelines, it is stated that selective neck dissection could be 
considered in certain cases of limited nodal disease. In the guideline from the UK, selective 
neck dissection is explicitly recommended for pathologically confirmed disease with a 
single ipsilateral positive lymph node smaller than 3 cm (pN1 disease).
Discussion
Our results demonstrate a distinct variation in the management of the neck in OCSCC both 
within and between countries.
One of the obvious differences concerns the use of USgFNAC, which is used in the 
Netherlands and the UK, versus the use of CT and PET/PET-CT in the USA. Also notable is 
that WW is not often considered to be an alternative for management of the cN0 neck in 
the UK, and especially not in the USA. Furthermore, SNB is used in all three countries, but 
only in a limited number of centers. A lot of variability between centers was seen in the 
use of primary tumor characteristics in the management of the cN0 neck. In the USA, most 
centers take tumor size, site, and depth of invasion into account when making a decision 
for END, WW, or SNB, while this was less in the UK and the Netherlands. In the case of cN+ 
necks, there is variation in the type of neck dissections performed in all three countries, 
and the frequent use of primary radiotherapy for N+ cases in the UK is remarkable. Finally, 
there is quite some variation in the standard follow-up interval that is used.
In the presented hypothetical cases, variation in the chosen strategies in the cN0 neck 
was indeed apparent. The presence of variability in used management strategies was 
confirmed by the two cases. More variability was present in scenario I of both cases, 
reflecting that decisions are more complex for early stage tumors.
To the best of our knowledge, this study is the first study to provide insight into the 
differences in management of oral cavity cancer both within and between countries. The 
study covers a large part of the treatment pathway for these patients, and shows detailed 
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information along all parts of the pathway. Others have performed similar surveys over 
the years within one country. Werning et al. used a survey with a clinical scenario which 
was comparable to scenario II of our cases to determine the approach to the cN0 neck 
in the USA. Of the 313 otolaryngologists, 66% would perform END, while 16% preferred 
radiotherapy, and 13% preferred to observe the patient. In our hypothetical cases, all 
respondents from the USA would perform END.71 In a study by van de Bree et al.a similar 
patient was presented to the eight main Dutch HNC centers.18 Of these centers, 75% would 
treat this patient with END, while 25% would opt for WW.72 In the current study, 67% or 
78% would choose END, depending on the overall status of the patient. The remaining 
centers would use SNB. It seems like the SNB has replaced WW in this presented case in 
the Netherlands. Looking at these two comparisons with earlier performed surveys, it 
seems that surgeons let tumor control prevail above the morbidity of surgery. 
The current study includes all main centers in the Netherlands and a high number of 
centers in the UK. The low number of responding centers in the USA was, however, the 
major limitation of this study. However, most of the responding centers from the USA were 
high-volume centers, treating a high number of patients per year (Table 1). We therefore, 
believe that the results provide a reasonable impression regarding the management of 
the neck in oral cancer in the USA. 
Some of the observed variation could be related to differences in healthcare systems and/
or guidelines. The frequent use of CT in the USA and the high use of USgFNAC in the 
Netherlands could be related to the differences in guidelines. Why these differences exist 
in the guidelines, despite the same available evidence, is unclear but may be explained by 
‘tradition’. Furthermore, the depth of invasion was used in all centers in the USA to guide 
the management of the cN0 neck. This may be caused by the fact that the US guideline is 
the only one that has a clear recommendation on the use of depth of invasion. Another 
finding that could be explained by the difference in guidelines is the higher use of selective 
neck dissection in cN+ necks in the UK compared with the Netherlands and the USA.
Besides differences in guidelines, differences in healthcare systems are also present 
between the included countries. This could be an explanation for some of the variations 
like the high use of CT in de USA. Although, it is difficult to directly link information about 
the healthcare systems to the existing variations, it is important to keep such differences 
in mind when evaluating the variation in used strategies, especially between countries.
Although some variation could be explained by differences in healthcare systems between 
countries, it is likely that an important part of the differences in the results is due to the 
absence of clear evidence about optimal management of the neck in early stage OCSCC. 
Much research on management of the neck in OSCC patients has already been published, 
but the evidence apparently is insufficient to guide decisions in an uniform manner. 
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Conclusion
In conclusion, there is high variation in the management of the neck in early OCSCC. Direct 
evidence about optimal management decisions, deriving from sources such as direct 
comparison in decision models or comparative effectiveness studies, seems to be needed 
to establish more evidence-based management and more uniformity in clinical practice. It 
is likely to result in better quality of care and facilitates international multicenter studies. 
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Appendix: More specific results of the questionnaire.
Table A1: Tumor size influencing the choice of primary treatment in early stage clinically 
negative oral cavity squamous cell carcinoma.
END =elective neck dissection, SNB sentinel node biopsy, WW, watchful waiting.
Table A2: Tumor sites where the strategy concerned is more often performed in clinically negative 
oral cavity squamous cell carcinoma.*
*Multiple sites could have been selected by one center.
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Table A3: Depth of invasion cut‐off points influencing the choice for primary treatment in early 
stage clinically negative oral cavity squamous cell carcinoma.
CT = computed tomography, END = elective neck dissection, MRI = magnetic resonance imaging.
Table A4: Diagnostic techniques performed to measure invasion depth of the primary tumor (in 
centers that perform END and use invasion depth as a parameter).
Table A5: Techniques used to detect the sentinel node(s) in centers performing SNB
SNB = sentinel node biopsy, SPECT = single-photon emission computed tomography.
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Table A6: SNB results and consequences in centers performing SNB.
SNB = sentinel node biopsy.
Table A7: Diagnostic modalities used to routinely detect regional failure during follow‐up.*
CT = computed tomography, MRI = magnetic resonance imaging, PET = positron emission tomography, 
USgFNAC = ultrasound-guided fine needle aspiration cytology.
*Multiple modalities could have been selected by one center.
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Abstract
Background: Contemporary operating theaters (OTs) are built that are targeted at research 
and development and evidence-based surgical innovation. We explored the benefits of an 
interactive evaluation (IE) in innovating HNC-care related to these OTs. 
Methods: An IE involves anonymously exchanging concerns, claims, and issues between 
stakeholders during interviews. Interviews were transcribed and analyzed. After the first 
interview cycle, we circulated a summary of important issues among stakeholders, to which 
they responded in the second cycle. Finally, we summarized topics and recommendations 
on which consensus was achieved. 
Results: Most stakeholders agreed that the time interval between diagnosis and treatment 
is too large. Secondly, communication and information across disciplines should be 
improved. Furthermore, all stakeholders agreed that research on resection margins is 
highly valuable. 
Conclusions: This pilot study showed that IE could be a valuable method for innovating 
HNC-care and other multidisciplinary fields.
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Chapter 4
Introduction
Every year half a million people worldwide are diagnosed with head and neck cancer (HNC). 
Involved risk factors are substantial alcohol use and smoking.8,73 Anatomic and pathological 
variability of HNC makes treatment complex and this contributes to the fact that quality of life 
of patients is affected by treatment.74 An important aspect of the complexity of treatment 
is the relative high incidence of occult metastasis; new techniques, are aimed at optimizing 
diagnosis and treatment of metastases.75 Furthermore, a lot of research and innovations 
are designed to improve survival and quality of life.8 Because of these complexities, the 
management of HNC patients urges a multidisciplinary approach.74
This study focuses on innovations in HNC care. In the Radboud University Medical Center, 
Nijmegen, the Netherlands (Radboudumc), state of the art operating theaters (OT’s) are 
being built, targeted at research and development of evidence based surgical innovations 
including the whole process before and after surgery. The ultimate goal is to deliver more 
efficient care and improve short- and long-term patient outcomes and satisfaction.76 
To reach this goal we have to know what stakeholders expect and how the health care 
pathway should be adapted to improve patient outcome and satisfaction. 
Successfully innovating the HNC health care pathway requires that complexities are 
acknowledged and that innovations conform to the perspectives of experts involved. Our 
hospital believes that this includes the perspective of the patients, as patient involvement 
is crucial to improving health service delivery and quality.77 Moreover, this implies that 
the whole health care process should be considered, not only the actual surgery in the 
OT.78
Interactive evaluation is a kind of fourth generation evaluation that is aimed at 
systematically eliciting the views of persons involved, particularly their norms and values, 
and on this basis identify shared values.79 Next, it seeks to develop a shared view on where 
the technology should develop, what are desirable scenarios, and what are appropriate 
outcome measures for assessment. 
Interactive evaluation matches the contemporary ideal of participatory medicine, a 
model of cooperative health care that seeks to achieve active involvement by patients, 
professionals, caregivers, and others across the continuum of care on all issues related 
to an individual’s health. Choices that are made in policy research should be such, that 
the various stakeholders consider the results relevant and valid. To help achieve this, it 
has been suggested that a scoping exercise should be conducted. That is, efforts should 
be made to elicit stakeholders’ perspectives and invoke these in the assessment. There 
are several reasons for performing such participatory research. First, it is acknowledged 
that a technology (defined as prevention and rehabilitation, vaccines, pharmaceuticals 
and devices, medical and surgical procedures, and the systems within which health is 
protected and maintained) is not just an isolated artifact or device, but something that 
is interwoven with a societal context to be addressed. Participatory research leads to a 
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better understanding of what a technology actually does in a societal context. Second, 
participation opens large sources of relevant expertise and thus generates potentially 
important information, i.e. it helps to identify a fairly comprehensive list of perspectives 
and issues related to a technology. Interactive evaluation as suggested in this proposal 
distinguishes itself from participatory evaluation in that participants are not only 
consulted, but interact with each other. The resulting learning process helps to ensure 
that views are well considered, that the expertise, knowledge and creativity available 
within the field is used, and that stakeholders have an opportunity to develop a shared 
view on the technology under consideration. Furthermore, the synthesis of perspectives 
may result in fairly creative solutions. In other words, interactive evaluation will help to 1) 
identify criteria of merit and acceptability of the new technology; 2) achieve agreement 
about regulations (policy recommendations) to be implemented to meet these criteria; 3) 
formulate relevant research questions.
An interactive evaluation seems a suitable tool to investigate all these views of stakeholders 
on the innovation of the HNC health care pathway. Therefore, the primary aim of this pilot 
study is to explore the benefits of an interactive evaluation in the context of innovating 
and improving HNC care. Hence, we answered the following questions: what is the 
perspective on improving the current head and neck cancer health care process shared by 
all stakeholders involved? How would these stakeholders define and prioritize targets for 
optimizing this process and goals for improvement?
Materials and Methods
We identified stakeholders on the basis of the HNC care pathway and snowball 
sampling(79). Subsequently, semi-structured, in-depth interviews were conducted with 
each of the stakeholders, who were visited in their natural environment, mostly at their 
workplace. After a first cycle of interviews, a second cycle ensued. Two interviewers were 
involved. Each stakeholder was interviewed twice by the same interviewer. 
The interviews were recorded, transcribed verbatim and analyzed using ‘Atlas.ti 7 
software’ for qualitative data analysis.80 We analyzed the interviews by open coding 
to mark relevant issues and topics.81 Moreover, we used the method of reconstructing 
interpretative frames to distinguish between problem definitions, solutions, empirical 
background knowledge, and normative preferences of each stakeholder.82 After each 
interview, a summary was returned to the participant for validation (member checking). 
A network analysis was performed to generate a network view and identify overarching 
issues.
During interviews, stakeholders were invited to respond to rival claims as forwarded by 
other stakeholders. In order to prevent power and the quality of existing relations having 
an unwanted impact on the evaluation, this exchange of arguments was performed 
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anonymously. The idea is that the ensuing interaction leads to a process of vicarious 
learning and the development of a shared view on the quality of the Health Care Pathway 
(HCP).
During the first interview cycle, we focused on quality of care and on the current HCP. 
After this cycle, we circulated an overall summary of the most important issues among 
stakeholders to which the stakeholders could respond in the second cycle. Eventually, the 
results from the interviews provided policy recommendations, based on issues on which 
the various stakeholders had reached consensus. 
Results
Respondents
Thirteen stakeholders were invited to participate in this study, of whom 12 were willing 
to take part (see Table 1). One stakeholder refused because of concerns about the 
interpretation of outcomes of the IE. Moreover, one stakeholder did not participate in 
the second interview cycle due to time constraints. Interviews lasted between 18 and 
90 minutes. We performed two interview cycles and anonymity of stakeholders was 
warranted. The results of the network analysis are shown in Appendix A. Topics that 
surfaced most often will be described in the following paragraphs. 
Current HCP
After visiting the General Practitioner or Dentist (GP/D), patients are sent (often via a 
general hospital) to a specialized hospital. Eight medical centers (with or without a preferred 
partner clinic) in the Netherlands provide HNC health care, which are all connected to the 
Dutch Head and& Neck Society (DHNS/NWHHT). In the Radboudumc, two departments 
preside in providing care for patients with (suspected) HNC: the department of Oral & 
Maxillofacial Surgery (OMF) and the department of Otorhinolaryngology and Head and 
Neck Surgery (ENT). All stakeholders were positive about this collaboration and they 
mentioned that many health care professionals are very dedicated to providing care for 
the HNC patients. The diagnostic process contains two days in which several examinations 
are done in order to diagnose patients. Subsequently, a multidisciplinary team meets 
weekly to discuss treatment options of specific patients. These treatment options are 
discussed with the patient, usually consisting of surgery, radiotherapy, chemotherapy or a 
combination of these. Consequently, the patient will be treated and afterwards follow-up 
care is given at the outpatient clinic. 
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Table 1: Overview of participating stakeholders
Continuity of care
Constraints and improvements were mentioned concerning the continuity of the HCP. 
Stakeholders described that the pathway from GP/D to one of the eight HNC centers, spans 
an unduly long time interval of approximately six weeks. Patients said they experienced 
much uncertainty during this period, caused by a lack of information. According to some 
stakeholders, creating awareness among health care professionals in primary health care, 
and consequently accelerating the referral to a specialized hospital can save time.
All stakeholders, except for one patient, mentioned that the waiting time between 
diagnosis and surgery should be reduced. The guideline of the NWWHT states ‘waiting 
time’ is defined, as that 80% of new HNC patients has to start their curative therapy within 
30 calendar days.83 They stated that being diagnosed in two days is out of proportion to 
a waiting time of about a month to the start of treatment. The capacity of the operating 
theatres (OT’s) was mentioned as the main cause of the long time interval. Another factor, 
which was also identified in relation to other issues, is the large fluctuation in the number 
of newly diagnosed patients. 
Ideas were suggested to shorten this ‘waiting-time’ interval, such as a flexible planning of 
available time at OT’s for ENT and OMF. Due to fluctuations in newly diagnosed patients 
and the sometimes complex and time-consuming procedures, it is not possible to exactly 
predict the hours needed at the OT’s. As a result, the only possibility to deliver care 
without knowing how many patients will need surgery a week, is to adjust the planning to 
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allow for more flexibility. A second solution would be to extend the current working hours 
and days. For example, health care professionals should start working in the evening or 
at a Saturday morning. Stakeholders were positive about this solution. However, more 
personnel should be hired to fill these hours, which raised the question whether this 
would be affordable. 
Information and communication
Continuity of care was also associated with communication between health care 
professionals. Many of the communication failures between health care professionals 
seemed to be caused by incorrect communication and provision of information. Four 
stakeholders mentioned that a better understanding of the work of colleagues in adjacent 
fields of health care would be beneficial for the health care process, partly because of 
such understanding could improve mutual acceptance of acknowledgement of choices 
made. In order to improve teamwork, communication, and streamlining of the process, 
two stakeholders proposed to implement a yearly audit with all health care professionals 
involved (GP/D, paramedical professionals, surgeons) and patient associations. One 
stakeholder proposed to create a head and neck oncology department at which all 
professionals within HNC care should be located. Most of the other stakeholders did, 
however, not agree. The most important reason was that this would be very costly and 
not efficacious. 
Many stakeholders said that treatment-information is hard to find and not clearly 
described. Patients experienced unmet information needs during the time interval 
between referral from a GP/D to a medical center. All stakeholders supported the idea 
of creating a national website with accurate information of all medical centers treating 
HNC. Moreover, stakeholders described that the post-treatment period is difficult for 
patients. For example, patients experience eating- and speaking problems, and have great 
difficulties finding relevant information. Patients no longer have (weekly) appointments at 
the medical center and they have to face their problems by themselves. Stakeholders said 
that patients cope differently with their HNC-related problems. 
Surgical innovation 
An issue raised by both surgeons and patients, was the completeness of resected tumors. 
The surgical margins are an important factor for prognosis and for determining whether 
further treatment is necessary. Patients said they lived in uncertainty for about a week 
after surgery, before receiving the results of the pathological examination of these margins. 
One of the patients mentioned that receiving unfavorable results account for the most 
impactful event during the disease. The surgeons mentioned that during surgery, they do 
not know whether they removed enough tissue to eliminate all tumor cells. Both patients 
and physicians indicated that solving this problem is of high importance and would have 
a significant impact on head and neck cancer. They suggested that studies at the research 
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Ots should be focused on imaging of the primary tumor and resection margins during 
surgery. From the perspective of radiotherapy, imaging by a CT- or MRI-scans could be 
feasible to improve the accuracy of radiotherapy. 
Currently, the status of the neck is a controversial topic in treatment of HNC, because 
of the relative low sensitivity of current diagnostics for cervical lymph node metastases. 
A sentinel node biopsy is a relatively new technique that has a high sensitivity for these 
metastases. The sentinel node biopsy technique (SNB) was discussed during the interviews 
with stakeholders. Stakeholders did, however, not agree as to whether this technique 
should be used regularly in the near future, because according to them, currently available 
literature is not consistent about this topic. Therefore, they stated that research into SNB 
at the new Ots would be valuable. 
Discussion
In this study, we explored the potential value of interactive evaluation for innovation in the 
field of HNC care. As a result, we found that stakeholders agree on the following issues. 
First of all, the continuity of the HCP should be improved. The most important issue in 
this respect was the ’waiting time’ between diagnosis and treatment. Most stakeholders 
stated that this interval was too large, and called for more flexible planning of the OT 
capacity and possibly extended working hours. Secondly, the study showed that the 
quality of information and communication across disciplines should be improved. Thirdly, 
all stakeholders agreed that research on resection margins is highly valuable and ought to 
be an important focus of research. 
As far we know this is the first interactive evaluation to study the quality of HNC care and 
identify priority targets for innovation. Although this has been an exploratory study, we 
already perceived some important benefits of our approach. First of all, we were able to 
include perspectives of different stakeholders in the field, and succeeded in identifying a 
few widely endorsed recommendations, whilst a few other suggestions could efficiently 
be shown to be less effective, feasible, or appropriate. Secondly, by including various 
stakeholders, we were able to study HNC care from an integrated perspective. As a 
result, continuity of care could properly be discussed across disciplines and departments, 
whereas otherwise such discussion would have been confined by the boundaries of a 
specific discipline or department (e.g. OT’s) and opportunities for improvement would 
have been limited accordingly. Furthermore, an important feature of this method is the 
incorporation of the patients’ perspective. The added value of this shows for instance in 
the issue of the interval between diagnosis and treatment, on which not every patient 
agreed with the health care professionals. Finally, this method prioritized the issues we 
should focus on in the future. The results showed that patients as well as health care 
professionals agreed on investigating innovative techniques regarding resection margins.
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Importantly, we believe that the procedure of involving stakeholders ought to be valued in 
itself, apart from the results. Six stakeholders mentioned that they were glad to read that 
other stakeholders shared their vision regarding specific topics. One stakeholder said that 
he learned from views of other stakeholders by participating in our study. By providing 
persons involved with a sense of ownership, future improvements in HCN care probably 
meet with more acceptance and therefore are more feasible.
Some limitations of this study should also be discussed. First, we included a limited 
number of stakeholders in this study, although we do believe that the included 
stakeholders represented the most important perspectives. Second, we were confronted 
with a stakeholder refusing to participate. Since the evaluation was targeted at the local 
situation and hence the person in question is properly regarded an expert rather than a 
stakeholder, it was not too problematic. However, it does alert us to the fact that by its 
very nature interactive evaluation depends on participants willing to discuss the status 
quo and abide by the results of the procedure. In this sense, interactive evaluation affects 
the power balance that usually shapes practice.84 
In conclusion, we showed that an interactive evaluation can be used to develop a widely 
endorsed perspective on how to identify and prioritize viable innovations in health care. 
The results obtained in this study suggest that innovation of HNC care should focus on 
flexible OT planning to reduce the time between diagnosis and treatment, improved 
interdisciplinary communication, and research into resection margins.
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Abstract
Background: The aim of the study was to systematically assess the accuracy of a sentinel 
lymph node biopsy (SLNB) in cT1/T2N0 oral cavity and oropharyngeal squamous cell 
carcinoma patients.
Methods: We searched electronic databases, including EMBASE and MEDLINE (Pubmed) 
up to November 7 2012, by combining oral cancer keywords with sentinel node biopsy 
keywords. We included diagnostic accuracy studies which used neck dissection or follow-up 
as a reference test for the sentinel node biopsy. Study characteristics and measures of 
accuracy were extracted. Diagnostic accuracy was calculated from 2 x 2 tables. 
Results: 21 studies (847 patients) could be included. Most of these patients had oral 
cavity squamous cell carcinoma (OCSCC). The pooled data showed an overall sensitivity 
of 0.93 [95% CI 0.90-0.95]. Subgroup analysis showed no significant differences between 
subgroups. 
Conclusions: The high sensitivity of SLNB supports a role in the diagnostic work-up of 
OCSCC.
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Introduction
Oral cavity and oropharyngeal squamous cell carcinoma (OCSCC and OPSCC) are 
considered an important part of the global burden of cancer, mainly due to the widespread 
use of tobacco and alcohol.61 The most important prognostic factor is the presence of 
cervical lymph node metastases, which can decrease the 5-year survival rates to lower 
than 50%.14 Exact staging of the neck is therefore crucial in managing this type of cancer. 
Staging by palpation and imaging techniques (eg. MRI, CT, ultrasound-guided fine needle 
aspiration cytology (USgFNAC) are not sensitive enough in detecting micrometastases, 
resulting in a high incidence of occult metastases in the neck.85 In the literature rates 
between 23% and 43% have been reported.86 Because of this, elective neck dissection 
(END) is the standard of care in clinically negative necks (cN0) of early stage (T1/T2) oral 
cavity and oropharyngeal squamous cell carcinomas in most institutions. However, this 
implies overtreatment and treatment-associated morbidity in the majority of patients.18 
Sentinel lymph node biopsy (SLNB) has emerged as an alternative or additional staging 
procedure. The SLNB procedure is based on the concept that tumor cells will spread 
from the primary site to a single node or group of nodes (the sentinel nodes), before 
progressing to the remainder of the lymph nodes. A radiotracer, possibly in conjunction 
with colored dye injected into the primary tumor allows for identifying the sentinel nodes. 
Radiolocalization of the sentinel node consists of a preoperative lymphoscintigraphy 
either or not with SPECT/CT and the intraoperative use of a hand-held gamma probe 
and/or portable gamma-camera.87 Histopathological evaluation of sentinel nodes may 
allow accurate prediction of the disease status. False negative results can have several 
causes  including uneven radionuclide injection, obscuring of sentinel lymph nodes by 
the radioactive signal of the primary tumor, and lymphatic obstruction by gross tumor, 
resulting in redirection of lymphatic flow.88 
Although SLNB is still an invasive procedure, it gives less morbidity than selective 
neck dissection by sparing relevant structures.63,64 Therefore, SLNB can have great 
consequences for the treatment of OCSCC and OPSCC patients. More accurate staging of 
the neck by SLNB could be a serious alternative for direct elective neck dissection. 
The aim of this diagnostic meta-analysis therefore was to study the diagnostic accuracy of 
SLNB in cT1/T2N0 oral cavity and oropharyngeal squamous cell cancer patients. 
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Materials and Methods
Data sources and searches
We searched electronic databases, including EMBASE and MEDLINE (Pubmed) from 
inception up to November 7 2012, by combining oral cavity cancer keywords with sentinel 
node biopsy keywords (see Appendix). No restrictions on language were used in the 
search. All citations identified by the search were imported into a EndNote bibliographic 
database.89 
Study selection
Initially the titles and abstracts of the search results were screened. Subsequently, the 
reports were reviewed according to pre-defined inclusion and exclusion criteria.
We included studies if they fitted the following criteria: Human cT1/T2N0 oral cavity and/
or oropharyngeal cancer patients; Full text available in English; Possible to derive absolute 
numbers of observations (True Positives [TP], False Positives [FP], False Negatives [FN] and 
True Negatives [TN]; Reference standard was a neck dissection or a follow-up of at least 18 
months; The target condition was metastasis in one on the lymph nodes of the neck (pN+). 
Case studies were excluded. 
Data extraction and quality assessment
In order to obtain 2 x 2 contingency tables from the included studies, we extracted or 
calculated TP, FN and TN. In sentinel node biopsies FP results are not possible. The number 
of observations (TP, FP, FN and TN) were extracted separately for OCSCCs and OPSCCs 
when possible.
We designed a data extraction form specifically to collect details from selected studies. 
The following data were extracted for each individual study: Sentinel node detection 
rate (percentage of patients in whom at least 1 sentinel node was detected for biopsy), 
previous diagnostics (N0 determination), age and gender distribution, SLN identification 
(lymfoscintigraphy, gamma probe and/or blue dye substance), histology (H&E staining 
and/or immunohistochemistry), levels of neck dissection or mean follow-up time as 
reference standard, study design, aim of study, country, year, and whether or not it was a 
multicenter study. The quality of the included studies was assessed using the QUADAS-2 
tool for diagnostic studies.90
Analysis
We constructed 2 x 2 contingency tables of TP, FP, FN and TN cases in RevMan 5.91 
We calculated sensitivity with a 95% confidence interval (CI) for each study separately. 
Because SLNB cannot be false positive, the specificity and the positive predictive value 
of the test are always 1. We used the the statistical software package SAS to carry out 
the meta-analyses.92,93 Two subgroups of clinically relevant covariates; primary location 
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(oral cavity or oropharynx) and sentinel node protocol were analyzed on the sensitivity 
of SLNB. Furthermore, we performed subgroup analyses to assess possible differences 
in sensitivity between studies using a neck dissection or follow-up as the reference test.
Results
In total 1884 studies were identified. After removal of duplicates and screening of 
titles and abstracts, 116 studies were selected for a full text evaluation. 21 studies 
fulfilled the inclusion criteria and a data extraction form was completed for these 
studies (Figure 1).88,94-113 Study characteristics and treatment protocols of the 21 
included studies are listed in Table 1A. Population characteristics are listed in Table 1B.
The studies contained 847 cases in total. Most studies also mentioned the detection rate 
of sentinel nodes. In these studies at least one sentinel node was detected in almost all 
patients and a sentinel node biopsy could thus be performed in 835 patients (Table 2). In 
8 studies it was possible to split the results of SLNB in OCSCCs and OPSCCs, in 3 studies 
it was not possible to split the results of OCSCCs and OPSCCs, 9 studies only included 
oral cavity patients and 1 study included only OPSCC patients. As a result, 508 cases had 
OCSCCs, 131 cases had OPSCCs cancers and in 195 cases it was unclear if they had oral 
cavity or oropharyngeal cancer. 
Figure 1: Flowchart of systematic search
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Table 1A: Study characteristics and protocols
* Oral/Orop: separation in results between primary locations (Oral cavity/Oropharynx) possible , 
Oral+Orop: separation in results not possible
† L= Lymfoscintigraphy, G = gamma probe, B = blue dye substance, SPECT=Additional single photon 
emission computed tomography
‡ H = H&E staining , I = Immunohistochemisty
# ND=neck dissection, FU=watchful waiting
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Table 1B: Population characteristics
*Characteristics are only known from the total population of the study which can include >T2, N+ 
or other primary sites than oral cavity or oropharynx. Characteristics are oral cavity + oropharynx 
if applicable
Quality of included studies
Risk of bias varied among the studies (Figure 2). Risk of bias regarding patient selection 
was high in seven (33%) studies mostly due to inappropriate exclusion of deeply invasive 
tumors. Risk of bias regarding index test and reference standard was unclear in 15 (71%) 
and 17 (81%) studies, respectively. In almost all these studies it was unclear if the index 
test and reference test were interpreted independently from each other. For risk of bias in 
flow and timing there were eleven (55%) studies with low risk and six (29%) studies with 
high risk. There was less concern about the applicability of the studies (Figure 3). Only 
in two (10%) studies there was concern about the applicability because of the patient 
selection, and in 1 (5%) study about the reference test .
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Table 2: Detection rate
Results are for oral cavity and oropharyngeal cancers if applicable
Diagnostic accuracy
The forest plot in Figure 4 shows the number of TPs, FPs, FNs, TNs and the sensitivity 
of all included studies. The pooled estimate of the sensitivity of SLNB was 0.93 [95% CI 
0.90-0.95]. Negative predictive values were ranging from 0.88 to 1 (Table 3). 
Subgroup analysis
Figure 5 shows the number of TPs, FPs, FNs, TNs and the sensitivity of the OCSCCs only. 
The pooled estimate of the sensitivity of SLNB in OCSCCs was 0.92 [0.86-0.95]. 
One study included oropharyngeal cancers only.113 There were low number of OPSCCs in 
the studies in which it was possible to split the results for oral cavity and oropharyngeal 
cancers. In six of the eight studies for which it was possible to split OCSCC and OPSCC, only
one or two patients had oropharyngeal cancer. These numbers were too low to calculate 
a pooled estimate for OPSCCs only.
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Figure 2: Results of QUADAS‐2
Figure 3: Results of QUADAS‐2
In six studies the triple procedure was used with lymphoscintigraphy, blue dye substance 
and the use of a (handheld) gamma probe. One study used blue dye only. The other 14 
studies did not use blue dye and did a procedure with lymphoscintigraphy and a gamma 
probe only. The procedure with lymphoscintigraphy and a gamma probe had a pooled 
sensitivity of 0.93 [0.91-0.98]. Triple procedure had a pooled sensitivity of 0.92 [0.77-0.96]. 
In 16 studies the results of a neck dissection were used as reference test, whereas the 
other four studies followed the patients to study whether the SLNB had predicted the 
neck status correctly. The pooled sensitivity of the studies with ND as reference test was 
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0.94  [0.90-0.97]. The pooled estimate of studies with follow-up as reference was 0.91 
[0.84-0.95].
The pooled estimates of all studies and the different subgroups are shown in Figure 6.
Subgroup analyses with the N0 determination procedure or the reference test used was 
not possible since these were not described clearly enough. 
Figure 4: Forest plot total, Oral cavity and Oropharyngeal cancers
Figure 5: Forest plot oral cavity cancers
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Table 3: Prevalence and negative predictive value
Results are for oral cavity and oropharyngeal cancers if applicable
Figure 6: Forest plot pooled data
Total = oral cavity and oropharynx, Oral cavity = Oral cavity only,
LG= Lymfoscintigraphy + Gamma probe
LGB = Lymfoscintigraphy + Gamma probe + Blue dye substance
ND= Neck dissection as reference test
FU= Follow-up as reference test
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Discussion
The results of this diagnostic meta-analysis demonstrate that sentinel node biopsy appears 
to be a sensitive method in the detection of neck metastases in cT1/T2N0 OCSCC. In almost 
all patients at least one sentinel node was detected and therefore a biopsy could be taken 
which means that the procedure appears to be applicable as well.
These results are in line with a previous conducted meta-analysis which also showed a 
high sensitivity of SLNB  in CT1/T2N0 patients.95 The major strengths of our study apart 
from being more up to date, is that we made a distinction in OCSCCs and OPSCCs and 
performed additional sub(group) analyses. OCSCCs and OPSCCs are often considered as 
one group under the heading of oral cancers. However they have different characteristics, 
which can cause different results for SLNB. Moreover, we performed a quality assessment 
on included studies.
However, some potential limitations should be discussed. First, the quality assessment 
showed that there is high risk of bias in patient selection in most studies, e.g. due to 
inappropriate exclusions of minimal invasive or small tumors. There was also some risk 
of bias in flow and timing because not all patients received the same reference standard 
and there was possible selection of patients in some studies. Second, the high sensitivity 
could only be ensured for oral cavity cancers. Only one study performed SNLB on a 
substantial amount of patients with oropharyngeal cancers. The low number of patients 
with oropharyngeal cancers in the other studies did not allow pooling the results of this 
type of tumor. Therefore, it is not certain that the high sensitivity of SLNB also applies 
for oropharyngeal cancers. Third, one study used blue dye only for detecting the sentinel 
nodes, which might be considered as an inappropriate method. A sensitivity analysis , in 
which we excluded this study, however, showed similar pooled outcomes. We therefore 
decided to include this study to provide a complete overview of the literature. Fourth, the 
methods used to classify the nodal status as N0 clinically, were unclear in too many studies 
to allow subgroup analysis. However, it is expected that the method of N0 determination 
influences only the percentages of occult metastases and therefore not the sensitivity. 
In most included studies the reference test was histopathological examination of a neck 
dissection specimen. Levels included in the neck dissection varied among the studies, 
but was at least  level I-III. The probability of metastases skipping the first three levels 
is expected to be very low and therefore no significant differences are expected due to 
these variations in the reference test. 
In conclusion, the high detection rate of the SLNB and the high sensitivity of the test justify 
an important role of SLNB in the diagnostic pathway of cT1/T2N0 oral cavity squamous cell 
carcinoma patients.
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Abstract
Objectives: To assess the cost-effectiveness of five strategies for diagnosing and treating 
cT1-2N0 oral cavity squamous cell cancer. 
Materials and methods: A Markov decision analytic model was used to evaluate the 
cost-effectiveness of 1) elective neck dissection (END), 2) watchful waiting (WW), 3) gene 
expression profiling (GEP) followed by neck dissection (ND) or WW, 4) sentinel lymph node 
(SLN) procedure followed by ND or WW, and 5) GEP and SLN (for positive GEP) followed 
by ND or WW. Uncertainty was addressed using one-way and probabilistic sensitivity 
analyses
Results: Base-case analysis showed that SLN procedure followed by ND or WW was the 
most effective and most cost-effective strategy. Compared with direct END the incremental 
cost-effectiveness ratio was €3,356 per QALY gained. Uncertainty analysis showed that the 
model was sensitive to changes in assumed occult metastases incidence and utility values. 
SLN was found to have the highest probability (66%) of being cost-effective of the five 
strategies, at a willingness to pay of €80,000 per QALY. 
Conclusion: Given the current evidence and costs the SLN procedure followed by ND or 
WW appears to be the most cost-effective strategy for diagnosing and treating oral cavity 
squamous cell cancer patients. Our model provides the foundation for future diagnostic 
and therapeutic research in this field and shows that further information on quality of life 
in this population is highly valuable.
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Introduction
Head and neck squamous cell cancer (HNSCC) is considered an important part of the 
global burden of cancer, mainly due to the widespread use of tobacco and alcohol.61 
The oral cavity is the most predominant location in the head and neck region for primary 
malignant tumours, and more than 90% consists of squamous cell carcinoma (SCC). The 
primary treatment of these tumours is surgery in most cases. For patients with oral cavity 
SCC (OCSCC) prognosis drops to nearly half when regional lymph nodes are involved.14 
Since regional metastases occur relatively frequently, adequate diagnosis and treatment 
of the neck are important besides optimal local tumour control. If nodal metastases are 
detected, therapeutic neck dissection as an integral part of regional treatment is beyond 
debate, to be followed by postoperative radiotherapy, with or without chemotherapy on 
indication. There is, however, still vigorous debate on how to manage the neck in patients 
without clinical evidence of metastases. The question is whether elective neck dissection 
(END), which usually consists of removal of lymph nodes of level I-III, is indicated in these 
patients. 
In most centres patients with clinically uninvolved (cN0) necks undergo an elective neck 
dissection if the known incidence of clinically occult metastases is greater than 20%. This 
implies a possible overtreatment, including its treatment associated morbidity and impact 
on quality of life, of up to 80% in this specific group. The alternative for END is a watchful 
waiting (WW) strategy, which may result in undertreatment.30 The prognostic impact 
of such a WW policy versus elective surgery is influenced by the delay in detection and 
treatment of any neck metastases.39 
Decision analyses by Weiss et al. and Okura et al. suggested thresholds of 20% and 44% 
of occult metastasis as cut off in the decision to operate or observe.114,115 Neither of 
them took into account the costs in relation to health outcomes (cost-effectiveness) 
and both are dated. New diagnostic techniques have been introduced, such as sentinel 
lymph node (SLN) procedures and gene expression profiling (GEP), which might add to 
better prediction of occult metastasis.116 The sentinel node concept is based on the 
assumption that tumour will spread from the primary site to a single node or group of 
nodes (the sentinel nodes), before progressing to the remainder of the lymph nodes. 
Histopathological evaluation of sentinel lymph nodes may allow accurate prediction of 
the disease status. Although SLN biopsy is still an invasive procedure gives less morbidity 
than a neck dissection (ND) by sparing relevant structures.63 GEP is a test to distinguish 
metastasizing cancers from non metastasizing cancers on basis of the expression of a 
set of genes of the primary tumour. Cost and morbidity could be reduced if one or a 
combination of these novel diagnostic techniques could avoid unnecessary elective neck 
dissections in cN0 oral cancer patients.117 An updated decision model, which takes into 
account these factors, is therefore warranted. 
We developed a new decision model addressing the important decisions for current 
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management of the cN0 neck, considering both cost and effects. With this model, we aim 
to make an important step to an evidence based decision for oral cavity cancer patients 
regarding possible regional metastases by determining the most cost-effective strategy of 
current relevant options.
Materials & Methods
Population
The target population consists of patients with clinical T1-2N0 OCSCC. cN0 was classified 
by palpation, computed tomography (CT) and/or Magnetic resonance Imaging (MRI) and 
ultrasound-guided fine needle aspiration cytology (USgFNAC). 
Decision model
We developed a decision-analytic Markov model to evaluate the cost-effectiveness of five 
different diagnostic and treatment strategies for possible occult regional metastases in 
cT1-2N0 patients with OCSCC. A decision model is a mathematical method to weigh risks, 
benefits, patient preferences, and costs of clinical strategies.118 
A decision tree was used to model the diagnostic pathways, and a Markov model 
represented the subsequent follow-up. The strategies were: 1) elective neck dissection 
(END), 2) watchful waiting (WW), 3) gene expression profiling (GEP) followed by neck 
dissection (ND) or WW, 4) sentinel lymph node (SLN) procedure followed by ND or WW, 
and 5) GEP and SLN (for positive GEP) followed by ND or WW. The created clinical settings 
are based on published clinical guidelines, published diagnostic and intervention studies, 
and expert opinion.119 Adjuvant radiotherapy on the primary tumour (which may involve 
part of the adjacent lymph nodes) is not explicitly included in the model as it is assumed 
to occur independent of the different strategies of the neck. 
In the model a hypothetical cohort of OCSCC patients moves between health states 
according to a set of transition probabilities. After each cycle (i.e. one year) patients in the 
cohort have a probability to move to different health states. In each health state, patients 
are assigned the corresponding costs and outcomes. This is modelled for a total of five 
cycles of one year each, representing five years.
Model structure
The diagnostic pathways of the five strategies are shown in Figure 1. Direct END (strategy 
I) or direct WW (strategy II) for all patients is considered to be correct or incorrect, true 
or false. In the END strategy ‘true’ means detected nodal metastasis on histopathological 
examination. In the WW strategy ‘true’ means no detectable metastases (regional failure) 
in follow up. Those patients classified as “N+” by the additional tests (strategy III-V), 
which can either be false positive (FP) or true positive (TP), are all treated with a ND. 
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Those classified as “N0”, which can be either False Negative (FN) or True Negative (TN), all 
undergo WW. After these classifications and corresponding treatment, patients move to 
the different health states in the Markov part of the model which represents the follow-up 
of patients. 
Possible health states for patients were: regional failure (RF), no regional failure, or dead. 
The structure of the Markov part of the model was the same for each diagnostic outcome 
(Figure 2). However, the probabilities of entering the different states (i.e. the chance of 
RF) were different among the diagnostic outcomes.
Figure 1: Model structure for the initial diagnostic and treatment pathway
The decision node is shown as the open square, chance nodes as open circles and Markov nodes as 
open circles with M.
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Figure 2: Influence diagram of Markov part of the model
The Markov part of the model represents follow-up of patients after diagnostic outcome and 
corresponding treatment. Patients that experience regional failure (RF) enter the Markov part of 
the model in the RF state and the other patients in the no RF state. Patients can either survive and 
stay in the state they entered in or die and go to the dead state. The no RF health state is different 
after WW, SLN procedure and ND. The RF health state is independent of previous treatment.
Transitions 
An overview of the probabilities used in the model is shown in Table 1. The diagnostic 
accuracy data used for transition probabilities in strategies with GEP were derived from a 
recent Dutch multicentre study.116 The accuracy data of SLN biopsies were derived from 
a meta-analysis of 13 studies which we performed alongside this study.88,95,96,98-107 
Data on percentage of occult metastases, regional failure probability and survival data 
after regional failure and no regional failure of patients that underwent a neck dissection 
were derived from the eight Dutch head and neck oncological centres. These results were 
based on 96 patients. WW outcomes regarding regional failure probability and survival 
data were derived from one centre, where WW is the standard for all cT1-2N0 patients. 
This was based on 69 patients. All cause mortality data were analyzed with Kaplan-Meier 
methods. 
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Table 1: Transition probabilities
Cost information
Cost analysis was performed from a health care perspective. Unit costs of neck dissection 
and SLN procedure were calculated according to the Dutch pharmaco-economic guidelines 
using available sources from the department of Otorhinolaryngology and Head and Neck 
Surgery of the Radboud University Nijmegen Medical Centre (RUNMC). Costs of GEP were 
obtained from Agendia BV (Amsterdam, The Netherlands).120 The volume of hospital days 
and medical specialist hours were collected from existing registries of the RUNMC and 
were multiplied by reference prices from the Dutch pharmaco-economic guideline.120
In each strategy a percentage of patients will experience regional failure. It was assumed 
that regional failure was followed by salvage therapy with the costs of a (modified) radical 
neck dissection. No differences in costs were expected for follow-up of patients between 
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the strategies and these costs were not included in the analysis. Also no differences were 
expected for the number of hospital days in the base case analysis since this is mainly 
determined by surgery of the primary tumour. However, the costs of the hospital days 
were included to be able to vary them in the deterministic sensitivity analysis and to give 
an indication of the total diagnostic and treatment costs of each strategy. The costs of 
11.8 hospital days were, therefore, included in each strategy. Costs were based on the 
year 2011, and future costs were discounted to their present value by a rate of 4%.121 An 
overview of the cost data used in our model is provided in Table 2. 
Table 2: Costs
Resource use was determined using data of the Radboud University Nijmegen Medical Centre 
(RUNMC)
Outcome measures
Health-related quality of life was used as outcome measure in the model. It was considered 
as a single index utility, on a scale from 0 (representing death) to 1 (representing perfect 
health).122 The use of utility scores allows the calculation of Quality Adjusted Life Years 
(QALYs) and costs per QALY. We used the utility data from the decision model of Weiss et 
al. in our model. These utilities are presented as disutility (reduction of quality of life) in 
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relation to WW patients without regional failure (to whom a utility of 1 was assigned).114 
These values were derived from expert consultation. We assumed a similar disutility for 
patients who underwent ND after SLN and those who only underwent ND. The disutility 
of patients with a WW strategy after the SLN procedure was assumed to be half of the 
disutility of ND. GEP was assumed to have no influence on quality of life. When regional 
failure occurred the disutility was assumed to be independent of previous strategy 
because of complete neck dissection after regional failure. An overview of (dis)utilities for 
each health state is provided in Table 3. Effects were discounted with a constant rate of 
1.5% according to the pharmacoeconomic guidelines.121
Table 3: Utility values
Data analysis
Strategies were compared in terms of mean costs, mean effects (in QALYs) and incremental 
cost-effectiveness ratios (ICERs). ICERs are calculated by dividing the additional costs of 
one treatment over the other by the additional QALYs. They thereby represent the extra 
costs that are needed to gain one QALY. Whether a strategy is deemed cost-effective 
depends on the willingness-to-pay (WTP) for a QALY. A WTP threshold of €80,000 per 
QALY was used, as recommended by the Dutch Council for Public Health and Care.123 
This means that a strategy is deemed cost-effective compared to another strategy when 
it costs €80,000 or less to gain an extra QALY, i.e. the ICER is lower than €80,000 per QALY. 
ICERs were calculated compared with the elective neck dissection strategy, and in a full 
incremental analysis. For the incremental analysis we ordered the strategies from lowest 
(A) to highest costs (E). If strategy B was more cost-effective than strategy A, we used 
strategy B as the comparator for strategy C. If strategy A was more cost-effective, strategy 
A remained the comparator for strategy C. We completed the incremental analysis by 
repeating this action for strategy D and E.
We performed one-way deterministic sensitivity analyses on the assumptions made 
regarding the diagnostic accuracy of SLN and GEP, percentage of occult metastasis, costs, 
probability of regional failure after ND, and the difference in quality of life (after SLN, ND 
and WW). We changed these parameters over a range of values to study the potential 
consequences on the outcome of the model. 
94
Management of the No neck in early stage oral squamous cell cancerChapter 6
In addition, probabilistic sensitivity analysis was performed to assess the impact of all 
uncertainty on the outcomes. This means that we assigned distributions to model 
parameters, to reflect the uncertainty in the estimation of that parameter when possible. 
All distributions are listed in Table 1 and 3. Cost parameters were not included in the 
probabilistic sensitivity analysis. Parameter values were drawn at random from the 
assigned distributions, using Monte Carlo simulation with 10,000 iterations. To illustrate 
the results of the simulation, cost-effectiveness acceptability curves (CEACs) were 
calculated. CEACs show the probability that a strategy is cost-effective for a range of WTP 
thresholds. 
As uncertainty exists, there is always a chance that the ‘wrong’ decision will be made. The 
expected value of perfect information (EVPI) reflects the expected costs of uncertainty 
relating to all input parameters in the decision model, based on the probability of making 
an incorrect decision and its consequences. We calculated the EVPI to measure the value 
of acquiring additional empirical information per patient.124 The population EVPI was 
calculated by multiplying this value by the effective population, which is based on the 
incidence of the disease. Also the expected value of partial perfect information (EVPPI) 
was calculated. The EVPPI represents the expected costs of uncertainty for one or a group 
of parameters. This shows which (groups of) parameters are most valuable for further 
research.
Results
Base-case analysis
WW was the least effective strategy with 3.43 expected QALYs while SLN procedure was the 
most effective strategy with 3.63 expected QALYs. WW was also the least costly strategy 
with on average €8,003 in costs per patient. The average costs for WW patients consist 
of hospital days related to the treatment of the primary tumor, and salvage therapy for 
regional failure for a percentage of patients. GEP + SLN procedure was the most expensive 
strategy with €11,515. The baseline deterministic results of the five strategies are 
presented in Table 4a and in Figure 3. SLN procedure was the most cost-effective strategy 
in the incremental analysis (Figure 4a). The costs of the SLN strategy were slightly higher 
than for the END strategy (€9,241 versus €9,180, respectively), whereas the corresponding 
QALYs were 3.63 and 3.61. The ICER was €3,356 per QALY gained. All other strategies were 
also compared to END, the results are presented in Table 4b.
95
Management of the No neck in early stage oral squamous cell cancer Chapter 6
6
Figure 3: Baseline results of the five strategies
Expected mean costs and QALYs per patient over five years
Table 4a: Incremental analysis
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Table 4b: ICERs compared to END
Deterministic sensitivity analysis
Deterministic sensitivity analysis showed that variations in the diagnostic accuracy, costs 
and regional failure rate after ND had no significant effect on the results, assuming realistic 
variations for this parameters. The results of this analysis showed that the results are 
sensitive to variations in the percentage of occult metastasis and quality of life.
SLN was the most cost-effective strategy when we modelled percentages of occult 
metastasis between about 11 and 53%. When we modelled percentages above 54%, END 
was the most cost-effective strategy, and with percentages of 11% or lower, WW was most 
cost-effective. 
The outcome of the model also changed when we changed the disutilities of patients who 
underwent ND and those assuming to undergo a SLN procedure, relative to the utility 
of patients with a WW strategy. Depending on the utility for the health state without 
regional failure following ND, WW (utility No RF after ND lower than 0.80), GEP followed 
by SLN (utility No RF after ND between 0.80 and 0.87), SLN strategy (utility No RF after 
ND between 0.88 and 0.98) and END alone (utility No RF after ND higher than 0.98) were 
found to be the most cost-effective strategy respectively. In these situations, the health 
state without regional failure after SLN always had a utility of half that of no regional 
failure after ND. 
Probabilistic sensitivity analysis
By performing probabilistic sensitivity analysis, it was possible to determine the optimal 
strategy for a range of values regarding willingness to pay for a QALY gained given the 
existing uncertainty. Figure 4 presents the cost-effectiveness acceptability curve (CEAC) 
for all strategies. With a WTP threshold of €80,000 per QALY, SLN procedure and END were 
cost-effective in 66%, and 33% of the simulations, respectively. Above a WTP threshold 
of €7,500/QALY SLN procedure appears to be the most cost-effective strategy. With a 
WTP threshold of €7,500 or less, WW had the highest probability of being cost-effective. 
The value-of-information analysis demonstrated an EVPI of €997 per patient. About 350 
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patients are diagnosed with a cT1/T2N0 OCSCC per year in the Netherlands. Over five 
years the discounted population EVPI will be 486 000 Euros, i.e. the expected costs for 
uncertainty relating to all input parameters in the decision model for all cT1/T2N0 OCSCC 
patients in the Netherlands over 5-year. The EVPPI of utility values only was the highest 
with €780 per patient. 
Figure 4: Acceptability curve for the five strategies
This figure presents in which percentage of simulations the strategies were cost-effective for a 
certain WTP
Discussion
The results of our study show the potential cost-effectiveness of five diagnostic and 
treatment strategies for patients with cT1-2N0 OCSCC. SLN strategy was found to be on 
average more effective than WW and slightly more effective than the other strategies. 
The extra effectiveness of the SLN strategy was about 0.2 QALYs compared with WW and 
approximately 0.02 QALYs compared with the other strategies over the first five years. This 
is equivalent to an increase of 2.5 months in full health compared with WW and one week 
extra in full health compared with the other strategies. Costs of the SLN strategy were 
somewhat higher than for the END strategy, but were lower than for strategies with GEP. 
The slightly higher effectiveness of SLN compared with END, and the slightly higher costs 
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of SLN, resulted in a favorable incremental cost-effectiveness ratio for the SLN strategy. 
Consequently, on the basis of currently available evidence, SLN appears to be the most 
cost effective strategy.
Our results follow on previous studies of Weiss et al. and Okura et al. whom reported that 
END was more effective than WW above thresholds of 20% and 44% of occult metastasis, 
respectively. However, both studies did not take into account the costs. Furthermore, we 
studied two new diagnostic techniques, i.e. SLN procedure and GEP, which have not been 
studied before in a decision analysis. 
Some potential limitations should also be discussed. First, our sensitivity analysis showed 
that the percentage of occult metastasis had some impact on the outcome. However, 
the SLN procedure was most cost-effective within the range of 23% to 43% reported in 
literature.86 Second, because utility values were not available for all health states, we had 
to make several assumptions regarding (dis)utility values in the different health states. 
We assumed that patients who underwent a SLN procedure, followed by WW had a 
utility between that of ND patients without regional failure and WW patients without 
regional failure. We also assumed that utility values of patients with regional failure were 
independent of previous treatment and were the lowest. Also, since the utilities were not 
collected from OCSCC patients themselves but by expert opinion, larger differences in 
utilities after ND, SLN procedure and WW may exist than the small differences included 
in the model. Our deterministic sensitivity analyses showed the impact of quality of life 
on the outcome in patients and the optimal strategy. It showed that a relatively larger 
difference in this strategy associated quality of life will favour GEP in combination with a 
SLN procedure (strategy 5), or when the difference is very large, WW alone will become 
the most cost-effective strategy. Third, we built a model with a time horizon of five years. 
Although differences in survival and quality of life narrow over time, a life-time model 
could have resulted in different outcomes due to possible life-time shoulder morbidity. 
Therefore, this choice of time horizon can be deemed a conservative approach. Fourth, the 
survival after regional failure was assumed independent of the initial treatment to prevent 
possible confounding by indication. It is possible that this assumption overestimates the 
survival of patients after ND. Fifth, the input for this model is based on the Dutch situation 
using costs in one centre. As costs in particular can vary between settings, the question 
may arise whether these costs are applicable in other centres and countries. Sensitivity 
analyses showed that costs could vary considerably without changing the outcome, i.e. 
SLN strategy was the most cost-effective strategy even when we doubled the costs of an 
SLN procedure.  
Despite these limitations our model provides clinically relevant information. Our model 
demonstrates that a SLN procedure is a valuable step in the diagnostic pathway of OCSCC 
patients since it will improve the outcome for patients without significant extra costs 
for healthcare by preventing unnecessary burdensome END. It is important to realize 
that the impact of strategies on the patients quality of life (utility) is important in the 
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decision making process. We expect that the disutilities after ND and SLN procedure, used 
in the model now, turn out to be different when obtained from the OCSCC population 
themselves. This could mean that SLN procedure could even be more effective but possibly 
also that GEP should be performed before making a choice for a SLN procedure, to avoid 
unnecessary sentinel node biopsies as well. For example, if GEP can be performed at 
lower costs in the near future, the combined procedure (i.e. GEP and SLN) might become 
the most cost-effective strategy.
The EVPI showed that future empirical research is warranted to reduce uncertainty of 
the outcome. Further research was found to be most valuable for the utility values, the 
EVPPI (expected costs of uncertainty for a single group of parameters) of the utility values 
showed that about 80% of the total expected costs were caused by uncertainty in utility 
values. Therefore, it is worthwhile to measure quality of life in patients who underwent 
ND, WW or a SLN procedure first. Second, survival data should be gathered in a group of 
patients with a (more) random selection of treatment (WW or END). In this way we could 
use different survival after regional failure after WW or ND when required. 
In conclusion, given the current evidence and cost the SLN procedure followed by a neck 
dissection or watchful waiting appears to be the most cost effective strategy for diagnosing 
and treating patients with cT1-2N0 oral cavity squamous cell cancer. Our model provides 
the foundation for future diagnostic and therapeutic research in this field and shows that 
further information on quality of life in this population is highly valuable.
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Abstract
Objectives: To examine health utilities in patients with cT1-2 oral cavity squamous cell 
carcinoma following different diagnostic and treatment modalities for the neck, and to 
investigate the relation between shoulder morbidity and health utility.
Design: Cross-sectional survey 
Setting: Two Dutch hospitals
Participants: Four subgroups of patients with oral cavity cancer who underwent watchful 
waiting, sentinel lymph node biopsy, elective supraomohyoid neck dissection, or 
therapeutic modified radical neck dissection
Main outcome measures: Patients received the EuroQol-5D-3L questionnaire and the 
shoulder disability questionnaire. Mean health utility, visual analogue scale, and shoulder 
disability scores were calculated. 
Results: 181 patients (62%) returned the questionnaires. Mean health utilities, adjusted 
for age, gender and time since treatment, were 0.804, 0.863, 0.834 and 0.794 for the 
watchful waiting, sentinel lymph node biopsy, supraomohyoid neck dissection and 
modified radical neck dissection subgroups, respectively. Mean shoulder disability scores 
(higher score means more shoulder complaints) for these subgroups were 8.64, 10.57, 
18.92 and 33.66. Patients with shoulder complaints had a mean utility of 0.78 while 
patients without shoulder complaints had a mean utility of 0.90.
Conclusions: This study shows that more invasive procedures appear to result in lower 
health utility. The high health utility for patients after sentinel lymph node biopsy supports 
a role for this procedure in oral cancer patients.
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Introduction
Effects of cancer treatment on Health-related quality of life (HRQoL) are gaining 
importance next to oncological effectiveness. Besides this, armamentarium for the 
diagnosis and treatment of cancer is expanding. These two factors make decision making 
around the optimal treatment strategy more complex. Decision analysis is very useful in 
this perspective. In these analyses, quality-adjusted life years (QALYs) are the preferred 
health outcome because they combine HRQL with oncological outcome.122 To calculate 
QALYs it is necessary to express HRQoL as a value that is anchored on a numeric scale 
ranging from death (0) to perfect health (1), the so-called utility score.125 
In the diagnosis and treatment of lymph nodes in the neck in oral cavity squamous 
cell cancer (OCSCC) patients, the trade-off between HRQoL and oncological outcome 
is important for decision making. More invasive procedures are more likely to be 
oncologically effective. However, they are also more likely to have a negative impact on 
HRQoL. Decrease in HRQoL in these patients is mostly caused by shoulder complaints 
that are associated with neck treatment.18,19 Other studies have confirmed that more 
invasive treatment indeed results in more shoulder complaints.23,25,126 However, it is 
unclear what the impact of these shoulder complaints is on health utilities. Therefore, 
the results of these studies cannot be used to calculate QALYs and are not useful for 
decision analyses. The importance of health utilities after different treatment modalities 
for choosing the optimal treatment modality for early stage oral cavity cancer patient with 
a clinical negative neck is also confirmed in our recent decision analytical model.127
Therefore, the aims of this study are: 1) to examine health utility in patients with cT1-2 oral 
cavity cancer following different diagnostic and treatment modalities and 2) to investigate 
the relation between shoulder morbidity and health utility.
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Patients and Methods
Ethical considerations
The study was approved by the institutional review boards of the participating centers.
Study design and patient enrollment 
We performed a cross-sectional survey of patients with early stage (T1-2) OCSCC in the 
Radboud University Medical centre (Radboud UMC) and the Antoni van Leeuwenhoek 
hospital Amsterdam (AvL) between 2001 and 2013. Four subgroups of patients who 
underwent different diagnostic and treatment modalities for the neck were selected: 
watchful waiting (WW), sentinel lymph node biopsy (SLNB), supraomohyoid neck 
dissection (SOHND) and modified radical neck dissection (MRND). MRND was performed 
in patients with node positive necks (detected by ultra sound guided fine needle aspiration 
cytology, SLNB or in a few cases after regional failure). The other three modalities were 
performed, as standard, in patients with cN0 necks for a certain period in one of the 
centers. The SLNB group consisted of patients who had a negative sentinel node and did 
not receive any additional treatment for the neck. For this study, the WW group could 
be seen as a reference to show the influence of the additional treatment of the neck 
in these patients. Electronic patient databases were used to gather information about 
the patients. The following data were retrieved from the medical records: date and type 
of treatment, tumor stage, tumor subsite, date of birth, gender, previous mucosal head 
and neck tumors, second primary tumors, local recurrences and the administration of 
(chemo-)radiotherapy in the head and neck region. 
The EuroQol-5D questionnaire (EQ-5D-3L) and the shoulder disability questionnaire 
(SDQ) were sent to the selected patients guided by a letter containing informed consent 
and instructions. We did not send reminders to the patients because informed consent 
stated that when they did not want to participate, patients did not have to respond to the 
questionnaire. 
Questionnaires
The EQ-5D-3L is the most frequently used multi-attribute health status classification system 
and is recommended by the National Institute for Health and Clinical Excellence.128 The 
EQ-5D-3L consists of five dimensions of generic HRQL (mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression) with three answer possibilities per dimension 
(severe problems, some problems, no problems).129 The answers to these questions can 
be combined to calculate health utilities using a scoring function, i.e. for each answer that 
represents a problem in one of the dimensions, the health utility of a patient is lowered 
with a certain amount.122 This scoring function is determined by the general population 
by valuing the possible health states (each possible combination of answers represent a 
health state). Scoring functions vary among countries depending on the preferences of 
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that particular population. These scoring functions for countries are called tariffs. Health 
utilities range from a negative score (health state worse than death, severe problems in all 
five dimensions), through 0 (death) to 1 (full health, no problems in all dimensions). Next 
to the five questions, a visual analogue scale (VAS) is included in the EQ-5D that ranges 
from 0 (worst imaginable health state) to 100 (best imaginable health state). The VAS 
measures the patients’ self-rated HRQoL (patients’ perspective). 
The SDQ questionnaire consists of 16 items and is designed to evaluate functional status 
limitation in patients with shoulder disorders.130 The SDQ score was calculated as the 
ratio of the number of items with an affirmative answer over the number of applicable 
items and was multiplied by 100. 
Analyses
Health utilities were calculated from the EQ-5D-3L outcomes, using the Dutch tariff.131
We performed analysis of covariance (ANCOVA) to calculate mean health utility, SDQ and 
VAS scores for the different procedures. HRQL scores are likely to decrease with increasing 
age, tend to be lower for females and can change after treatment due to recovery. 132-134 
Therefore, we adjusted for potential confounding by age (at time of questionnaire), gender 
and time since treatment. Time since treatment was calculated as time since surgery of 
the primary tumor for the WW group. For the SOHND, MRND and SLNB groups this was 
time since the neck dissection or sentinel node procedure, which generally corresponds 
to the time since surgery of the primary tumor, since these are mostly performed during 
the same procedure. The analysis was repeated for the group of patients without any 
previous mucosal malignancy in the head and neck region, local recurrence or second 
primary tumor because this can influence the choice for a certain strategy. The analysis 
was repeated, a third time, in which also patients who received any (chemo)radiotherapy 
in the head and neck region were excluded.
We used correlation to assess the relation between the health utility and SDQ score.
Finally, we examined which percentage of patients had shoulder complaints at the 
moment of completing the questionnaire (SDQ>0) in each of the subgroups and checked 
whether these patients had a lower mean health utility than patients without shoulder 
complaints (SDQ=0).
All analyses were performed with SPSS version 20. 
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Results
Population characteristics 
Of the 291 eligible patients (39 WW, 36 SLNB, 168 SOHND and 48 MRND), 181 patients 
(62%) returned the questionnaires. Most of these patients underwent a SOHND strategy 
(60%), followed by MRND (15%), WW (14%) and SNB (11%). The response rate was 
between 56 and 67 percent among the subgroups. In all treatment groups the majority 
of respondents were males. Overall mean age at completion of the questionnaire was 
64.4 years. The mean age was higher in the WW group (71.4 years) as compared with the 
other subgroups. In the WW and SLNB group most tumors were staged T1 while in the 
SOHND and MRND group most tumors were T2. In all groups most tumors were located 
on the tongue. Population characteristics of the respondents are presented in Table 1. 
Some patients only filled out one of both questionnaires or did only fill out half of the 
EQ-5D-3L questionnaire (only the questions or only the VAS). 174 Patients answered the 
five questions of the EQ-5D-3L (and thereforea health utility could be calculated) , while 
173 completed the VAS. 168 patients answered the questions of the SDQ. However, 17 
patients (13 SOHND, 1 MRND, 2 SLNB and 1 in the WW group) answered all questions of 
the SDQ with non applicable and therefore no SDQ score could be calculated for these 
patients in accordance with the instruction of the questionnaire.(130) For 146 patients 
it was possible to both calculate a health utility and a SDQ score and with these results 
assessment of the relation between shoulder complaints and health utility was possible. 
Health utility, SDQ and VAS scores
The adjusted mean utility scores for WW, SLNB, SOHND and MRND were 0.804, 0.863, 
0.834 and 0.794 respectively (p value 0.700). The adjusted mean SDQ scores were 8.64, 
10.57, 18.92 and 33.66 respectively (p value 0.019) and the VAS scores 69.7, 79.6, 76.2 
and 71.5 respectively (p value 0.234). The mean scores were adjusted for age, gender and 
time since treatment (Table 2a). 
In Table 2b the adjusted mean utility scores for patients who did not have any previous 
mucosal malignancy, local recurrence or second primary tumor are presented. Table 2c 
shows adjusted mean utility scores for patients who also did not receive adjuvant (chemo)
radiotherapy.
Relation shoulder complaints and health utility
The correlation coefficient between SDQ score and health utility was -0.499 (p-value 
0.000) and the  beta coefficient was -0.003 (se 0.001), i.e. patients with more shoulder 
complaints appear to have a lower HRQo. 
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Table 1: Patient characteristics
Patient Characteristics of the study population per subgroup: supraomohyoid neck dissection 
(SOHND), watchful waiting (WW), sentinel lymph node biopsy (SLNB), modified radical neck 
dissection (MRND). *The response rate is the percentage of returned questionnaires. Not every 
question was answered by every respondent.
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Table 2a: Adjusted mean quality of life scores
Mean scores (with standard errors) for: Health utility (number between 0 and 1 in which 1 stands for 
perfect health), SDQ score (higher score means more shoulder complaints) and VAS score (higher 
VAS means higher self-rated quality of life). P-value is between groups.
Table 2b: Adjusted mean quality of life scores in patients without previous mucosal malignancies, 
local recurrences or second primary tumors in the head and neck region
Mean scores (with standard errors) for: Health utility (number between 0 and 1 in which 1 stands for 
perfect health), SDQ score (higher score means more shoulder complaints) and VAS score (higher 
VAS means higher self-rated quality of life). P-value is between groups. 
Patients with shoulder complaints compared to patients without shoulder complaints
When we defined SDQ>0 as shoulder complaints, the percentage of respondents with 
complaints in the complete subgroups (at the moment of filling out the questionnaire) 
are: 32 percent in the WW group (8 out of 25), 36 percent in the SLNB group (5 out of 14), 
43 percent in the SOHND group (39 out 91) and 77 percent in the MRND group (16 out 
of 21).
The mean utility of patients with shoulder complaints (SDQ>0, n=67 patients) was 0.78, 
while patients without shoulder complaints (SDQ=0, n=79 patients) had a mean utility of 
0.90 (p-value 0.043). 
109
Quality of life after different procedures for regional control in oral cancer patients Chapter 7
7
Table 2c: Adjusted mean quality of life scores in patients without previous mucosal malignancies, 
local recurrence or second primary tumors and without adjuvant (chemo)radiotherapy in the 
head and neck region
Mean scores (with standard errors) for: Health utility (number between 0 and 1 in which 1 stands for 
perfect health), SDQ score (higher score means more shoulder complaints) and VAS score (higher 
VAS means higher self-rated quality of life). P-value is between groups. Number of patients with 
MRND were too low (n=4 for health utility and VAS and n=2 for SDQ score) to present meaningful 
adjusted mean scores.
Discussion
This study provides health utility scores for patients who underwent different procedures 
for the neck in early OCSCC and the impact of shoulder complaints on health utilities. As 
expected, our results show that more invasive procedures for diagnosing and treating 
neck metastases result in more shoulder complaints, and that shoulder complaints lead 
to a lower health utility.
Strengths
To our knowledge, this is the first study describing health utilities for patients who 
underwent different diagnostic and treatment modalities for the neck. Furthermore, 
we are also the first examining the relation between shoulder complaints and health 
utility in the OCSCC population. Other studies did examine shoulder complaints after 
neck dissections, and our results are in agreement with these studies regarding shoulder 
complaints after the different procedures.25,63,126
Limitations
Some potential limitations should also be discussed. First, the number of patients in the 
WW and SLNB groups was low. This could explain the relatively low health utility after 
WW, which was caused by a few outliers. Also the low VAS scores for the WW group 
indicate that the WW group is probably selective. We expect that if more patients were 
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included, the mean utility after WW would have been, relatively, higher than reported now. 
Although not statistically significant, utilities showed a trend in being favorable in patients 
with less invasive procedures against more invasive procedures. A power calculation using 
the number of available patients in this study showed that the difference that could be 
shown with an alpha of 5% and a power of 80% was 0.18, whereas the reported minimally 
important difference (MID) is 0.06.135 To detect this MID of 0.06 we should have included 
a minimum of 174 patients per group. However, our results show differences which are 
in a range around the MID and are, although not statistically significant due to the low 
numbers, thus clinically important. Second (partially coherent with the first limitation), 
we could not adjust for baseline quality of life as this was not available in our population. 
The WW group could be seen as a reference for the other groups to study the difference in 
quality of life and occurrence of shoulder complaints. However, confounding by indication 
could have influenced the results. We did try to correct for T-stage and subsite and the 
influence of these parameters seemed to be very low. Besides this we performed subgroup 
analyses in which we only included patients without previous or second malignancies in 
the head and neck region and patients without radiotherapy treatment. The differences 
in mean health utilities between WW, SLNB, SOHND and MRND were different in these 
subgroups without previous or second malignancies and patients without radiotherapy, 
as compared to the analyses in which all patients were included. Especially the health 
utility in the WW subgroup was relatively higher in these subgroup analyses. However, 
we still expected relatively higher values in the WW group and therefore expect that also 
other factors caused the lower scores in the WW group besides previous malignancies 
or radiotherapy.  Besides this, WW, SLNB and SOHND are strategies used for the clinical 
negative neck, while MRND is used for the positive neck. Using the WW group as a reference 
group should therefore be done with caution. Third, we used the Dutch tariffs for the 
utilities and therefore results could be different in other countries. However, calculating 
utilities using the UK and US tariffs showed similar results. We, therefore, believe that our 
utilities could also be used to support treatment decisions in other countries. Fourth, the 
response rate of 62 percent may have introduced some selection bias. It is possible that 
for example only the patients with the best quality of life returned their questionnaire. 
However it is expected that this would have caused bias in the same direction in each of 
the groups and therefore did not influence the results greatly.
Clinical implications
This study provides important new information about quality of life after several diagnostic 
and treatment modalities in OCSCC patients. Choices which are made with respect to 
management of the cN0 neck seem to influence quality of life. Therefore, quality of life 
should be included in the decision making process for cT1-2N0 OCSCC patients. Health 
utilities can be used in combination with survival to calculate QALYs which should be used 
in decision analysis. Prospective measurement of health utilities could be performed to 
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improve the quality of these values.  However, prospective research takes time and until 
this is performed the utility measures from this study are the best available and could help 
in treatment decisions.
Conclusion
The relatively low percentage of shoulder complaints and the high health utility value 
after SLNB, in combination with the high sensitivity reported in our recent meta-analysis 
support a strategy including SLNB.65 When we introduced the utilities, calculated in 
this study, into our previously constructed decision analytical model (in which they are 
weighed against oncological outcomes), the strategy including SLNB was indeed the most 
(cost-)effective strategy and was even more (cost-)effective than previously calculated.127 
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Abstract
Background: Choosing between a more or less extensive neck dissection implies a trade-off 
between survival, quality of life and costs. This study aims to determine if selective neck 
dissection (SND= level I-III or I-IV) is cost-effective compared with modified radical neck 
dissection (MRND = level I-V) in cT1-2 oral cavity squamous cell carcinoma (OCSCC) patients 
with singular nodal disease confined to level I or II.
Methods: A decision-analytic model was developed to model quality-adjusted life years 
(QALYs) and costs over a life time horizon, based on literature. 
Results: The SND strategy resulted in an expected health loss of 0.06 QALY and savings 
of €1,351 per patient compared with MRND. The  results were sensitive to differences in 
regional failure probabilities between the strategies. 
Conclusion: With the evidence used in this model, SND was not cost-effective compared 
to MRND. Prospective research on regional failure is needed to provide optimal treatment 
for OCSCC patients. 
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Introduction
Oral cavity squamous cell carcinoma (OCSCC) is the sixth most common cancer worldwide, 
accounting for an estimated 4% of all cancers. Despite significant technical advances in the 
treatment of oral cancer, survival following a diagnosis of OCSCC remains poor with 5-year 
survival around 50% overall, with only limited improvement in the past decades.136 OCSCC 
has a significant propensity of regional lymph node metastases. If nodal metastases are 
detected the usual treatment consists of neck dissection, to be followed by postoperative 
(chemo)radiotherapy on indication.137
Traditionally, modified radical neck dissection (MRND) is performed in these cases 
irrespective of the number of affected nodes and levels of the neck, a procedure in which 
all levels (I-V) of the involved neck side are removed. Common sequellae of this procedure 
are shoulder dysfunction and pain, loss of sensitivity of the overlying skin, cranial nerve 
impairment and anatomic deformities, all of which have an effect on the quality of life of the 
patient.18 In more recent years, the alternative of performing a selective neck dissection 
(SND) is considered in cases with singular nodal disease confined to level I or II. Since 
SND is limited to level I-III or I-IV, shoulder morbidity is lower compared to MRND. 24,25 
This difference is explained by the fact that removal of level V in particular is associated 
with this type of morbidity.18 On the other hand, the preservation of certain lymph node 
levels may lead to higher rates of regional failure, requiring additional treatment with 
re-surgery and/or radiotherapy and possibly resulting in worse survival. Moreover, the 
burden and costs of regional failure and corresponding treatments may exceed those of 
one single surgical procedure removing all levels of the neck. The choice between more 
or less invasive treatment, therefore, implies a trade-off between survival, quality of life 
and costs. The resulting question is whether neck levels associated with higher morbidity 
(especially level V) could be spared in patients  with limited nodal disease.
The aim of this study is to determine if selective neck dissection (SND level I-III or I-IV) is 
cost-effective compared with modified radical neck dissection (MRND level I-V) in patients 
with T1-2 OCSCC and clinical singular nodal disease (stage cN1 or cN2a) confined to level I 
or II.
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Methods
Decision model
A decision-analytic model was developed to evaluate survival, quality of life and costs 
associated with SND and MRND in T1-2 OCSCC patients with clinical singular nodal disease 
(stage N1 or N2a) confined to level I or II (referred to as limited nodal disease for the rest 
of the article). 
Decision modelling provides a framework for decision-making under conditions of 
uncertainty. It can provide a structure that reflects the possible prognoses of patients and 
how the treatments being evaluated may impact these prognoses. It offers an analytical 
framework within which evidence relevant to the study question can be synthesized and 
provides a means of translating this evidence into estimates of effects and/or costs for the 
options being compared. Besides this, it facilitates an assessment of uncertainty relating 
to the evaluation and therewith identifies priorities for future research.122
Model structure
The first part of the model consisted of a decision tree to model the direct effects of 
treatment for the two strategies. In both treatment options patients had a chance of 
suffering from shoulder morbidity or no shoulder morbidity after treatment (Figure 1). 
The number of cases requiring postoperative radiotherapy in addition to neck dissection 
was assumed to be equal in both treatment options and was therefore not explicitly 
included in the model. The decision tree was followed by a Markov model to simulate the 
long-term consequences. The Markov model involved the transition of patients across 
health states over time. The health states were ‘regional failure with shoulder morbidity’, 
‘regional failure without shoulder morbidity’, ‘no regional failure with shoulder morbidity’, 
‘no regional failure without shoulder morbidity’ and ‘dead’ (Figure 2). Regional failure was 
defined as having ipsilateral regional recurrence after neck dissection. 
A hypothetical cohort of patients was sent trough the model to evaluate the consequences 
of both strategies. The model had a cycle length of one year and a lifelong time horizon 
was used. Patients who suffered from shoulder morbidity after neck dissection were 
assumed to experience these complications within one year after surgery. It was assumed 
that patients experienced these shoulder complaints for each following year. After each 
cycle the patients could stay in their health state or die. Costs and effects were assigned 
to each health state. The model was constructed and analysed using TreeAge Pro 2012 
software (TreeAge Software Inc, Williamstown, MA, VS). 
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Figure 1: Model structure for the decision tree
The square represents a decision node, the open nodes are chance nodes and the open circles 
with M are Markov nodes (the Markov part of the model starts after the M nodes). Abbreviations: 
Selective neck dissection (SND), Modified radical neck dissection (MRND)
Figure 2: Influence diagram of Markov part of the model
Patients with shoulder complaints could experience regional failure and enter the Markov part of 
the model in the Failure with shoulder complaints state. Otherwise they enter the Markov state in 
the no failure with shoulder morbidity state. These states have different survival probabilities. The 
same applies to patients without shoulder complaints
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Transition probabilities
Transition probabilities were included in the model to distribute patients over the 
pathways. The probabilities of shoulder morbidity and probability of regional failure 
differed between strategies. Probabilities of shoulder morbidity after SND and MRND were 
derived from a Dutch retrospective study based on 65 and 51 patients, respectively.24 
Probabilities for regional failure after neck dissection were derived from 64 patients of 
a published retrospective study.138 Survival after regional failure was the same in both 
treatment options. Data on survival for the first 5 years (for patients with and without 
regional failure) were based on a previous modelling study.127 In these survival rates it is 
included that not all patients are able (or want) to receive salvage therapy. After 5 years, 
survival was assumed to be equal to the overall mortality rates of the relevant age group, 
which were derived from Statistics Netherlands (Table 1).139 An overview of the transition 
probabilities used in the model is presented in Table 2.
Table 1: Survival
Abbreviations: standard deviation (sd)
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Table 2: Transition probabilities
Outcome measures
To be able to take into account both survival and quality of life, effectiveness was measured 
in quality-adjusted life years (QALYs). To calculate QALYs, health utilities were assigned to 
the health states and were combined with the survival rates (life years). 
Data on utilities, for the group of patients with shoulder morbidity and without shoulder 
morbidity, were derived from a database including 136 patients who underwent SND or 
MRND (Table 3) (unpublished data). In the dataset, shoulder morbidity was measured 
using the shoulder disability questionnaire (SDQ). Patient with a score above 10 on the 
SDQ were defined as patients with shoulder morbidity. The utilities assigned to the 
health states were numbers between 0 (dead) and 1 (perfect health). The EuroQol-5D 
questionnaire (EQ-5D) was used to measure health utilities. This was done by combining 
the answers of the questionnaire with Dutch tariffs.131 We did assume that utilities 
only changed due to shoulder complaints and not directly by a regional recurrence. A 
discount rate of 1,5% was applied to effects as recommended by the Dutch guidelines for 
pharmaco-economic research.140 
Table 3: Quality of life
Abbreviations: standard deviation (sd)
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Costs
The cost analysis was performed from a societal perspective. Volumes for hospital stay 
after the neck dissection were derived from an internal database from the Radboud 
University Medical Centre. Volumes for physical therapy treatment were obtained from 
expert consultation of a physical therapist. It was assumed that all patients underwent 
physical therapy if they suffered from shoulder morbidity. The number of outpatient 
consultations were based on the follow-up guidelines for patients with oral cavity and 
oropharyngeal carcinoma of the Dutch Head and Neck Society.141 The number of days 
of absenteeism were derived using data from the Dutch patient association for head and 
neck cancer.142 These volumes are shown in Table 4.
Costs of surgery for the two types of neck dissection were obtained from the Radboud 
University Medical Centre. Standard unit costs were used for hospital days, absenteeism, 
consultation and physiotherapy.143 Academic unit costs were used for hospital days 
and consultation. Every patient who underwent a neck dissection was assumed to have 
received a pre- and postoperative consult by a physical therapist to examine shoulder 
function. The costs of these consultations are equal to the costs of one physical therapy 
session, each. 
It was assumed that a regional failure was followed by salvage therapy with the costs of 
a complete cycle of radiotherapy, independent of type of neck dissection.144 For all costs 
in the model, price index numbers from Statistics Netherlands were used to convert them 
to the 2012 price level.145,146 The annual discount rate for costs was set at 4%.140 Table 
4 summarizes costs, in Euro, used in the model.
Table 4: Volumes
Abbreviations: standard error (SE)
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Table 5: Unit costs
Analysis
A base case analysis was conducted by calculating expected life years, QALYs and costs 
of the two strategies. In general there were three possible outcomes. First, one of the 
treatments is more effective (i.e. gains more QALYs) and is also less expensive. That 
treatment dominates the other treatment. Second, SND is more effective than MRND 
but also more costly. In this case the difference in effects has to be weighed against the 
difference in costs. This is done by calculating an incremental cost-effectiveness ratio 
(ICER), by dividing the estimated difference in costs by the difference in QALYs. This ICER 
represents the additional cost made to gain a QALY. Third, SOHND is less effective than 
MRND but also less costly. Again an ICER (weighing the difference in effects against the 
difference in costs) is calculated, which will represent the cost savings per QALY lost. We 
used a threshold value, i.e. the amount society is willing to pay to gain a QALY or willing to 
accept to lose a QALY, of €80,000.148 
In addition, deterministic and probabilistic sensitivity analyses were performed to 
evaluate the sensitivity of the results to changes in  parameter values. The deterministic 
sensitivity analyses included a one-way sensitivity analysis and an analysis from a 
healthcare perspective. First, one-way sensitivity analysis was performed on the transition 
probabilities of regional failure, by varying this parameter through a range of possible 
values. The probability of regional failure after MRND was fixed and the probability of 
regional failure after SND was varied between 0.05 and 0.11 using six intervals. In this way 
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the impact of a number of possible values of this parameter on the outcome of the model 
was evaluated. Second, an analysis from a healthcare perspective was performed using 
only costs for healthcare. In this analysis costs for absenteeism were, therefore, excluded.
To investigate sampling uncertainty, probabilistic sensitivity analysis was performed with 
1000 (Monte Carlo) simulations. For this purpose, beta distributions were assigned to 
transition probabilities and utilities, and gamma distributions to costs of absenteeism 
(Table 2 and 4). The results were presented in a scatter plot, where each point represents 
a single iteration of the  simulation.149 
Results
Base case analysis
By performing MRND on average 16.87 life years were yielded compared to 16.48 with 
SND.
Taking into account quality of life (i.e. calculating QALYs), MRND was on average still the 
most effective strategy, yielding 12.38 QALYs, compared with 12.33 QALYs in the SND 
strategy (Table 6). SND was found to have lower expected costs (€17,291) than MRND 
(€18,642). The loss of 0.06 QALYs and savings of €1,351 in the SND strategy compared with 
the MRND strategy resulted in an ICER of €24,268 saved per QALY lost. 
Table 6: Base case analysis based on societal perspective
Abbreviations: Modified radical neck dissection (MRND), Selective neck dissection (SND), Quality 
adjusted life years (QALY)
Deterministic sensitivity analysis
For the base case analysis a transition probability of 0.11 for regional failure after 
SOHND was used, compared with a probability of 0.05 after MRND. When we changed 
the transition probability after SND to 0.10 the ICER was €801,724 per QALY lost. For 
each value below 0.10 the MRND strategy was dominated by the SND strategy. When the 
difference in probability of regional between the strategies was lower than 5 percent, SND 
was the most cost-effective strategy (Table 7).  
The analysis from a healthcare perspective (using only healthcare costs) showed a saving 
of €768 with SND (€12,046) compared to MRND (€12,814). Using the earlier calculated 
effect of 0.06 QALYs lost, this resulted in an ICER of €13,798 saved per QALY lost (Table 8). 
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Table 7: Sensitivity analysis
*ICER was given in savings per QALY lost. Abbreviations: Modified radical neck dissection (MRND), 
Selective neck dissection (SND), Quality adjusted life years (QALY)
Table 8: Analysis based on health care perspective
Abbreviations: Modified radical neck dissection (MRND), Selective neck dissection (SND), Quality 
adjusted life years (QALY)
Probabilistic sensitivity analysis
The scatter plot of SND versus MRND presents the spread in incremental costs and effects 
of the 1000 Monte Carlo simulations (Figure 3). In 60% of the simulations SND was less 
effective than MRND. Only in 6% of the simulations SND was more costly. The red line 
in Figure 3 represents the WTA/WTP threshold of €80,000 per QALY. In the simulations 
which are to the right of the red line (41%), SND was cost-effective compared to MRND. In 
the simulations to the left of the red line (59%) MRND was more cost-effective.  
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Figure 3: Scatter plot of probabilistic sensitivity analysis
Each of the dots represents one of the 1000 Monte Carlo simulations. For these simulations, 
distributions were assigned to parameters in the model. Abbreviations: Quality adjusted life years 
(QALYs)
Discussion
Our model provides insight in treatment strategies for T1-2 OCSCC patients with limited 
nodal disease. On average, SND yielded less life years than MRND. Taking into account 
quality of life (i.e. calculating QALYs) MRND was still the most effective strategy, although 
differences between the strategies became smaller with lower quality of life after MRND. 
The better survival rate of MRND seems to outweigh the loss in quality of life after this more 
extensive procedure. SND was less costly than MRND. The incremental cost-effectiveness 
ratio was in favour of the MRND strategy, i.e. the savings in costs that can be reached with 
SND do not outweigh the loss in effectiveness. However, deterministic sensitivity analysis 
showed that the outcomes were highly sensitive to the assumed probabilities of regional 
failure after both strategies. When the difference in probability of regional failure between 
the strategies is lower than about 5 percent, SND is the most cost-effective strategy. 
As far as we are aware, we are the first studying the cost-effectiveness of the two strategies 
in OCSCC patients with limited nodal disease. In this model we used QALYs to take into 
account both survival and quality of life. Furthermore we included indirect costs such as 
costs of physiotherapy and absenteeism. Therefore it seems to provide a comprehensive 
reflection of reality. 
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Some potential limitations should also be discussed. First, we used quality of life data 
on selective neck dissections of level I-III, whereas selective neck dissections for the 
cN+ neck will sometimes include level I-IV (depending on the involved levels and the 
preference of the surgeon). This could have overestimated the utility after selective neck 
dissection. However, dissection of level IV does not give much extra morbidity relatively 
to dissection of level V.18 Second, we used a study of Schiff et al.for the regional failure 
probabilities of both strategies.138 This study, however, also included  some higher 
N-stages. Approximately 60% was stage N1, 19% N2a, 14% N2b and 5% N2c (Written 
personal communication with the authors). Therefore, a higher absolute risk of regional 
failure could have been found in these data for both strategies than one would find in a 
population with limited nodal disease only (cN1 and CN2a). This higher absolute risk in 
both strategies could have caused an overestimation of the relative risk of regional failure 
between the strategies (i.e. the difference in regional failure probabilities between SND 
and MRND). On the other hand, patients in the MRND group had higher pathological 
N-stages (pN-stages) compared to patients in the SND group, in this particular study. This 
in turn could have reduced a possible overestimation of the difference in regional failure 
probability between the strategies.  We performed sensitivity analysis on the difference in 
probability of regional failure to assess the influence of these possible limitations. 
Third, indications for radiotherapy in addition to neck dissection were assumed to be 
equal in both treatment options and were therefore not taken into account in this model. 
In the study of Schiff et al. more patients in the MRND group received postoperative 
radiotherapy. This could have reduced regional failure probability in this group. However, 
as mentioned above, these patients also had higher pathological N-stages. 
Fourth, OCSCC is most prevalent among older, often retired, people. We, however, used 
average wages for absenteeism, which might have resulted in an overestimation of the 
costs of absenteeism. The analysis from a healthcare perspective, excluding the costs of 
absenteeism, did not alter our conclusion. 
Fifth, in our model the same utility rate for shoulder morbidity was assigned every year. 
Since patients will receive physiotherapy it is expected that shoulder morbidity will 
decrease and the quality of life will improve over time. Furthermore, patients may learn 
to cope with their shoulder morbidity which could have a positive effect on their quality 
of life.24 Possibly this will lead to an underestimation of the effects of both strategies, 
which seems largest for MRND where most shoulder complaints occur. On the other 
hand, shoulder complaints after MRND may be more permanent and less responsive to 
physiotherapy than after SND, which would imply a larger underestimation for SND. 
Sixth, we assumed that salvage therapy after regional failure was equal in both strategies. 
In practice there will be a difference in salvage therapy after a regional failure between 
SND and MRND. It is likely that more effective treatment options may be available for 
regional failure after SND. To model the costs of salvage therapy we assigned the costs 
of a complete cycle of radiotherapy to every patient with regional failure. This may be an 
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overestimation of the actual costs of salvage therapy. Since this overestimation was made 
in both strategies it did not influence the results.  
Despite these possible limitations our model provides clinically important information 
and a concept of how to evaluate and give insight in the consequences of changes in 
treatment algorithms and strategies. To provide optimal treatment not only survival 
should be taken into account but also quality of life. In this study we combined these 
outcomes by using quality-adjusted life years. The model shows that, with used evidence, 
the overall survival gain with MRND outweighs the extra shoulder complaints and extra 
costs associated with this strategy. However, performing SND could save costs for society 
and healthcare. With raising healthcare costs, consideration of less expensive treatment 
options becomes more and more important. This raises the question if we are willing to 
drop effective conventional procedures to save costs. And, if so, how much savings would 
be required to accept a loss in effectiveness.150,151 The €1,351 that are saved per patient 
when performing SND instead of MRND seem insufficient to accept the loss of 0.06 QALYs 
per patient. 
The model shows that small changes in the assumed probabilities of regional failure have 
high impact on the outcomes. If the difference in probability of regional failure between 
the strategies is lower than 5%, SND was found to be more effective and cost-effective 
than MRND. Regional failure probabilities for both strategies could only be derived from 
a retrospective study with several limitations and were therefore uncertain. Therefore, 
prospective research on this parameter is highly valuable. With the results of such 
research (including subgroup analysis) our model can be used to show which strategy is 
optimal for each group of patients. 
In conclusion, given the evidence used in our model, SND was not cost-effective compared 
to MRND for T1-2 OCSCC with limited nodal disease (N1-2a), since this strategy was on 
average more effective without significant extra costs compared with SND. Prospective 
research on regional failure probabilities is highly valuable to obtain better data to reduce 
uncertainty and provide optimal treatment for subgroups of HNSCC patients and OCSCC 
in particular. 
Part III
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Abstract
Objective: To show how prediction models can be incorporated in decision models, to allow 
for personalized decisions; and to assess the value of this approach in the management of 
the neck in early stage oral cavity squamous cell carcinoma (OCSCC).
Study design and setting: In a decision model, three approaches were compared: a 
‘population-based’ approach in which patients undergo the strategy that is optimal for the 
population; a ‘perfectly predicted’ approach, in which each patient receives the optimal 
strategy for that specific patient; and a ‘prediction model’ approach in which each patient 
receives the strategy that is optimal based on prediction models. The differences in costs 
and Quality Adjusted Life Years (QALYs) between these approaches were studied.
Results: The population-based approach resulted in 4.9158 QALYs with €8,675 in costs, 
per patient. The perfectly predicted approach yielded 0.21 more QALYs and saved €1,024 
per patient. The prediction model approach yielded 0.0014 more QALYs and saved €152 
per patient compared with the population-based approach. 
Conclusion: The perfectly predicted approach shows that personalized care is worthwhile. 
However, current prediction models in the field of OCSCC have limited value. Incorporating 
prediction models in decision models appears to be a valuable method to assess the value 
of personalized decision making.
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Introduction
In the last years personalized healthcare has gained increasing attention. Personalized 
healthcare may be thought of as the tailoring of medical treatment to individual 
characteristics, needs and preferences of a patient during all stages of care.152 The 
evidence-based medicine (EBM) approach historically focuses on randomized clinical trials. 
In such comparative studies, which can include economic evaluations, often little attention 
is paid to patient heterogeneity. As a result, reimbursement decisions are generally based 
on average (cost-)effectiveness of the intervention in a selected population.153 This is 
also reflected in clinical guidelines, in which recommendations are often based on studies 
that pertain to the average population. They often do not guide in dealing with individual 
patient characteristics.154,155
In recent years, EBM research increasingly takes into account patient heterogeneity.156 
For example, prediction models are developed to estimate a probability of a certain 
outcome in an individual, given his or her personal or disease characteristics.157,158 
These probability estimates can guide care providers as well as the individuals themselves 
in deciding upon further management.159 Such models are becoming increasingly 
abundant in medical literature. Often multiple outcomes (e.g. survival and side effects) 
are relevant for one patient and therefore multiple prediction models are relevant for 
such an individual patient. This implies a trade-off between different outcomes, which 
makes the use of these prediction models for clinical decision making difficult.
This is for example the case in early stage oral cavity squamous cell carcinoma (OCSCC) 
patients. If they have no clinically detected lymph node metastases in the neck (cN0), 
the decision whether to remove the lymph nodes or not implies a trade-off between 
survival, quality of life and costs. In a previous study we used decision analytical modeling 
to inform this trade-off for an average cohort of patients.127 Sensitivity analysis showed 
that predictions for individual patients, based on their characteristics, such as a patient’s 
probability of occult metastases or his quality of life after surgery, influence which strategy 
is deemed optimal. Therefore it seems worthwhile to include patient characteristics into 
this decision model to weigh risks, benefits and costs for individual patients, to allow for 
more personalized evidence-based treatment decisions.
The aim of this study was to show how prediction models can be incorporated in decision 
models, and to assess the value of personalized decisions based on these prediction 
models using the case of the management of the neck in early stage oral cavity squamous 
cell carcinoma (OCSCC) as an example. 
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Methods
The case
In about 30% of patients with early stage (T1-2) OCSCC, who have no clinically detected 
regional lymph node metastases (cN0), occult metastases are present in the lymph nodes 
of the neck.86 Therefore the decision needs to be made whether to remove those lymph 
nodes at risk for involvement by metastatic cancer, or to follow a watchful waiting strategy. 
Removing the lymph nodes at risk by performing a neck dissection increases prognosis.14 
However, this invasive procedure is unnecessary in 70% of patients, and quality of life 
could be reduced due to shoulder complaints as a result of the neck dissection.23 Watchful 
waiting on the other hand implies undertreatment in 30%, which could result in lower 
survival when occult metastases are present.14 
Decision Model 
We used our previously published decision model as the basis for this study.127 In this 
model five management strategies for the neck in cT1-2N0 OCSCC patients were evaluated. 
The strategies were: (1) elective neck dissection (END), (2) watchful waiting (WW), (3) 
gene expression profiling (GEP) followed by neck dissection (ND) or WW, (4) sentinel 
lymph node (SLN) procedure followed by ND or WW, and (5) GEP and SLN procedure (in 
case of positive GEP) followed by ND or WW. 
A decision tree was used to model the diagnostic and treatment pathways, and a Markov 
model represented the subsequent follow-up. The diagnostic and treatment pathways are 
shown in Figure 1. Patients who actually do have occult metastases can either be correctly 
classified as positive (true positive) or falsely classified as negative (false negative). Those 
that do not have occult metastases can either be true negative or false positive. The false 
positive and true positive patients receive ND while the false negative and true negative 
patients undergo WW. All patients who are classified as positive are treated and therefore 
have a probability of having shoulder complaints. In the END (strategy 1) all patients are 
considered positive and are therefore true positive or false positive. In the WW strategy 
(strategy 2) all patients are considered negative and are therefore true negative or false 
negative. After this diagnostic and treatment pathway, patients move to the different 
health states in the Markov model, which represent the follow-up of patients. Possible 
health states for patients were: regional failure (RF), no RF, or dead. The structure of the 
Markov part of the model (Fig. 2) was the same for each diagnostic outcome. However, 
the probabilities of entering the different states (i.e. the chance of regional failure) were 
different among the diagnostic outcomes. Patient with occult metastases had a higher 
probability of regional failure if they are classified negative (false negative) than when 
they are classified positive (true positive). The utility values of the regional failure and 
no regional failure states depend on whether patients have shoulder complaints or not. 
Patients who are classified positive have a higher chance of having shoulder complaints 
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and therefore on average, a lower health utility which was unnecessary in case of a false 
positive classification.
The time horizon of the model was 10 years, with yearly cycles. The model was built in 
Treeage Pro 2014. 
Figure 1 Model structure decision tree
Decision Tree part of the model. Gene expression profiling (GEP) and GEP + sentinel lymph node 
(SLN) procedure were left out of the Figure. GEP had the same structure as the SLN strategy. GEP + 
SLN has an extra possibility after False positive to go to True negative.
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Figure 2: Markov part of the model
Influence diagram of the Markov part of the model. The Markov part of the model represents 
follow-up after diagnostic outcome and corresponding treatment. Patients have a probability of 
entering the Markov model in the Regional failure (RF) or No RF state, depending on whether they 
have occult metastases and received treatment. These states could be with or without shoulder 
complaints. Patients can either survive and stay in the state they entered or die. The transition 
probabilities between the RF state and dead and the No RF state and dead were not depended on 
having shoulder complaints. However, the utility values of the RF or no RF state did differ between 
patients with and without shoulder complaints. 
Prediction models
Our previous decision model showed that results were sensitive for changes in percentage 
of occult metastases and utility values. Although not tested in the previous study, we 
also expected survival to be an important parameter. Therefore we included prediction 
models for percentage (chance of) occult metastases, utility values (for patients with and 
without shoulder complaints) and survival (for patients with and without regional failure). 
Because of the inclusion of multiple prediction models it was important that we did not 
double count the effect of patient characteristics by incorporating the same effect of a 
characteristic in multiple prediction models. First, we searched for prediction models for 
these parameters in the literature which were suitable for the use in the decision model. 
In absence of suitable models we searched for data to develop such a model. Because 
the development and description of these models was not the aim of our study, we only 
present basic information about the models. However, we are aware that normally newly 
developed prediction models deserve a more comprehensive description. When these 
prediction models are further developed or used in practice, a more comprehensive 
description is warranted.157 
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Prediction model 1 - Probability of occult metastases 
We searched for a multivariable logistic model to predict absolute risks of occult 
metastases in cN0 patients. Multiple studies regarding predictors of occult metastases 
have been performed in OCSCC patients.160-163 However, none of the identified models 
could be incorporated in our decision model. Some studies also included cN+ patients 
164,165, while other studies did not perform multivariable analyses, or absolute risks were 
neither provided nor calculable. 160-164,166 Therefore we developed a new prediction 
model based on registry data of the Radboudumc. This multivariable logistic regression 
model was based on 235 Dutch patients diagnosed with early stage cN0 OCSCC between 
2000 and 2013 in the Radboudumc. These patients were treated surgically for the 
primary tumor and underwent an END which was the standard treatment in this period. 
The predicted outcome was occult metastases (yes/no), which was defined as the pN 
stage (pN+ or pN0) after pathological examination of the neck specimen. The final model 
consisted of four predictors: T-stage (T1/T2), vasoinvasive growth (yes/no), spidery growth 
(yes/no), and depth of invasion (in mm). The C-index of the model was 0.725. Further 
details about this prediction model are listed in Appendix A. This model was incorporated 
in the decision model to define the probability of having occult metastases (Figure 1).
Prediction model 2 - Utility values
Because it is known that utility values depend on age and gender,we wanted to include 
a model with at least these two predictors.132 No studies were available that predict 
utility values in OCSCC patients based on patient characteristics. Therefore we developed 
two multivariable linear regression models based on information we obtained in our 
previous quality of life study in 153 early stage OCSCC patients.167 These patients were 
treated in the Radboudumc or the Netherlands Cancer Institute between 2001 and 2013 
with different strategies for the neck (WW, SLN procedure or ND). One model predicted 
the utility value for patients with shoulder complaints (n=68), while the other model 
predicted the utility value for patients without shoulder complaints (n=83). Both models 
consisted of two predictors: age and gender. The R-squares of the models were 0.075 for 
the model for patients with shoulder complaints and 0.040 for the model for patients 
without shoulder complaints. Further details about these prediction models are listed in 
appendix B. The prediction models were used to assign utility values to patients with and 
without shoulder complaints, who could either be in the RF or no RF health states (Figure 2).
Prediction model 3 - Survival 
We found relevant and validated prediction models for survival developed by a Dutch 
group which was suitable for our decision model.168,169 We collaborated with this group 
to include two Cox proportional hazards models predicting survival for patients with and 
without regional failure (RF). These prognostic models were based on 1369 consecutive 
patients diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC) between 1981 
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and 1999. The yearly survival was predicted over 10 years in both models. Age at diagnosis 
and clinical tumor stage (cTNM) were taken into account in the original model.168 Levels 
of co-morbidity (coded by the Adult Comorbidity Evaluation-27 (ACE27 )) were added 
as a prognostic factor in an updated version of the model.169,170 Internal validation of 
the updated model, including outcomes on patients with and without regional failure, 
showed a Harrell’s Concordance Index of 0.76. A subset of this model was included in the 
Markov model to determine the probability of dying each year from the RF and no RF 
state for patients with early stage OCSCC (Figure 2). Details about this model are listed in 
appendix C.
Other input decision model
Input for parameters for which no prediction models were obtained was equal to our 
previous decision model.127 Probabilities of having shoulder complaints  were 32% after 
WW, 36% after SLN and 43% after (E)ND.167 Patients with a positive SLN (strategy 3 and 
5) received an ND and were assumed to have a probability of shoulder complaints of 
43%. When the result of the GEP test was negative, the same probability of shoulder 
complaints as for the WW was assigned. A total overview of the input, including the 
average predictions of the prediction models, is listed in appendix D. 
Analysis
For each of the five management strategies the expected costs and QALYs were simulated. 
The most cost-effective strategy was selected as the optimal strategy. To select the most 
cost-effective strategy a willingness to pay of €80,000 per QALY gained was used. For this 
purpose we simulated the costs and effects for 500,000 patients. Three approaches to 
select the most cost-effective strategy for patients were compared.
In the first approach, the population-based approach, all patients received the same 
strategy (of the five possible strategies): the one that is optimal for the average population. 
This was determined by using the basic input with average values (e.g. a probability of 
22% for each patient to have occult metastases). The average costs and effects associated 
with this optimal strategy were calculated over all 500,000 patients. 
In the second approach, the ‘perfectly predicted’ approach, each patient received the 
strategy that leads to optimal expected outcomes in that individual patient. In this 
approach we assumed that the optimal strategy for every individual patient could be 
perfectly predicted, i.e. a theoretical approach in which the ratio between observed 
and predicted was always 1 for each probability. For instance we assumed that we could 
perfectly predict which 22% of the patients had occult metastases and which patients 
belonged to the other 78% that did not have occult metastases. Again, we calculated 
the average costs and effects per patient when giving all 500,000 patients the optimal 
strategy.
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In the third approach, the prediction model approach, each patient received the strategy 
that was deemed optimal based on the prediction models that were implemented in the 
decision model. For this prediction model approach patients with certain characteristics 
were simulated in the model. These characteristics were linked to the prediction models. 
Patients (including disease) characteristics were simulated based on a database of 248 
patients from the Radboudumc, which was a small expansion on the database that was 
used to develop the prediction model for occult metastases. The ACE scores were not 
available in this database. The distribution of ACE scores was obtained from the database 
that was used for the survival model. The different distributions are presented in Table 
1. Again, average costs and effects for the optimal strategies were calculated for the 
simulated patients. Similarly, we assessed the value of each of these prediction models 
separately, by using a fixed value (the average population value) for the other parameters.
Table 1 Distributions of patient characteristics of 248 patients from the Radboudumc database
*Obtained from the database used for the survival model All other distributions were based on 248 
patients from the Radboudumc database
We compared the average costs and QALYs of the population-based approach with the 
perfectly predicted approach and the prediction model approach. The population-based 
approach was also compared with the prediction model approach for each of the three 
prediction separately. The difference between the perfectly predicted approach and 
the population-based approach indicates the maximum value of personalized care with 
respect to management of the neck in OCSCC patients. The difference between the 
prediction model approach and the population-based approach represents the value of 
personalized care based on the three prediction models together, or based on one of the 
prediction models, independently. 
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Results
The results of the three approaches are presented in Table 2. The SLN strategy was on 
average the most cost-effective strategy. On average, the SLN strategy resulted in 4.9158 
QALYs and costs €8,675 per patient, which represent the results of the population-based 
approach. In the perfectly predicted approach each patient will receive his or her optimal 
treatment under the assumption that the optimal strategy for each patient could be 
perfectly predicted. This approach resulted in 5.1252 QALY per patient and €7,651 in 
costs, on average. Therewith, 0.21 QALYs were gained and €1,024 was saved per patient if 
management decisions could be perfectly predicted, compared to the population-based 
approach. These increments represent the maximum added value of personalizing care. 
With the prediction model approach the SLN strategy was predicted as the optimal 
strategy in 78% of the patients while END and WW were both predicted as the optimal 
strategy in 11% of the patients. This resulted in an average effect of 4.9172 QALYs per 
patient and average costs of €8,523 per patient. This implies that the effects increased 
with 0.0014 QALYs per patient, while costs were reduced with €152 per patient, which 
represents the value of personalizing care base on the included prediction models. 
Table 2 also shows the value of the separate prediction models, which represents the 
value of decision-making using each prediction model separately. The prediction model of 
the chance of occult metastases reduced the costs per patient with €136 and increased 
the expected QALY with 0.0004 per patient. The survival model slightly reduced the 
expected QALY per patient with 0.00002 and reduced expected costs with €17. The utility 
model slightly increased the expected QALY with 0.0002 and increased the expected cost 
with €5 per patient.
Table 2. Results of the three approaches (per patient)
139
Decision modeling to inform evidence-based personalized decisions Chapter 9
9
Discussion
This study showed how prediction models can be incorporated in decision models, and 
assessed the value of personalized decisions regarding the management of the neck in 
early stage cN0 OCSCC. In the perfectly predicted approach, 0.21 QALYs were won and 
€1,024 was saved per patient as compared to a population approach in which each 
patient receives the same treatment. This shows that there is considerable value of 
personalized care with respect to management of the neck in OCSCC patients. Selecting a 
strategy based on the prediction models yielded only 0.0014 extra QALYs and saved €152 
per patient as compared to the population-based approach. The model for the chance of 
occult metastases was the most influential of the three prediction models. 
The main strength of this study is that it combines multiple prediction models to assess 
the potential value of personalized care. We therewith combined existing methods to 
acknowledge heterogeneity in patients, i.e. predictions models, with methods to calculate 
the value of personalized care.171-173 This provides insight in the actual efficiency of the 
efforts in personalizing healthcare.57 
Some limitations of this study should also be discussed. First, the prediction models have 
not been validated in other populations, since this was not the aim of our study. If the 
models have sufficient value for improving clinical decisions, it is worthwhile to perform 
such an external validation.157 Second, we did not incorporate the imprecision of the 
prediction models in our analysis. Hence, the consequences of making a wrong prediction 
were not taken into account. This could, however, be taken into account by implementing 
the uncertainty of the prediction models using probabilistic sensitivity analyses.149 This 
makes the model more complex because variability and uncertainty are combined and 
require separate simulations.174 As the main purpose of our study was to illustrate the 
combination of decision and prediction models, we decided to keep the model as simple 
as possible. Third, characteristics of the simulated patients such as age, tumor stage and 
depth of invasion were simulated independently, whereas it is known that for example 
stage and depth of invasion are related. This may have caused an overestimation of the 
added value of the prediction model approach. Because the model only includes early 
stage tumors, this overestimation is expected to be small. Fourth, we used the same utility 
values for each year that patients had shoulder complaints after an operation. In reality 
it is more likely that shoulder complaints cause more disutility in the first period after the 
operation.25 This could have an influence on the optimal strategy because this implies a 
more important trade-off between quality of life (utilities) and survival in patients with 
low expected survival. For example, a high disutility in the first year after surgery might not 
be worth a slightly higher expected survival. Taking into account these different disutility 
values over time, by making a model with year to year predictions of utility values, could 
have caused a higher added value of the prediction model approach compared to the 
population approach, especially for the utility and survival prediction models. Further 
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research is needed to obtain these data and make the model more precise. 
Despite these limitations this model is an important step towards evidence-based and 
personalized decision making. With regard to the case of neck management in OSCC 
patients, the perfectly predicted approach showed that there is a considerable potential 
value of personalizing care. Although it is unrealistic that this full potential can be reached, 
it seems worthwhile to invest in personalizing OCSCC care. Since the prediction model 
approach, with the currently available prediction models, showed to have low added 
value for personalized decision making, more information should be obtained about the 
influence of patient heterogeneity in the field of OCSCC to expand the prediction models 
and improve the personalized decision model. For instance, the models for utility values 
had limited value in their current state. Since predicted utilities should be weighed against 
predicted survival, both the utility models and the survival model may be more valuable 
when utilities can be predicted over time. The model for prediction of chance of occult 
metastases showed the highest added value. It seems worthwhile to further develop this 
prediction model. There are indications that some characteristics in the occult metastases 
model, i.e. vasoinvasive growth and spidery growth,  could only be reliably assessed after 
excision of the primary tumor. This would imply a different use of this model in practice, 
and should therefore be taken into account in further development of this prediction 
model. 
More general, including multiple prediction models could be a basis for clinical decision 
support systems which often have shown to have added value in clinical practice.175 When 
a solid model is developed this could be automatically updated when new information 
from patients becomes available. By using decision models we could also assess the 
potential value of the individual prediction models and therewith we can decide whether 
it is worthwhile to further develop and validate one or multiple prediction models or to 
start using them in clinical practice. With regard to research, an individual decision model 
could therewith be used as an informative method before the actual value of a prediction 
model is evaluated in clinical practice by prognostic impact studies.176 
In this study we used cost-effectiveness as the criterion for the optimal strategy. It is 
also possible to use the most effective (highest gain in QALYs) as the optimal strategy. 
The question is which criteria should be used in personalized decisions in general and in 
this particular case. Both the added value of the perfectly predicted approach and the 
prediction model approach would be different when considering the strategy with the 
highest effect as the optimal strategy. This is an important consideration as we continue 
developing personalized decision modeling. However, when simulating costs as well as 
effects, the definition of optimal care can be easily changed.
In conclusion, personalizing the management of the neck in early stage OSCC could 
improve health outcomes of patients and reduce costs. However, decision-making on 
a personalized level based on the combination of currently available prediction models 
does not seem to be sufficiently valuable to be used in clinical practice. Prediction models 
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related to the neck management in OCSCC should be further developed. More generally, 
incorporating prediction models in decision models appears to be a valuable method 
to inform decisions on a personalized level and to assess the value of this personalized 
decision making.  
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Appendix A: prediction of chance of occult metastases. 
A multi variable logistic regression model was developed to predict the presence of 
occult metastases (i.e. metastases present or metastases not present).  This model 
was based on 235 patients diagnosed with OCSCC in the Radboudumc (Nijmegen, The 
Netherlands) between January 2000 and January 2013. These patients were treated 
surgically for the primary tumor and underwent an elective neck dissection. The predicted 
outcome (presence of occult metastases) was defined as the pN stage (pN+ or pN0) after 
pathological examination of the neck specimen. In this population 58 (25%) patients had 
occult metastases. The information was obtained from registry data of the Radboudumc. 
Table 1 shows the variables (predictors) in the prediction model together with the 
coefficients and levels of significance. Also the concordance index (c-index) is presented. 
Vasoinvasive growth, spidery growth and tumor depth of invasion was determined on the 
excision specimen of the primary tumor. Stage was determined after diagnostic work up. 
Table 2 shows the frequencies of the included variables in the population on which the 
prediction model was developed. 
Table 1 prediction model occult metastases
C-index = 0.725
Range of predicted values: 0.057 to 0.76
Table 2 Frequencies of population of occult metastases prediction model
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Appendix B: Prediction of utility values
Linear multivariable regression models were developed to predict utility values which 
represent the quality of life in patients with early stage OCSCC. The models were based 
on patients who were treated in the Radboudumc or the Netherlands cancer institute 
between 2001 and 2013 with different strategies for the neck (WW, SLN procedure or 
ND). One model was developed to predict utility for patients with shoulder complaints 
(n=68) and one model for patients without shoulder complaints (n=83). Information was 
obtained from a cross-sectional survey study to measure quality of life in these patients. 
In this study patients were sent questionnaires to measure shoulder complaints (Shoulder 
disability questionnaire) and health utility (EQ-5D-3L). 
Table 1 (patients with shoulder complaints) and Table 2 (patients without shoulder 
complaints) show the variables (predictors) in the prediction model together with the 
coefficients and levels of significance. Also the level of explained variation (R-square) of 
both models is presented. Table 3 and 4 show the frequencies of the included variables in 
the population on which the prediction models were developed.
Table 1 prediction model of patients with shoulder complaints
R-square 0.075 
Range of predicted values: 0.619 to 0.968
Table 2 prediction model of patients without shoulder complaints
R-square 0.040 
Range of predicted values 0.858 to 0.971
Table 3 Frequencies model patients with shoulder complaints
Table 4 Frequencies model patients without shoulder complaints
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Appendix C: prediction survival model
A Cox proportional hazard model was obtained from a Dutch group.  
The model was based on 1369 patients with Head and Neck Squamous Cell Carcinoma 
(HNSCC) from the Leiden University Medical Center between 1981 and 1999. 
We used a subset of this model to predict survival for patients with early stage (cT1-T2) 
N0M0 OCSCC. Survival was predicted for 10 years both for patients with and without 
regional failure. The model included a factor y, which was built out of 3 predictors: Stage, 
age and co-morbidity (ACE-stage).
With regional failure: Y=-2.009+0.3229*Stage+0.0359*age+ACE-stage+0.57575
Without regional failure: Y=-2.009+0.3229*Stage+0.0359*age+ACE-stage
With:                 With average survival (Table 1):
Stage: T1=0 and T2=1
Age: Age in years
ACE-stage: ACE1=0, ACE2=0.0847, ACE3=0.3577 and ACE4=0.44
Factor Y is translated to 10 year survival probabilities with:
Individual survival = average survival ^ EXP (y-2.499908291)
Table 2 Frequencies of population of survival                  Harrell’s C: 0.7
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Appendix D: input
D1: Transition probabilities
*Average predictions from prediction models
D2 Costs
D3 Utility values
*average predictions from prediction models
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As described in chapter 1, the overall aim of this thesis was to inform evidence-based decisions 
in the management of oral cavity squamous cell carcinoma (OCSCC) patients. To achieve 
this overall aim, this thesis is structured around three specific objectives: 1) to evaluate the 
need for evidence-based surgery in general, and more particularly for diagnostic and surgical 
innovations in OCSCC; 2) to assess the cost-effectiveness of various management strategies 
for the neck in early-stage OCSCC patients; and 3) to bridge the gap between evidence-based 
decision-making and personalized healthcare in the management of the neck in OCSCC 
patients. In this discussion, I will outline the main findings and then put the results into a 
more general perspective. Furthermore, since the overall aim was to inform evidence-based 
decisions, I will discuss three aspects related to decision modeling which will be relevant 
for future incorporation of decision modeling into evidence-based decision-making. Finally, 
specific recommendations will be given to further enhance these aspects. 
Main findings
As to the need for evidence-based surgery in general, and more particularly for innovative 
surgical procedures and diagnostics in OCSCC (objective 1), we showed that health care 
spending could be reduced by no longer performing lower-value surgery. We estimated 
that approximately 250 million Euros a year could be saved by no longer performing 
lower-value surgical procedures in the Netherlands. With regard to OCSCC surgical care, the 
management of the neck shows a considerable variation between centers and countries. 
For instance, the relevant parties in OCSCC management did not agree on the necessity 
to use the sentinel node procedure regularly in OCSCC patients with a clinically negative 
neck (cN0). As a result, the use of this procedure varied between centers and countries. 
Variations in practice and rising health care costs indicate a lack of clear evidence and the 
need for evidence-based surgery. Decision modeling could provide us with information on 
the added value and cost-effectiveness of innovations and procedures. As a result, we may 
reduce variation and health care spending and improve patients’ health. 
To assess the (cost-)effectiveness of various management strategies for the neck in OCSCC 
patients (objective 2), we performed a diagnostic meta-analysis showing that the sentinel 
lymph node biopsy (SLNB) procedure has a sensitivity of 93%. This outcome was used as 
an input value for our decision analytic model, which compared the costs and effects of 
five available strategies for the cN0 neck in early-stage OCSCC patients. This evaluation 
showed that the SLNB procedure was the most effective and cost-effective strategy. 
However, the model was sensitive to changes in assumed quality of life (expressed in 
utility values). It showed that further information on quality of life in this population 
was very useful. We therefore studied the quality of life after different diagnostic and 
treatment modalities for the neck and we found relatively high utility values after a SLNB 
procedure was performed. When using the updated utility values for our decision-analytic 
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model, SLNB remained the most (cost-)effective strategy. Another modeling study showed 
that selective neck dissection was not cost-effective compared to modified radical neck 
dissection in early-stage patients with a cN+ neck and singular node disease. However, 
sensitivity analysis suggests that there may be subgroups for whom selective neck 
dissection is cost-effective. Overall, decision-analytic modeling proved to be a valuable 
method to assess the (cost-)effectiveness of various management strategies for the neck 
in OCSCC patients.
To bridge the gap between evidence-based decision-making and personalized healthcare 
in the management of the neck in OCSCC patients (objective 3), we incorporated three 
prediction models into the decision model for the cN0 neck. Separate prediction models 
predicted the probability of a patient having occult metastases, survival, and the quality of 
life in patients with and without shoulder complications. This allowed us to calculate the 
costs and effects of the different management strategies taking into account the patient 
and disease characteristics instead of providing average population-level outcomes. In 
addition, we were able to calculate the value (expressed in health benefits and health 
cost savings) of making more personalized decisions in the management of the neck in 
OCSCC patients. Incorporating prediction models into a decision-analytic model seems to 
be a promising method to bridge the gap between evidence-based decision-making and 
personalized healthcare. 
Decision modeling and evidence-based decisions
The clinical example of the management of the neck in patients with early stage OCSCC 
showed that decision modeling can be useful in providing a more evidence-based insight 
into decision-making regarding clinical issues. The decision model offers a framework for 
linking relevant evidence regarding a specific clinical issue, allowing important assessments 
of such matters to become transparent. As a result, more specific choices can be made. 
For instance, a wider use of the sentinel node procedure is currently being discussed by 
the Dutch Group of Head and Neck Tumors (NWHHT) partly as a result of the findings 
described in this thesis. Furthermore, these decision models can offer guidance for 
further research as they provide insight into what additional information is of great value, 
similar to the information provided on quality of life in OCSCC patients after undergoing 
various modalities for the neck. I have also shown opportunities to support patient-level 
decisions by using decision models. Our examples demonstrate that decision models can 
contribute to evidence-based decision-making within the field of head and neck surgery. 
Our examples focused on supporting clinicians in evidence-based decision-making 
regarding new procedures. However, decision modeling in the field of surgery seems to be 
infrequently used to actually support decisions. In order to develop a more evidence-based 
approach to surgery we must see to it that methods are being developed further, allowing 
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strategies to be evaluated in an evidence-based manner. We should also see to it that 
these evaluations are actually used in the decision process. During my doctoral research 
activities I discovered three aspects which in my opinion play a role in the limited use of 
decision modeling: the way the models and results are presented to the intended user, 
the current evaluation phase of the innovations, and the ever-recurring area of tension 
between average population-based outcomes and the treatment of individual patients. In 
the following sections, I will examine each of these three aspects further.
Presentation of the model and results
The aim of decision modeling is to provide relevant stakeholders with information 
regarding the consequences of different options when a decision is being made. In order 
to achieve this result, it is necessary for them to understand the model and therefore 
trust the subsequent results produced.177 However, methodological developments in the 
field of decision modeling lead to a higher level of complexity. As a result, results are 
increasingly difficult to interpret.178,179
It is important that the model and results are presented well to the people who need 
to make the ultimate decision. Currently, decision models are most frequently used 
for economic evaluations to support decisions on reimbursement for medicines. 
Reasons for this include the way access for different types of care has been regulated. 
A so-called closed description applies to drugs, which means the minister is allowed to 
make additional demands for admission regarding efficiency, i.e. manufacturers have to 
provide information regarding the cost-effectiveness of a new medicine. For other forms 
of care, including surgery, an open description applies in which no clear demands are 
being made regarding cost-effectiveness.180 For this reason, cost-effectiveness does not 
seem to play an important role in the Netherlands (and most of the other countries) in 
deciding whether or not to offer reimbursement for these other forms of care.Therefore, 
clinicians have more influence on the use of medical interventions not involving drugs, 
such as new surgical procedures and medical devices. In general, they will make decisions 
in daily practice, for instance when deciding whether a procedure will be actually used. 
Furthermore, clinicians are the main link in the development and evaluation of new 
procedures. In the field of surgery, clinicians therefore seem to be a relatively important 
target group to focus the decision evaluation regarding new procedures on. It should be 
mentioned that clinicians will initially be interested in the effectiveness of the procedures. 
However, it is also possible to only study effectiveness by using a decision model. In order 
to create not only better but also affordable care it is important for clinicians as well to 
be aware of the necessity to weigh costs and effects against each other and therewith 
to provide clinicians with information on this. Cost-effectiveness may play a future role 
in decisions on paying for non-drug-related interventions.180 Especially with regard to 
surgical innovations (new techniques, modified strategies or innovative instruments), 
which can often be used in various ways, it is important for clinicians to stay involved in 
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modeling studies in order to ensure they are relevant and the results are implemented 
into practice in the right manner. 
The target group will have to understand the model and results in order to actually 
use them. Reporting checklists have been developed to make decision modeling more 
transparent and reduce ambiguity.177,181-183 One of these checklists, the joint guideline 
from the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
and the Society for Medical Decision Making (SMDM), is specifically designed to report 
decision modeling in a transparent manner.177 This guideline comprises a list of fourteen 
aspects, which need to be described when presenting model-based economic evaluations. 
Furthermore, they indicate that in a number of cases the model itself (computer code 
or program) could be added in order to give more insight into the model. However, 
the recommendations are rather concise. For instance, although it is mentioned what 
information should be given (i.e. information on input, output, model validation and 
effects of insecurity), it is not mentioned how this information should be described.  The 
way in which this information is described, will determine whether relevant stakeholder 
will truly understand it. 
Although we used the ISPOR-SMDM guideline for reporting our articles, it was shown that 
the information provided did not always fit the clinicians’ needs. Clinicians expressed their 
wish to have a better understanding of how the model works and how certain parameters 
and assumptions affect the results.
Evaluation phase
Currently, surgical innovations and devices are hardly evaluated. In general, if an 
evaluation does take place, the innovation under evaluation is already being used 
frequently.3,4 The IDEAL collaboration has defined various phases of surgical innovation 
with recommendations regarding evaluations during those phases. The real evaluations 
only begin when the technique is already widely used.6 In the initial phases, a description 
of the procedure and a report of complications, among other things, are recommended 
in particular. Potential (cost-)effectiveness of the new procedure is left aside. When new 
equipment (medical aids) is being purchased, which is usually a hospital-level decision, 
the (potential) added value from a therapeutic point of view and the effectiveness of 
the intervention are rarely a point of consideration.184 For instance, the da Vinci robot 
has been purchased by many hospitals and has been used for an increasing number of 
indications without the presence of clear evidence. One of the main reasons for this 
type of technology being rapidly implemented is its high-tech and innovative character. 
Clinicians and hospitals want to remain in a leading position. The opportunities provided 
by the new technique in particular are presented to the public, whereas uncertainties are 
pushed into the background. As a result, patients tend to prefer innovative technologies 
as well.185 The current policy followed by various health insurers is to only pay for robotic 
surgery unless it is shown to be of added value.186
152
General discussionChapter 10
So a new procedure is often evaluated when it has been used frequently, a lot of money 
and energy has been put into the development and purchase of this intervention 
technique, and professionals have become familiar with it. Previous studies as well as our 
study into costs of lower value surgery (chapter 2) have shown that common procedures 
are not abandoned just like that, even if they seem to be of no added value.187 Therefore, 
de-implementation of existing procedures has proven to be very difficult.187-190 A report 
written by the Health Council of the Netherlands mentions several reasons for difficulties 
regarding de-implementation, including resistance to change in general and the occasional 
effectiveness of a procedure in a small group of patients despite the absence of added 
value for the majority of patients. Due to the previous-mentioned factor, the public 
opinion in particular may interfere with de-implementing procedures.184
An early evaluation of procedures and devices with regard to whether they have added 
value may offer a solution and avoid the need for de-implementation. An early evaluation 
preferably started in the development phase may be able to stop or adjust the development, 
because there are fewer reasons for resistance if a procedure has not yet been widely 
implemented. These early forms of evaluations are called early Health Technology 
Assessments (HTAs).191 In the literature on this subject, various methods and frameworks 
for early HTAs are described. These evaluations are based on decision models designed to 
map out the potential (cost-)effectiveness of new procedures or equipment.191-195 The 
headroom method is an important method which examines whether there is room for 
improvement within a particular indication area in which the innovation technique can 
be used, showing whether it is useful to invest in (further) development of this particular 
innovation technique.194,196 A study conducted by Chapman et al. shows that the 
headroom method has a predictive value for medical devices regarding future inclusion by 
Britain’s National Health Service, which does consider cost-effectiveness to be an important 
criterium.197 When a procedure or innovation is being developed, decision modeling can 
provide helpful information to make decisions regarding further development, research 
and implementation, depending on the development phase.193, 194 An example of the 
opportunities offered by early HTA can be showed with the case of the gene expression 
profile, evaluated in chapter 6. This evaluation showed that the gene expression profile 
with its currents characteristics is not cost-effective. Despite the gene expression profile 
being in a relatively early stage of development, time and money had already been spent 
on it. For instance, a validation study had been carried out after its development and 
initial accuracy tests.116 After the initial tests a decision model could have examined in 
an objective manner whether the gene expression profile was of potential value based 
on the first test results. Next, it could have been decided whether a validation study or 
further (technical) development of gene expression should have followed, if the gene 
expression profile was not likely to be cost-effective at that point based on the results.
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Figure 1: Minimally required accuracy of a new diagnostic test to find potentially occult metastases 
in the neck in cN0 patients (Willingness to pay €80,000/QALY)
An evaluation prior to the development could have determined whether there is room for 
improvement and if so, how big this room for improvement will be at most. For instance, 
prior to the development of the gene expression model for cN0 neck, evaluation could 
have taken place regarding the minimal diagnostic value of this test in order for it to 
be or become cost-effective. By carrying out this type of evaluation, it can be decided 
whether developing such tests provide chances of improving treatment regimens. After 
the development and after carrying out the initial tests, it can be decided whether this 
minimal level of accuracy has been or can be reached. Figure 1 shows the combination 
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of sensitivity and specificity in which a new diagnostic test would be cost-effective. In 
this figure we have estimated the costs of the diagnostic test at 1,000 Euros. This seems 
to be a realistic cost price for the gene expression profile (because the costs of these 
tests are going down). The figure shows that the specificity of the diagnostic test must be 
around 70% at least for it to be cost-effective. In that case, the sensitivity should be high, 
around 90% at least. Apart from the minimally required diagnostic accuracy, it can also 
be determined what the effects of an improved accuracy are in terms of health profit and 
change in costs. This information could enable the developers and clinicians involved to 
make better informed choices regarding research and development. 
Towards personalized healthcare
In general, decision modeling involves making a comparative assessment in a population. 
However, doctors do not treat an average population, but individual patients to whom 
they want to give the best possible information on potential results and consequences of 
different treatment options based on their own patient and disease characteristics.
Therefore, we tried to develop a more evidence-based approach to decision-making 
in individual patients by using an individual model in chapter 7. The incorporation 
of prediction models into decision models seems to be a useful method to inform 
individual-level evidence-based decisions and to evaluate the value of these individual 
decisions. However, further steps need to be taken and several questions need to be 
answered before these models will and can actually be used in practice. 
It is important to know how an individualized decision model can be used best in practice, 
if an analysis of the model will show that individualized decisions are indeed useful. It 
is mentioned before that decision modeling is a method aimed at making comparative 
assessments between different outcomes (for instance, quality of life and survival). 
Patients may differ in the way they value these outcomes. Furthermore, we want to 
support decisions regarding the individual patient. Therefore, the needs of individual 
patients have to be taken into account when deciding which management strategy fits 
their preferences.198,199 
When making preference-sensitive decisions, it is important to have a collaborative process 
that allows patiens and their care providers to make health care decisions together, taking 
into account the best scientific evidence, as well as the patient’s values. This approach 
is called shared decision making, and is likely to result in better professional-patient 
relationships, better decisions and better outcomes.200 Shared decision-making is often 
facilitated by decision aids. These are tools designed to help patients make decisions 
regarding different options. These tools provide information on the different options 
available and help patients design, clarify and communicate their personal values in 
relation to the various options.155,201 A limitation to the currently available decision aids 
is that they are often not being based on up-to-date information. Furthermore, clinicians 
may find the format impractical to use in consultations and may be just as unfamiliar with 
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risk estimates and the inherent uncertainty associated with probabilities as their patients 
are.202 Decision models can offer a framework for linking relevant data and therefore 
seems to be useful for selection tools. Individual decision models provide specific and 
detailed information on comparative assessments between the likelihood of a particular 
outcome and the consequences of this outcome for individual patients. The question is 
whether this can help in the application of shared decision-making and if so, in what way.
Although decision modeling offers a framework for linking relevant evidence, it remains 
difficult and time-consuming to collect all relevant evidence in every aspect. This goes for 
individual models based on numerous data in particular. If individual modeling is proven 
to be useful for selection tools, it remains an important challenge to keep these individual 
models and selection tools based on these up to date.
Shared decision-making has also implications for the evaluation of the value of individual 
care. In our individual model (described in chapter 9) we have not included patient 
preferences. However, by applying shared decision-making these preferences would 
be taken into account in practice when making decisions on a particular management 
strategy. If we evaluate the value of individual care by using individual decision models, 
patient preferences should be taken into account in these models as well.
Recommendations
Based on the previous discussion I would like to make a number of recommendations 
for future research which in my opinion will contribute to the further dissemination and 
implementation of decision modeling. 
In order to improve transparency and the stakeholders’ insight into decision models, 
it may be useful to examine whether stakeholders would benefit from having the 
opportunity to change parameters themselves and being able to see the influence on 
the results. In this way, they would be provided with more insight into the model, as 
is the case with prediction models in which apps or nomograms are being used for the 
presentation. This could be achieved by adding a computer-based overview of the model, 
for instance, in which the value of parameters can be ‘shifted’ by using certain panels, 
after which the influence on the results is directly visible. Cost-effectiveness studies have 
been carried out in which such overviews are added as web interface.203,204 This web 
interface provides the user with an overview of all relevant input. The value of this input 
can be changed within set ranges in order to see what influence a certain input has on the 
results. In addition, different scenarios can be looked at such as differences in availability 
of facilities between hospitals. It should be examined which type of interface with what 
sort of information improve transparency towards the relevant stakeholders. This may not 
be the same for the different stakeholders (clinicians, policymakers et cetera). Based on 
this information, existing guidelines such as the ISPOR-SMDM guideline could be adjusted 
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by giving examples of how to best describe certain information.
Not all innovations entering the market lead to better and affordable care, because 
most innovations are currently evaluated in a late stage. Therefore, we believe that it is 
important to carry out and further develop early health technology assessments in order 
to enable companies/developers, clinicians and other parties involved to make better 
informed and early choices regarding the development of new procedures.
In order to apply these early evaluations in practice at a larger scale when new surgical 
procedures are being developed, it would be logical to include early HTAs into the IDEAL 
framework for developing and evaluating surgical procedures.6 Our group has already 
been discussing this with IDEAL. An important issue is legislation on the evaluation of 
surgical procedures and medical equipment with regard to entering the market. Although 
this issue has not been arranged yet, efforts are being made at a European level to draw 
up such legislation.205 Hopefully, it is possible to develop legislation which allows valuable 
innovations to enter the market relatively quickly. This can only be achieved by having 
the courage to diverge from existing legislation on drugs. The incorporation of (early) 
HTAs into legislation can help ensure that valuable innovations continue to be developed 
without an increase in development and heathcare costs. For instance, in the field head- 
and neck oncology the development of new techniques for intraoperative evaluation 
of the resection margins of the primary tumor would be a candidate for an early HTA. 
Multiple technologies are suggested.206,207 However their potential (cost-)effectiveness 
is unknown. 
The claim that early HTAs allow procedures and innovations to be more efficient should be 
further proved by carrying out proper evaluation. We could achieve this by following the 
innovations which have been evaluated by carrying out early HTAs. The correspondence 
between the potential value of innovations and the actual cost-effectiveness after 
implementation as well as the relationship between the potential value and the extent to 
which an innovation is being used in the health care sector should be evaluated. We have 
already started to register the early HTAs conducted by us in order to allow this evaluation 
to be carried out. If a future evaluation study into early HTAs indeed shows that these 
kinds of assessments contribute to the development of useful innovations, the result will 
hopefully be a more frequent use in practice by the stakeholders. 
We will also have to examine how individual models can be used in practice, if the analysis 
shows that individualized care is of value in a certain field. Basically all desired outcomes 
important to make a comparative assessment can be included into the models, such as 
expected risk of recurrence, survival prognosis, risk of shoulder complaints, quality of life 
and costs. The outcomes that are important to the patient (patient reported outcome 
measures) could be used to help define individual patients’ preferences regarding 
treatment, for instance by incorporating these into a decision aid. It should also be 
considered how these decision aids can be kept constantly up to date. The emergence of 
cognitive computing, artificial intelligence and deep learning (IBM’s Watson, for instance), 
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seems to lead to many changes in this field as well.208
Concluding remarks
By giving a concrete clinical example of treatment of the neck in OCSCC patients, I have 
shown that decision modeling can be a valuable method to inform evidence-based 
decisions regarding surgical procedures and innovations. Increased and better use of such 
decision models in the future will result in better and affordable care.
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Surgical innovations comprise modified strategies, new techniques, and innovative 
instruments. Evaluation of these innovations, e.g. in surgical trials, is difficult and rare due 
to practical and methodological challenges like the right timing of the evaluation, using the 
right comparator and the difficulties to achieve blinding. Furthermore, the introduction 
of new surgical procedures and devices is not regulated yet. Hence, these procedures 
and devices may become widely used with little evidence of their efficacy and (cost-)
effectiveness. Since others have shown that only half of all new experimental treatments 
will prove to be better than established treatments when tested in randomized trials, 
many used surgical procedures and devices may not have added value for patients. At the 
same time technological innovation is an important driver of the increasing healthcare 
cost.
An efficient and evidence based health care system should enhance the ability of medical 
professionals, their patients, health care insurers, manufacturers, and policy makers to 
make informed choices about the implementation of new procedures and devices, without 
jeopardizing innovation. Therefore, there is a need to improve the scientific tools and 
methods to inform evidence based decision making. Decision analytical modeling can be 
an ideal starting point for clinical decision making and the development of technologies. It 
can provide a basis for further research and an evaluative framework for decision making. 
The aim of this thesis was to inform decisions in the management of early oral cavity 
squamous cell carcinoma (OCSCC) patients in an evidence based manner. This empirical 
example offers the opportunity to assess the opportunities and challenges of an evidence 
based approach for the evaluation of (surgical) innovation. 
This thesis consists of three parts. In Part 1 we evaluate the need for evidence based surgery 
in general and more particularly for OCSCC. In part 2 we assess the cost-effectiveness of 
various management strategies for the neck in early stage OCSCC patients, and in part 
3 we try to bridge the gap between evidence based decision making and personalized 
healthcare. 
Part 1: the need for evidence‐based surgery. 
Chapter 2 provides an overview of the estimated costs associated with lower value surgery. 
Several initiatives have focused on defining healthcare services (including surgery) that 
provide little or no benefit. It is important to translate these lists of lower value services into 
meaningful metrics of avoidable costs to inform policy makers and providers how to bend 
the cost curve. To provide these metrics we calculated avoidable costs associated with 
surgical procedures included in the ‘do not do’ recommendations of the National Institute 
for Health and Clinical Excellence. We used both indication specific Dutch utilization data 
and more general utilization data from England in combination with actual costs from 
cost-(effectiveness) studies and reimbursement tariffs. In addition, we extrapolated the 
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results to all potential lower value surgical procedures, varying the assumption of lower 
value surgery to be between 5 and 33% of all surgical procedures. The estimated costs 
that could be saved by not performing proven lower value surgery in the Netherlands 
were €11 million and €8 million per year using actual costs and reimbursement tariffs, 
respectively. An extrapolation of this result to all surgical procedures showed a potential 
cost saving that varied between €63 million and €419 million per year. Data from England 
showed cost savings of about 48.5 million using actual costs. Extrapolation of the data 
from England showed a potential cost saving between €382 million and €2.5 billion. 
Therewith chapter 2 shows that lower value surgical procedures result in a significant 
waste in healthcare.
Chapter 3 reports on the variation in practice with regard to management of the neck 
in OCSCC patients within and between countries.  Such practice variation can be an 
indication of a lack of evidence-based management. The practice information was 
obtained by questionnaires, which were sent to representatives of head and neck cancer 
centers (HNC) in the Netherlands, UK, and USA. In total, representatives of 45 HNC centers 
completed the questionnaire; 10 from the Netherlands, 26 from the UK and 9 from the 
USA. Our results demonstrate a distinct variation in the management strategy of OCSCC, 
both within and between countries. Variation was found in the diagnostics, treatment 
and follow up of patients with OCSCC. Only a small part of this variation could be linked 
to differences in guidelines and differences in health systems, which indicates that the 
absence of clear evidence about optimal management strategies in OCSCC plays a role in 
the variation. 
Chapter 4 describes the results of an interactive evaluation in the field of HNC. An 
interactive evaluation involves anonymously exchanging concerns, claims and issues 
between all relevant stakeholders during interviews. It is aimed at systematically eliciting 
the views per persons involved, particularly their norms and values, and to identify 
shared values. It seeks to develop a shared view on where technology should develop, 
what are desirable scenarios (for research and development), and what are appropriate 
outcome measures for assessment. We asked the stakeholders about their expectancies 
for future OCSCC management options, taking into account the opportunities that the 
new state of the art operating theatres that are being built in the Radboudumc should 
offer. Twelve stakeholders in the field of head and neck cancer, i.e. doctors, a nurse, 
patients and paramedicals were included in the interactive evaluation. Most stakeholders 
agreed that the time interval between diagnosis and treatment is too large in some cases. 
Communication and exchange of information across disciplines should be improved. 
Stakeholders also agreed that research regarding the merits of the sentinel lymph node 
biopsy (SLNB) procedure and research on resection margins should be performed. 
Chapter 4 showed important and shared targets for future research and development in 
the field of head and neck cancer. Interactive evaluation was demonstrated to identify and 
prioritize viable innovations in head and neck cancer care.  
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Part 2: cost effectiveness of management strategies for the neck in OCSCC patients.   
Chapter 5 shows the results of a diagnostic meta-analysis of the accuracy of a sentinel 
lymph node biopsy (SLNB) for the prediction of neck node involvement in early stage 
OCSCC. A systematic search was performed in electronic databases to identify all relevant 
articles on the diagnostic accuracy of the SLNB. On basis of this search 21 diagnostic 
accuracy studies (including 847 patients), which used neck dissection or follow up as a 
reference test could be included. The pooled results of these 21 studies showed an overall 
sensitivity of 93% and a specificity of 100%. This high sensitivity and specificity supported 
a role of SLNB in the diagnostic work-up of OCSCC.
Chapter 6 describes the results of a decision analytical model assessing the cost-effectiveness 
of five management strategies for possible occult lymph node metastases in the clinically 
negative neck (cN0) in early stage OCSCC. The five strategies were (1) elective neck 
dissection (END), (2) watchful waiting (WW), (3) gene expression profiling (GEP) followed 
by neck dissection (ND) or WW, (4) sentinel lymph node biopsy (SLNB) procedure followed 
by ND or WW, and (5) GEP and SLNB (for positive GEP) followed by ND or WW. The 
cost effectiveness of a strategy was expressed in terms of costs, Quality Adjusted Life 
Years (QALYs) and incremental cost-effectiveness ratios, which show the extra costs of a 
strategy to gain a QALY as compared to the next best strategy. The model showed that 
the SLNB procedure followed by ND or WW was the most effective and cost-effective 
strategy. Compared with END the incremental cost-effectiveness ratio for SLNB was €3356 
per QALY gained, which is lower than the often used willingness to pay of €80,000 per 
QALY. The model was, however, sensitive for changes in quality of life (expressed in utility 
values), suggesting that further information on quality of life in this population was highly 
valuable.  
In chapter 7 we measured this quality of life in terms of health utilities in patients with 
early stage OCSCC following different diagnostic and treatment modalities for the neck 
.Patients with oral cavity cancer who underwent WW, SLNB, END (dissection of levels 
I-III), or therapeutic modified radical neck dissection (MRND; dissection of levels I-V) were 
included in this cross-sectional survey study. Patients received the EuroQol-5D-3L and the 
shoulder disability questionnaire to measure health utilities and shoulder complaints. A 
total of 181 patients (62%) returned the questionnaires. Mean health utilities were 0.804, 
0.863, 0.834 and 0.794 for the WW, SLNB, END and MRND subgroups, respectively. Mean 
shoulder disability scores (higher scores mean more shoulder complaints) for these groups 
were 8.64, 10.57, 18.92 and 33.66. Patients with shoulder complaints had a mean utility 
of 0.78 while patients without shoulder complaints had a mean utility of 0.90. When we 
imputed these utilities into our previously constructed decision analytical model (chapter 
6), the strategy including SLNB remained the most (cost-)effective strategy and was even 
more (cost-) effective than calculated in chapter 6.
Chapter 8 presents the results of a study in which we compared the cost-effectiveness 
of selective neck dissection (SND), consisting of the dissection of levels I-III or I-IV, with 
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modified radical neck dissection (MRND), which consists of dissection of levels I-V, in 
patients with early stage OCSCC with singular nodal disease confined to level I or II. For 
this purpose a decision analytical model was developed to model QALYs and costs of SND 
and MRND in the target population. The SND strategy resulted in an expected health loss 
of 0.06 QALY and savings of €1351 per patient compared to MRND. Overall, based on 
currently available evidence the SND was not cost-effective compared to MRND. However, 
sensitivity analyses revealed that there could be subgroups within the target population 
for which SND is cost-effective compared to MRND.
Part 3: Evidence based personalized decision making
Chapter 9 shows how prediction models can be incorporated in decision models to allow 
more personalized evidence based decisions; and to assess the value of this approach in 
decisions regarding the management of the neck in early stage OCSCC.  Using the decision 
model from chapter 6 three approaches were compared: 1) a population-based approach 
in which all patients undergo the strategy that is optimal for the average population; 2) a 
perfectly predicted approach, in which each patient undergoes the optimal strategy for 
that patient, and 3) a prediction model approach in which each patient undergoes the 
strategy that is predicted to be optimal based on a combination of predictions models (for 
the probability of occult metastases, survival and quality of life). The optimal strategy was 
chosen on the basis of a trade-off between costs and effects (quality-adjusted life years, 
QALYs). We studied the difference in average costs and effects per patient between these 
three approaches to assess the value of a personalized approach in OCSCC. The population 
based approach resulted in 4.9158 QALYs with mean costs of €8,675 per patient. The 
perfectly personalized approach yielded 0.21 more QALYs and saved €1,024 per patient 
compared with the population based approach. The prediction model approach yielded 
0.0014 more QALYs and saved €152 per patient compared with the population based 
approach.  The results of the perfectly personalized approach show that developing a 
more personalized approach appears to be promising in early OCSCC. However, the 
prediction model approach shows that decision-making based on the combination of 
currently available prediction models has only limited added value, probably due to the 
limited accuracy and discriminative power of these models. On a more general level, 
incorporating prediction models in decision models appears to be a valuable method 
to inform decisions on a personalized level and to assess the value of this personalized 
decision making. 
In chapter 10 the main findings of this thesis are summarized followed by a discussion 
regarding the use of decision modeling to inform evidence-based decisions. Three 
particular aspects were highlighted. First, the transparency of decision modeling is 
discussed. We developed our modeling studies for and with clinicians since we believe 
that they will take the important decisions with respect to new surgical procedures and/
or medical devices. Due to new and more sophisticated methodologies, modeling studies 
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are becoming more complex which reduces transparency. To increase the use of decision 
modeling for evidence based decision making, the transparency of the models should be 
improved. Second, the assessment of surgical procedures and medical devices is currently 
often performed when the procedure is already widely used. De-implementation of 
procedures has proven to be very difficult. We demonstrated that the assessment of 
potential value of innovations at early stages of development is possible and informative. 
Third, incorporating prediction models in decision models appears to be a valuable method 
to inform decisions on a personalized level. We should evaluate how these models could 
be used in clinical practice, for instance by incorporating them in decision aids.
By giving a concrete clinical example of treatment of the neck in OCSCC patients, I have 
shown that decision modeling can be a valuable method to inform evidence-based 
decisions regarding surgical procedures and innovations. Increased and better use of such 
decision models in the future will result in better and affordable care. 
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Chirurgische innovaties omvatten aanpassingen in chirurgische strategieën, nieuwe 
technieken en innovatieve instrumenten. De evaluatie van deze innovaties, bijvoorbeeld 
in chirurgische trials, is komt weinig voor en is ingewikkeld. Dit komt met name door 
praktische en methodologische uitdagingen, zoals het kiezen van het juiste moment van de 
evaluatie, het gebruiken van de juiste vergelijking en de moeilijkheden rondom blindering. 
Daarnaast is er nog maar weinig regelgeving rondom de introductie van chirurgische 
innovaties. Dit betekent dat deze innovaties breed ingezet kunnen worden zonder dat 
er duidelijk bewijs is over de werkzaamheid en kosten(effectiviteit). Er is aangetoond 
dat slechts de helft van alle nieuwe experimentele strategieën beter blijken wanneer 
deze worden getest in gerandomiseerde trials. Daardoor lijkt het waarschijnlijk dat een 
relevant deel van de gebruikte chirurgische innovaties geen toegevoegde waarde hebben 
voor de patiënt. Tegelijkertijd spelen deze chirurgische innovaties wel een belangrijke rol 
in de toename van de kosten in de gezondheidszorg.
Een gezondheidszorgsysteem dat efficiënt en ‘evidence-based’ is, moet ervoor zorgen 
dat medische professionals, patiënten, verzekeraars, de ontwikkelaars van innovaties en 
beleidsmakers goed geïnformeerde beslissingen kunnen maken over de implementatie 
van nieuwe strategieën en technieken. Aan de andere kant moet het verzamelen 
van deze informatie innovatie niet in de weg staan. Daarom is het belangrijk om de 
wetenschappelijke methoden rondom chirurgische innovaties te verbeteren. Besliskundig 
modelleren kan een goed startpunt zijn voor het nemen van beslissingen rondom nieuwe 
strategieën en de ontwikkeling van nieuwe technieken. Het kan een raamwerk zijn voor 
het maken van keuzes en de basis voor vervolgonderzoek.
Het doel van dit proefschrift was om de besluitvorming rondom de behandeling van 
vroeg stadium plaveiselcelcarcinomen (PCC) van de mondholte te informeren op basis 
van wetenschappelijk bewijs.  Deze casus geeft ons de mogelijkheid om de kansen en 
uitdagingen van het modelleren als basis voor de evaluatie van chirurgische innovaties te 
onderzoeken. 
Dit proefschrift bevat drie delen. In deel 1 evalueren we de behoefte aan chirurgie op 
basis van wetenschappelijk bewijs, in het algemeen, en meer specifiek in de behandeling 
van mondholte tumoren. In deel 2 evalueren we de kosteneffectiviteit van verschillende 
strategieën voor behandeling van de hals bij vroeg stadium PCC van de mondholte. Tot 
slot proberen we in deel 3 de brug tussen het maken van wetenschappelijk onderlegde 
keuzes voor de populatie aan de ene kant, en individuele zorg aan de andere kant, te 
overbruggen. 
Deel 1: De behoefte aan chirurgie op basis van wetenschappelijk bewijs
Hoofdstuk 2 geeft een overzicht van de geschatte kosten die gerelateerd zijn aan 
het uitvoeren van chirurgische procedures die weinig toegevoegde waarde lijken te 
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hebben voor de patiënt. Er zijn verschillende initiatieven die strategieën binnen de 
gezondheidszorg in kaart brengen die weinig of geen waarde toevoegen. Het is belangrijk 
om deze inzichten te vertalen naar daadwerkelijke kosten die mogelijk voorkomen 
kunnen worden door deze strategieën niet langer uit te voeren. Dit geeft beleidsmakers 
en aanbieders van zorg mogelijkheden om de stijgende kosten te reduceren. We hebben 
daarom de kosten berekend die gerelateerd zijn aan chirurgische procedures die 
opgenomen zijn in de ‘do not do recommendations’ van het ‘National Insitute for Health 
and Clinical Excellence’ (NICE). Om te bepalen hoe vaak deze procedures nog worden 
uitgevoerd is gebruik gemaakt van zowel indicatie specifieke volume data uit Nederland 
en van meer algemene volume data uit Engeland. Deze volumes zijn gecombineerd 
met cijfers over zowel de daadwerkelijke kosten van deze procedures (vanuit kostenef-
fectiviteitanalyses) als de vergoedingen (vanuit zorgverzekeraars). Daarnaast hebben 
we de potentiële kostenbesparingen gerelateerd aan deze procedures vertaald naar 
de potentiële kostenbesparingen gerelateerd aan alle procedures die mogelijk weinig 
toegevoegde waarde hebben. Hiervoor hebben we aangenomen dat tussen de 5% en 
33% van alle chirurgische procedures van weinig toegevoegde waarde zijn. De kosten 
die bespaard kunnen worden met het niet langer uitvoeren van de procedures die zijn 
opgenomen in de ‘do not do recommendations’ zijn geschat op €11 miljoen en €8 miljoen 
per jaar in respectievelijk daadwerkelijke kosten en vergoedingen. De extrapolatie naar 
alle procedures kwam uit tussen de €63 miljoen en €419 miljoen per jaar. Met de Engelse 
data kwamen we op een schatting van een potentiële besparing van ongeveer €48,5 
miljoen per jaar in daadwerkelijke kosten. Extrapolatie van deze data liet een potentiële 
kostenbesparing zien van tussen de €382 miljoen en €2,5 miljard euro. Daarmee hebben 
we in hoofdstuk 2 laten zien dat er waarschijnlijk een significante verspilling ontstaat door 
het uitvoeren van chirurgische procedures met weinig toegevoegde waarde.
Hoofdstuk 3 geeft een overzicht van de praktijkvariatie in de behandeling van de hals in 
patiënten met mondholtetumoren, binnen landen en tussen landen. Deze praktijkvariatie 
kan wijzen op een praktijkvoering die niet gebaseerd is op wetenschappelijk bewijs. 
Om deze informatie te verzamelen zijn vragenlijsten gestuurd naar vertegenwoordigers 
van hoofd-halskanker centra (HNC) in Nederland, het Verenigd Koninkrijk (VK) en de 
Verenigde Staten (VS). In totaal hebben 45 vertegenwoordigers van HNC de vragenlijsten 
beantwoord; 10 uit Nederland, 26 vanuit het VK, en 9 vanuit de VS. De resultaten 
laten een duidelijke variatie zien in de behandeling van de hals in patiënten met 
mondholtetumoren, zowel binnen landen als tussen landen. Er is variatie in de gebruikte 
diagnostiek, de daadwerkelijke behandeling en het traject na de behandeling. Slechts een 
klein gedeelte van deze variatie kon worden verklaard door verschillen in richtlijnen en 
verschillen in de gezondheidssystemen van de geïncludeerde landen. Dit suggereert dat 
de afwezigheid van duidelijke informatie over optimale strategieën in de behandeling van 
mondholtetumoren een rol speelt in de gevonden variatie. 
Hoofdstuk 4 beschrijft de resultaten van een interactieve evaluatie van de zorg voor 
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patiënten met hoofd-halskanker. Een interactieve evaluatie omvat de uitwisseling van 
zorgen, beweringen en kwesties tussen relevante belanghebbenden rondom een bepaald 
onderwerp. Het heeft als doel om de inzichten van de belanghebbenden, met name hun 
normen waarden, te achterhalen en om hieruit gezamenlijke waarden te identificeren. Het 
beoogt een gezamenlijk inzicht te vormen over hoe nieuwe technologie zich zou moeten 
ontwikkelen, wat daarin de gewenste scenario’s zijn (qua onderzoek en ontwikkeling) en 
wat geschikte uitkomstmaten zijn bij een evaluatie van de nieuwe technologie. 
Middels interviews hebben we de belanghebbenden binnen de  zorg voor hoofd-halskanker 
gevraagd naar hun verwachtingen omtrent toekomstige behandelmogelijkheden. Daarbij 
hebben we meegenomen dat er in het Radboudumc nieuwe operatiekamers worden 
gebouwd  waarin deze mogelijkheden uitgewerkt zouden kunnen worden. Twaalf 
belanghebbenden binnen de zorg voor hoofd-halskanker (artsen, verpleegkundigen, 
patiënten en paramedici) zijn geïncludeerd in de interactieve evaluatie. De meeste van 
deze belanghebbenden vonden dat in bepaalde gevallen de tijd tussen de diagnose en 
de behandeling op dit moment te lang is. Ze vonden dat communicatie en uitwisseling 
van informatie tussen de betrokken disciplines verbeterd zou moeten worden. Daarnaast 
waren ze het er over eens dat er  onderzoek gedaan zou moeten worden naar de 
schildwachtklier oftewel de ‘sentinel node’  procedure en naar verbetering van snijranden. 
Hoofdstuk 4 laat hiermee belangrijke doelen zien voor toekomstig onderzoek binnen de 
hoofd-halskanker, die gedeeld worden door de belanghebbenden.
Deel 2: Kosteneffectiviteit van strategieën voor behandeling van de hals in patiënten 
met plaveiselcelcarcinomen van de mondholte. 
Hoofdstuk 5 laat de resultaten zien van een diagnostische meta-analyse naar de 
nauwkeurigheid van de sentinel node (schildwachtklier) procedure (SNP) voor het 
voorspellen van metastasen in de hals bij vroeg stadium PCC van de mond- en keelholte. 
Relevante studies naar de nauwkeurigheid van de SNP werden op een systematische manier 
verzameld uit elektronische databases. Er werden 21 studies gevonden (met in totaal 847 
patiënten) die een halsklierdissectie of actief volgen (‘watchful waiting’) gebruikten als 
de referentietest. De gepoolde resultaten van deze studie lieten een sensitiviteit zien van 
93% en een specificiteit van 100%. De hoge sensitiviteit en specificiteit van de SNP wijzen 
richting een rol van deze procedure binnen de diagnostiek van vroeg stadium PCC van de 
mond- en keelholte. 
Hoofdstuk 6 beschrijft de resultaten van de evaluatie van de kosteneffectiviteit van vijf 
verschillende strategieën voor de diagnostiek en behandeling van mogelijke verborgen 
metastasen in de klinisch negatieve hals (cN0) bij vroeg stadium PCC van de mondholte. 
De vijf strategieën waren: (1) electieve halsklierdissectie, level I-III (HKD), (2) ‘watchful 
waiting’ (WW), (3) genexpressie profilering (GEP) gevolgd door HKD of WW, (4) sentinel 
node procedure (SNP) gevolgd door HKD of WW, en (5) GEP en SNP (SNP bij positieve 
GEP) gevolgd door HKD of WW. De strategieën zijn vergeleken op kosten, voor kwaliteit 
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gecorrigeerde levensjaren (zogenaamde QALYs) en incrementele kosteneffectiveitsratio’s. 
Een incrementele kosteneffectiviteitsratio laat zien wat het bij een bepaalde strategie 
kost om een QALY te winnen ten opzichte van een andere strategie. Uit het model bleek 
de SNP procedure, gevolgd door HKD of WW, de meest effectieve en kosteneffectieve 
strategie. De incrementele kosteneffectiviteitsratio van de SNP strategie ten opzichte van 
een strategie met direct een electieve HKD was €3.356 per gewonnen QALY. Dit is lager 
dan de veelgebruikte drempelwaarde van €80.000 per QALY. Het model was met name 
gevoelig voor veranderingen in kwaliteit van leven (uitgedrukt in utiliteiten) en liet zien 
dat meer informatie over kwaliteit van leven in deze populatie van grote waarde is voor 
het maken van de juiste keuzes. 
In hoofdstuk 7 hebben we daarom de kwaliteit van leven (utiliteiten) gemeten na 
verschillende diagnostische en behandelingsmethoden voor de hals in patiënten met 
vroeg stadium PCC van de mondholte. Patiënten met PCC van de mondholte die oftewel 
WW, SNP, electieve HKD (levels I-III) of therapeutische gemodificeerd radicale HKD 
(level I-IV) ondergingen werden geïncludeerd in deze cross-sectionele studie. Patiënten 
ontvingen de EuroQoL-5D-3L vragenlijst en de ‘shoulder disability’ vragenlijst om 
utiliteiten en schouderklachten te meten. In totaal beantwoordden 181 patiënten (62%) 
de vragenlijsten. De gemiddelde utiliteiten na WW, SNP, electieve HKD en gemodificeerde 
radicale HKD waren respectievelijk 0,804; 0,863; 0,834 en 0,794. De gemiddelde scores 
van de ‘schouder disability’ vragenlijst (hogere scores betekenen meer schouderklachten) 
waren voor deze groepen respectievelijk 8,64; 10,57, 18,92 en 33,66. Patiënten met 
schouderklachten hadden een gemiddelde utiliteit van 0,78, terwijl patiënten zonder 
schouderklachten gemiddeld een utiliteit lieten zien van 0,90. Wanneer we de utiliteiten 
uit deze studie terugbrachten in ons besliskundig model rondom de cN0 hals (hoofdstuk 
6) bleef de SNP de meest effectieve en de meest kosteneffectieve strategie, en bleek zelfs 
kosteneffectiever dan eerder berekend in hoofdstuk 6.
Hoofdstuk 8 laat de resultaten zien van een studie waarin de kosteneffectiviteit van een 
selectieve HKD (level I-III of level I-IV) is afgezet tegen de gemodificeerde radicale HKD (level 
I-V), in patiënten met een vroeg stadium PCC met enkelvoudige lymfekliermetastasen die 
zich beperken tot niveau I of II in de hals. Om de kosten en effecten van deze strategieën 
tegen elkaar af te wegen is een besliskundig model ontwikkeld. De selectieve HKD strategie 
resulteerde in een verwacht verlies in QALYs van 0,06 en een besparing van €1.351 per 
patiënt ten opzichte van de gemodificeerde radicale HKD. Gebaseerd op de beschikbare 
informatie was de selectieve HKD strategie daarmee niet kosteneffectief ten opzichte van 
de gemodificeerd radicale HKD. Echter lieten de sensitiviteitsanalyses zien dat er mogelijk 
subgroepen bestaan waarvoor dit wel het geval is. 
Deel 3: Geïndividualiseerde beslissingen op basis van wetenschappelijk bewijs
Hoofdstuk 9 laat zien hoe predictiemodellen kunnen worden toegevoegd aan 
beslismodellen om zo geïndividualiseerde beslissingen te kunnen nemen op basis van 
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wetenschappelijk bewijs, en om de waarde hiervan te bepalen. Hiervoor hebben we de 
casus van de behandeling van de hals bij patiënten met vroeg stadium PCC als voorbeeld 
gebruikt. Met het besliskundig model uit hoofdstuk 6 als basis, zijn drie benaderingen 
met elkaar vergeleken: 1) Een populatie benadering, waarin alle patiënten de strategie 
krijgen die het meest optimaal is voor de populatie; 2) een ‘perfecte voorspelling’ 
benadering, waarin alle patiënten de strategie ondergaan die optimaal is voor die 
patiënt; 3) een predictiemodel benadering, waarin alle patiënten de strategie ondergaan 
waarvan op basis van een combinatie van predictiemodellen (voor de kans op occulte 
metastasen, overleving en kwaliteit van leven) is voorspeld dat deze het meest optimaal 
is. De optimale strategie in de verschillende benaderingen werd gekozen op basis 
van een afweging tussen kosten en effecten (in QALYs). De verschillen tussen de drie 
benaderingen werden uitgedrukt in het gemiddelde verschil in kosten en effecten per 
patiënt. Dit laat de potentiële waarde van het individualiseren van de zorg voor de hals 
bij PCC van de mondholte zien. De populatie benadering resulteerde in 4,9158 QALYs en 
kostte gemiddeld €8.675 per patiënt. De perfecte voorspelling benadering resulteerde 
in een winst in QALYs van 0,21 en een besparing  van kosten van €1.024 per patiënt ten 
opzichte van de populatiebenadering. De predictiemodel benadering zorgde voor een 
winst van 0,0014 QALYs en een kostenbesparing van €152 per patiënt in vergelijking met 
de populatiebenadering. De resultaten van de perfecte voorspelling benadering laten zien 
dat er winst te behalen is door het individualiseren van de zorg bij vroeg stadium PCC van 
de mondholte. Echter liet de predictiemodel benadering zien dat het maken van keuzes 
op basis van de momenteel beschikbare predictiemodellen slechts weinig toegevoegde 
waarde heeft. Dit komt waarschijnlijk door de beperkte nauwkeurigheid en een gebrek 
aan discriminerend vermogen van de predictiemodellen. Meer algemeen lijkt het 
toevoegen van predictiemodellen aan besliskundige modellen een waardevolle methode 
om beslissingen rondom het individualiseren van zorg te evalueren. 
In hoofdstuk 10 worden de belangrijkste bevindingen uit dit proefschrift samengevat. Dit 
wordt gevolgd door een discussie die met name gaat over het gebruik van besliskundig 
modelleren voor het maken van beslissingen op basis van wetenschappelijk bewijs. In deze 
discussie worden drie aspecten benadrukt. Ten eerste de transparantie bij het besliskundig 
modelleren. De besliskundige modellen in dit proefschrift zijn ontwikkeld voor en met de 
artsen aangezien zij uiteindelijk leidend zijn in de beslissingen rondom nieuwe procedures 
en medische apparatuur. Door de ontwikkelingen in modelstudies worden deze steeds 
complexer maar daarmee ook minder transparant voor de uiteindelijke beslissers. Om 
ervoor te zorgen dat besliskundige modellen meer worden gebruikt zal de transparantie 
ervan moeten worden verbeterd. Ten tweede wordt de evaluatie van chirurgische 
procedures en medische apparatuur op dit moment pas gedaan wanneer een procedure 
al vrij uitgebreid wordt gebruikt. Het blijkt dat het de-implementeren van procedures 
lastig is. Besliskundig modelleren maakt het mogelijk om innovaties al in een 
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vroeg stadium, voordat ze gebruikt worden, te evalueren. Het derde aspect ligt in het 
individualiseren van zorg. We hebben laten zien dat het toevoegen van predictiemodellen 
aan besliskundige modellen een waardevolle methode kan zijn om het individualiseren van 
zorg te evalueren. We moeten echter onderzoeken hoe we deze modellen daadwerkelijk 
in de praktijk kunnen gebruiken, bijvoorbeeld door ze te verwerken in keuzehulpen.
Met dit voorbeeld over de behandeling van de hals in patiënten met PCC van de mondholte 
hebben we laten zien dat besliskundig modelleren een waardevolle methode kan zijn om 
de besluitvorming rondom chirurgische procedures en innovaties te informeren op basis 
van wetenschappelijk bewijs. Meer en beter gebruik van deze modellen in de toekomst 
kan zorgen voor betere en betaalbaardere zorg. 
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